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Haemophilia  A  is  a genetic bleeding disorder in  which  the plasma  level  of the clotting 
protein FVIII  is  reduced or absent  Treatment of haemophilia  is  by  replacement of the 
missing  FVIII  with  FVIII  concentrates  made  from  human  plasma,  or  by  recombinant 
technology.  The two  widely  used  assays  for FVIII  measurement (one-stage  APTT and 
chromogen ic  assay)  have  disagreements  in  potency  of FVIII  concentrates  and  in  post­
infusion plasma samples; these discrepancies are largest for the recombinant products.  The 
aim  of this  project  was  to  use  a  modified  thrombin  generation  test  (TGT)  for  a  more 
physiological approach to FVIII measurement.
Two  different TGTs  were used,  a  clotting based and  a fluorogenic  method.  Thrombin 
generation  was  carried  out  in  commercial  FVHI  deficient  plasma  to  which  a  FVIII 
concentrate  was  added,  the  reaction  was  triggered  with  the  addition  of phospholipid, 
calcium and FIXa.  A range of FVHI concentrates were investigated, four plasma-derived, 
three  recombinant  products  (two  full-length,  one  B-domain  deleted).  There  were  no 
substantial  differences  between  the  concentrates  under  the  various  conditions  tested. 
Platelets were added to the system to investigate if the different amounts of von Willebrand 
factor  (VWF)  in  die  concentrates  affected  the  thrombin  generation,  but  no  substantial 
differences  were observed between  low purity plasma-derived and  recombinant products 
containing no VWF.
It was also found that a large amount of thrombin could be generated at low levels of FVTn, 
and both assays were sensitive to FVIII levels of 0.001  IU/ml.  However, it was dependent 
upon the high amount of FIXa used to trigger the reaction.  A wide variation in the amount 
of thrombin generated by several commercial FVHI deficient plasmas was also observed, 
both  between  different  manufacturers,  and  between  batches  of the  same  plasma.  The 
ability to  detect  low  levels  of FVHI  could  be  beneficial  for  monitoring  patients  during 
prophylaxis, gene therapy and in phenotyping patients with severe haemophilia.
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15CHAPTER 1 
INTRODUCTION
1.1 Haemostasis.
1.1.1 Overview
Haemostasis is a physiological process by which a clot is formed after injury to a blood 
vessel to prevent blood loss.  Haemostasis can also occur in pathological states in which it 
is termed thrombosis.
Injury to the vessels causes an initial vasoconstriction which helps to slow the blood flow. 
The damaged endothelium of the vessel exposes the subendothelial tissue which attracts 
platelets and causes them to adhere to the damaged area to form the primary haemostatic 
plug.  The  adhesion  of the  platelets  cause  them  to  release  soluble factors  such  as  von 
Willebrand factor (VWF), which, together with tissue factor (TF) initiates the coagulation 
pathway.  This involves the activation of a series of proteases in sequence.  Each protease 
activates  the  next  protease  in  the  pathway  leading  to  an  escalating  response  which 
culminates  in  the  production  of  a  stable  fibrin  clot  from  fibrinogen  by  the  protease 
thrombin.
1.1.2 Clotting cascade
Coagulation is a series of reactions in which one serine protease activates the next one in 
the  series.  This  was  likened  to  a  waterfall  or  cascade  of reactions  (Davie  &  Ratnoff, 
1964;Macfarlane, 1964) and allows amplification of the process.
Coagulation was originally thought to follow two different paths, the “extrinsic” which is 
caused  by tissue  factor (TF) activation  and  “intrinsic”  which  is  contact activation  by  a 
negatively charged surface such as glass (in vitro) or collagen (in vivo) (Fig 1.1). However, 
it is now known that there are many positive and negative feedback loops to the system and 
it is not quite as straightforward as was initially envisaged (Fig 1.2).  The intrinsic pathway 
causes Factor XII (FXII) to become activated FXH (FXIIa).  FXIIa in turn activates FXI,
16which  in  turn  activates  FIX.  The  extrinsic  pathway  is  initiated  by  TF  which  forms  a 
complex with FVII or FVTIa  Both FIXa, with cofactor FVIIIa, and TF-VIIa are able to 
activate FX on a phospholipid (PL) surface and the subsequent steps of coagulation are 
termed the common pathway.  FXa activates prothrombin to thrombin, also in the presence 
of the cofactor FVa and PL.  Thrombin is the crucial component of coagulation cascade, 
causing back activation of coagulation  factors higher up  in  the pathway,  allowing  more 
thrombin to be generated, and importantly activating fibrinogen to fibrin which allows a 
clot to form.
These extrinsic and intrinsic definitions are still used in laboratory diagnosis.  Prolongation 
of the prothrombin  time  (PT)  reflects  a  deficiency  in  the  extrinsic pathway,  whereas  a 
prolongation in the activated partial thromoboin time (APTT) would suggest a deficiency in 
one  of the  components  of the  intrinsic  pathway.  A  prolongation  in  both  suggests  a 
deficiency in the common pathway.
INTRINSIC PATHWAY EXTRINSIC PATHWAY
Col agen
FXEE  ►   FXHa
Tissue Factor
FXI— —►   FXIa FVIIa  * FVII
FIX  ►FIXa
FX *  FXa
COMMON PATHWAY
FVa  -----►
Prothrombin Thrombin
Fibrinogen * Fibrin
Fig 1.1 Intrinsic and extrinsic pathways of  coagulation
17There are however, limitations with these definitions as deficiency of FXII despite causing 
a prolongation of the APTT does not result in a bleeding problem, whereas deficiencies in 
FVm and FIX can cause severe bleeding tendencies and are termed haemophilia A and B. 
The  study  of a  patient  whom  was  FVII  deficient  led  to  the  conclusion  that  in  vivo 
haemostasis proceeded via the extrinsic system (Josso & Prou-Wartelle, 1965).
1.1.2.1  Initiation
TF,  which  is  exposed  following  vessel  damage  is  thought  to  be  the  main  initiator  of 
coagulation in vivo (Rapaport & Rao,  1995).  TF is a transmembrane glycoprotein which 
comprises  of  three  regions,  the  transmembrane  domain,  a  cytoplasmic  tail  and  an 
extracellular domain  which  is  required  for haemostatic activity.  For TF to  be  active in 
haemostasis,  lipid  binding  is  required  (Paborsky  et al,  1991).  TF  was  not  thought  to 
circulate in the blood due to the lipid binding requirements, there is now evidence though 
that  TF  is  contained  on  microparticles  which  are  small  fragments  of cell  membranes 
predominantly derived from platelets (Berckmans etal, 2001).
FVIIa is an inefficient enzyme to activate FX, however when TF is in complex with FVIIa 
the activity increases by over a millionfold (Morrissey, 2001).  The initial TF-VIIa complex 
is formed with small amounts of FVIIa which circulates under normal conditions.  FVII in 
complex with TF can  undergo  autoactivation  to form  TF-FVTIa (Nakagaki  et al,  1991), 
which  is an additional  mechanism by which sufficient TF-VIIa complex can be formed. 
The  trace  amounts  of activated  FVQa-TF  are  held  in  check  by  tissue  factor  pathway 
inhibitor (TFPI) (van't Veer & Mann, 1997).
Under basal  conditions  one  percent of total  FVII  circulates  as  FVIIa  (Wildgoose et al, 
1992).  It  is  thought that  FVIIa  which  circulates  during  basal  conditions  arises  through 
activation by FIX or FIXa as patients deficient in FtX have reduced levels (Wildgoose et al, 
1992), which can be increased following FIX infusion (Eichinger et al, 1995).  In addition 
small amounts of activated FIX and FX also circulate under normal basal condition, these
18are markedly reduced in FVII deficient patients (Bauer et al, 1992), which would suggest 
that TF-VIIa pathway is responsible for the generation of FIXa and FXa under normal basal 
conditions.
1.1.2.2 Tenase complex
The circulating TF-FVIIa  forms  a  complex with  Ca2+  and a source of PL,  such  as  cell 
surfaces or activated platelets, this complex is able to activate FX to FXa in the “extrinsic 
tenase”  complex  (Williams,  1964;Radcliffe  &  Barton,  1973;Jesty  &  Silverberg, 
1979;Baugh et al, 2000).  However, the “extrinsic tenase” complex does not generate the 
majority of the FXa, this is generated by the “intrinsic tenase” in which FIXa activates FX 
on a phospholipid surface with FVLHa acting as a cofactor for this reaction, which increases 
the catalytic efficiency of the complex by eight-fold (McGee & Li, 1991).
FIX can be activated by two mechanisms, the first to occur in coagulation is by the TF-VIIa 
complex (0sterud & Rapaport,  1977;Lawson & Mann,  1991 ;Bauer et al,  1990) and  the 
second is FXIa.  It is thought that activation by TF-VIIa is more rapid than FXIa (Bajaj et 
al,  1983).  Before FXIa can activate FIX, it must be activated by thrombin, and therefore 
sufficient thrombin must be generated first (Naito & Fujikawa,  1991).  This  pathway  is 
important when low TF concentrations initiate haemostasis (Keularts et al, 2001a;von dem 
Borne et al,  1995) and for thrombin generation as activation by TF-FVIIa is  short lived 
owing to inhibition by TFPI.
During the initiation phase FXa is solely generated by FVIIa-TF, whereas initial thrombin 
(Flla)  is generated  by FVa-Xa or FV-Xa.  Once a small  amount of thrombin  has  been 
generated, it can activate FVIII, FV, FVII and FXI leading to a burst and amplification of 
thrombin generation (Butenas etal, 1997).
1.1.2.3 Prothrombinase complex
Prothrombin  is activated to  form  thrombin by the action of FXa and  in the presence of 
cofactor FVa, Ca2+and on a phospholipid surface.  Initially FV is able to act as a cofactor in 
the prothrombinase complex, although it is  100-fold less effective than FVa (Foster et al,
191983).  Once a small amount of thrombin has been generated, thrombin can activate FV to 
FVa (Giddings & Bloom, 1975).
TFPI
- X I   a -TF-VIIa  -
VIIIa  i   i  VIII
_   THROMBIN.
Prothrombi
/Antithrombin
A PC
A
P C
Fibrinoqen  Fibrin
Fig  1.2  Coagulation  cascade.  Initial  thrombin  generation  in  black  arrows,  explosive 
thrombin generation in blue, termination of thrombin generation in purple.
201.1.2.4  Thrombin
Pro-thrombin is activated to thrombin in the prothrombinase complex.  The first cleavage of 
pro-thrombin results in the pro-piece and pre-thrombin 2, this is followed by a further 
cleavge in pre-thrombin 2 to a-thrombin which consists of an A and B-chain which are 
held together by a disulphide bridge.  Further cleavages in the B chain lead to the 
haemostatically inactive p and y thrombin forms.
Thrombin contains four binding sites for substrates, inhibitors, cofactors and sodium ions, 
Sodium ions determines if thrombin is procoagulant (present) or anticoagulant (absent) in 
which case thrombin activates protein C.
Thrombin is the key serine protease in coagulation by activating fibrinogen to fibrin and 
hence forming a clot.  In addition, thrombin also activates FV, FVU, FVIII and FXI in the 
clotting cascade causing an explosion of thrombin generation.  In addition thrombin 
activates FXm and TAFI which lead to clot stabilisation. Thrombin cleaves after arginine 
ester and amide bonds in both natural and artificial substrates by forming an intermediate 
covalent tetrahedral complex (Hemker, 1983).
Thrombin is inhibited by a number of proteins, AT and a2-macrogloublin are the main 
inhibitors accounting for 64 and 23% respectively (Hemker et al, 1986;Jesty, 1986).  a2- 
macrogloublin comprises of four identical subunits, which consists of two pairs of subunits 
which are held together by disulphide bonds, with a plasma concentration of 3pM. a2- 
macrogloublin is a non-specific inhibitor if proteinases.  Proteinases bind to the “bait” 
region of a2-macrogloublin, this causes a conformational change in the a2-macrogloublin 
complex which traps the proteinase.  However, the active site of proteinase is not involved 
in binding to a2-macrogloublin, therefore small substrates can still be cleaved (Ganrot, 
1967).
Synthetic substrates
Synthetic substrates for the detection of thrombin consist of a tri or tetrapepetide to which a 
chromophore or fluorophore is attached at the caboxy terminal via an amide bond.  When
21the enzyme of interests cleaves this bond the chemophore is released, and this has an 
absorption maximum at a different wavelength to that of the whole substrate.  Fluorogenic 
substrates are ten fold more sensitive than chromogenic (Hemker, 1983). The first 
chromogenic substrate for thrombin was Bz-Phe-Val-Arg-pNA (Blomback et al, 1974). 
There are now many substrates which include H-D-Phe-Pip-Arg-pNA (S-2238), Tos-Gly- 
Pro-Arg-pNA (Chromozyme-TH)
1.1.2.5Thrombin generation
Initially thrombin is generated through the extrinsic pathway, this  enables  low levels of 
thrombin to be generated.  Only a minute amount of thrombin 0.5-2nM  is necessary to 
activate  platelets,  FXHL,  FV  and  cause  fibrin  formation  (Brummel  et al,  2002).  In  a 
computational  model  of coagulation the intrinsic complex was at a higher concentration 
than the extrinsic at 300 seconds (Hockin et al, 2002).  The bulk of thrombin is generated in 
the propagation phase which accounts for 96% of the total thrombin generated (Brummel et 
al, 2002), this thrombin is generated mainly by the intrinsic pathway because TF-VIIa is 
rapidly inactivated by TFPI (Baugh et al, 1998).
1.1.2.6  Inhibition of thrombin generation
Protein  C  and  S  are  key  components  of  the  anti-coagulant  pathways  which  bring 
coagulation to an end.  They also prevent coagulation from  occurring  in the absence  of 
damage to the vessel wall.  When thrombin binds to the endothelial cell membrane protein, 
thrombomodulin,  this  causes  a change  in  thrombin  function  from  pro-coagulant to  anti­
coagulant (Esmon et al,  1982;Ye et al,  1992).  The thrombomodulin-thrombin complex is 
able to activate protein C to activated protein C (APC) which inactivates FVilla and FVa. 
In addition, the light chain of FVa acts as a cofactor in thrombin activation of APC (Salem 
etal, 1983).  The action of APC on inactivation of FVHIa and FVa is augmented by protein 
S, which acts as a cofactor (Walker, 1980).
Another important component of coagulation inhibition is the action of antithrombin (AT) 
which is enhanced in the presence of heparin.  AT can inactivate FXa (Yin et al,  1971), 
FIXa (Rosenberg et al,  1975) and  thrombin  (Machovich et al,  1976).  TFPI  suppresses
22activation of FX and FIX by TF-VIIa by forming a quaternary complex with FXa, FVTIa 
and TF in the presence of Ca2+ (Broze, Jr. et al, 1988).
1.1.2.7  Clot stabilisation
The final stage of the coagulation mechanism is the formation of a fibrin clot.  Thrombin 
cleaves fibrinogen to form fibrin.  Fibrinogen comprises of three chains held in a dimeric 
conformation AaBPy, thrombin cleaves the N-terminal of Aa which allows binding of the 
y chain of another fibrin monomer. Thrombin also cleaves the N-terminal of the Bpchain 
which allows branching to form.  In addition, thrombin activates FXDI, which stabilises the 
fibrin network by creating cross-links between the y chains of adjacent fibrin monomers. 
Each monomer can form up to six cross-links with neighbour monomers, thus an insoluble 
fibrin network is created
1.1.3 Fibrinolysis
The  clot structure  is  broken  down  by  the process  of fibrinolysis.  Plasmin  is  the  main 
fibrinolytic agent in vivo, however, it circulates in the inactive form plasminogen which is 
activated  by tPA  (tissue type plasminogen activator)  or uPA (urinaiy type plasminogen 
activator).  Plasmin hydrolyses peptide bonds in fibrin to create two degradation products, 
Fragment D and E, which are soluble.  Plasmin is  inhibited by a 2-antiplasmin, although 
while  bound  to  fibrin,  plasmin  is  protected  from  inactivation.  FXIIIa  cross-links  a 2- 
plasmin  inhibitor to a  chains  of fibrin, thereby  increasing resistance to  degradation.  In 
addition,  FXI  can  also  inhibit clot lysis  with as little as 0.01%  FXIa required to  totally 
inhibit fibrinolysis (von dem Borne etal, 1995).
1.1.4 Platelets
Platelets  are  small  anucleated  cells,  which  are  derived  from  the  cytoplasm  of 
megakarocytes.  Platelets circulate within the blood at 150-400 x 109/L and have a life span 
of 7-10 days.  Activation of platelets by soluble agonists such as adenosine diphosphate 
(ADP) and thrombin, or by adhesion leads to shape change with formation of pseudopods 
that  represent protrusions  of the  plasma  membrane,  in  this  way  the  surface  area  of the 
platelet increases.
231.1.4.1  Platelet structure
Platelets consist of a cytoplasmic membrane, a structural zone, organelles and a membrane 
system.  The structural zone consists of microtubuli, and the structural proteins, actin and 
actin binding protein.  The function of these are to maintain the resting discoid shape, and 
actively participate in the shape changes of activated platelets.  The organelles consist of 
mitochondria,  glycogen  stores  and  three  storage  granules: a granules,  dense  bodies  and 
lysosomes.  The membrane system consists of the open canalicular system and the dense 
tubular system.  The dense tubular system is one of the main storage sites for intracellular 
calcium and is derived from the rough endoplasmic reticulum of the megakaryocyte.
The cytoplasmic membrane is a phospholipid bilayer containing phosphatidylcholine 38%, 
phosphatidylethanolamine (PE) 27%, sphingomyelin (SPH)  17%, phosphatidylserine (PS) 
10%  and  phosphatidylinositol  (PI)  5%.  However the  phospholipid  composition  of the 
bilayer is asymmetrical, the negatively charged phospholipids are almost exclusively on the 
inner membrane (PE, PS, PI, see Table 1.1), which is maintained by an active process.  The 
organisation  of the  plasma  membrane  “flip-flops”  during  activation  to  expose  the  pro­
coagulant negatively charged phospholipids.  The exposure of procoagulant phospholipids
2 'b is  mediated  through  the  intracellular  rise  of Ca  and  subsequent  signalling  pathways 
(Martinez et al, 1999;Heemskerk et al, 1997).
Table  1.1  Phospholipid  composition  (percentage)  of the  exterior  and  interior platelet 
membranes. Adapted  from Williams Haematology (Ware & C oiler, 1995).
Exterior
Leaflet
Interior
Leaflet
PC 45 55
SPH 93 7
PE 20 80
PI 16 84
PS 9 91
241.1.4.2 Adhesion
In intact blood vessels, endothelial cells line the procoagulant subendothelial matrix and in 
the resting state exert an anticoagulant effect through the action of thrombomodulin.  At a 
site  of vascular  damage  endothelial  cells  are  removed  and  procoagulant  collagen  and 
fibrinonectin  are  exposed  to  flowing  blood.  Endothelial  cells  may  also  become 
procoagulant  through  inflammatory  pathways  to  expose  P-selectin.  Circulating  VWF 
attaches to collagen to create a surface on which platelets can attach. Platelets are also able 
to bind through the glycoprotein (GP) VI receptor to exposed collagen.  Platelets attach 
through the receptor complex GPIb-IX-V to P-selectin on activated endothelial cells or to 
VWF. Platelets can then roll along this surface by making new contacts through the GPIb- 
IX-V complex in the direction of flow and dissociating previous interactions.  Platelets can 
detach at this stage and return to normal blood flow or attach through binding of the GPIIb- 
Hla.
The manner in which platelets adhere depends upon the levels of shear stress in the vessel, 
with more platelet tethering occurring with increasing shear stress. Platelets tether through 
interaction with GPIba, although only 60% of platelets tether through this mechanism at 
low  shear  levels.  At  low  shear  rates  the  interactions  of the  platelet  with  collagen, 
fibrinonectin and fibrinogen are sufficient to withstand the shear stress.  In addition, release 
at low shear of endothelium VWF from the Weible-Palade bodies can recruit platelets to 
the endothelium surface through interactions with the GPIba receptor (Andre et al, 2000). 
Finally the integrin am>P3. is necessary for stationary adhesion contacts at all shear levels 
(Kulkami et al, 2000).
1.1.4.3 Activation
Once platelets are bound to the vessel surface they can be activated by a variety of ligands, 
most  notably  thrombin.  Thrombin  can  activate  platelets  through  protease  associated 
receptors (PAR).  There are four PARs, although only 1  and 4 are found on human platelets 
(3 and 4 in mice).  Thrombin binds to the N-terminal end of the PAR receptor and cleaves
25the N-terminal, this then allows the remaining N-terminal to interact with the receptor and 
activate internal messengers and calcium release through the receptor associated G proteins 
(Vu etal, 1991).
It is thought that the PARI receptor alone is necessary for platelet response at low thrombin 
concentrations, as blocking PAR4 still resulted in full platelet activation (Kahn et al, 1999). 
However, PAR4 does seem necessary for a more intense  intracellular signal.  Khan et al 
blocked  both  PARI  and  PAR4  which  abolished  platelet  aggregation  through  thrombin 
activation (Kahn et al, 1999).  There is also a thrombin binding site on GPIba although the 
exact  role  of this  interaction  in  platelet activation  is  uncertain.  Dubois  et  al  following 
desensitisation  of the  PAR  receptors  reported  that  platelet  aggregation  still  occurred 
through  thrombin  binding  to  the  GPIb-IX-V  complex  and  was  able  to  induce  platelet 
aggregation through binding of fibrin to GPIIa-IIIb (Dubois et al, 2003).  PAR-1  can be 
activated  by  FXa  in  a  manner  which  is  independent  of  thrombin,  although  high 
concentrations  of FXa  are  required  (Riewald  et al,  2001),  this  FXa  however,  may  not 
activate platelets, but rather produce a proinflammatory response (Riewald & Ruf, 2001).
Adhesion and activation of the platelet through collagen requires both the GPVI receptor 
and integrin (X 2P1.  When platelets are activated, shape change occurs, the platelet flattens, 
and the membrane flip-flops exposing procoagulant phospholipids on the platelet surface. 
This exposure is necessary for the generation of more thrombin and provides a surface on 
which more platelets are able to aggregate leading to the formation of a thrombus.
1.1.4.4  Thrombus propagation
Platelets translocate on the subendothelial VWF then arrest and recruit additional platelets 
into  growing  thrombi.  Platelets  adherent  to  collagen  expose  more  PS  than  platelets 
adherent to fibrinogen which are less able to support the prothrombinase complex, although 
this is not a limiting factor if sufficient plasma FVa is available (Briede et al, 2001).
A real time experiment, under shear conditions, found that there was a rapid deposition of 
platelets and fibrin onto collagen coated glass plates, and that circulating TF was recruited
26to areas in which there was a large deposition of platelets and thrombi (Balasubramanian et 
al, 2002).  In an in vivo model in which injury was induced in the endothelium with a laser, 
TF was concentrated at the thrombus-vessel wall interface, which suggests that the vessel 
wall is the source of TF, and not circulating TF (Falati et al, 2002).
1.1.5  FVIII
The gene for FVIII is located on the X chromosome.  It is a large gene and comprises 1% of 
the chromosome.  The FVIII gene was sequenced in  1984 (Vehar et al,  1984;Wood et al, 
1984;Gitschier  et  al,  1984).  FVIII  comprises  two  A  domains  one  B  domain,  two  C 
domains and three acidic regions (Fig 1.3).
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Fig 1.3 Structure of FVIII showing binding sites and activation cleavage sites.  Taken from 
(Saenko et al, 2000).
271.1.5.1  Synthesis
FVm is synthesised in a wide range of tissues, which includes the liver, kidney, spleen, and 
muscle  (Wion  et  al,  1985;Hollestelle  et  al,  2001).  Quantitative  reverse  transcriptase 
polymerase chain reaction (RT-PCR) in mice has shown similar mRNA levels of 257 and 
209 pg/pg total RNA for liver and kidney respectively, which would account for 75 and 
12.5%  of plasma FVIII  respectively  (Hollestelle et al,  2001).  Liver transplantation  in 
haemophiliacs also corrects FVIII level (Bontempo et al,  1987), which supports the idea 
that the liver is the primary site of FVIII synthesis.  A number of studies have found that 
FVm is produced in sinusoidal endothelial cells and not in hepatocytes (Stel et al, 1983;Do 
et al, 1999;Zelechowska et al, 1985;Hollestelle et al, 2001 ;Hollestelle et al, 2004).
The concentration of FVQI mRNA is much higher than that of the carrier protein VWF, for 
which  synthesis is highest in the lungs (0.22pg/pg) and lowest in the liver (Hollestelle et 
al, 2001;  Yamamoto et al, 1998).  It is surprising that so much mRNA for FVTQ is produced 
considering that the plasma level is so low, and likewise that the major sites of synthesis for 
the two proteins should be so spatially separated.  In an in vitro model the AtT-20 mouse 
pituitary tumour cell line was transfected with both VWF and FVIII.  FVIII was trafficked 
from the transgolgi network to vesicular storage, and this was dependent upon functional 
VWF (Rosenberg et al,  1998).  It is unknown if this happens in vivo as VWF and FVIII 
appear to be synthesised in different locations.  However, this may account for the rise in 
both  VWF  and  FVIII  following  administration  of  1-deamino-8-D-arginine  vasopressin 
(DDAVP) to mild haemophiliacs or normal people (Garcia et al, 1982).  The rise in FVIII 
following  DDAVP  administration  is  not  due  to  an  increased  synthesis  of  FVIII  as 
demonstrated by Kaufman et al in which mRNA levels of FVIII did not increase in porcine 
livers following DDAVP infusion (Kaufman et al,  1999).  However, clearance of FVTQ is 
slower  in  the  presence  of VWF  VWF  and  FVIII  can  also  be  increased  following 
administration of interluekin-11, however, this occurs steadily over time, and in a manner 
which is different to DDAVP increases (Olsen etal, 2003).
281.1.5.2 Secretion of FVIII
The initial stage of secretion  involves translocation of the mature full  length amino acid 
polypeptide into the lumen of the endoplasmic reticulum (ER), where glycosylation occurs. 
Transfer of FVIII from the ER to the Golgi is not yet fully elucidated, but is mediated in 
part by the ER-Golgi intermediate compartment (ERGIC).  Mutations in ERGIC-53 result 
in a rare homozygous condition in which both FV and FVIII levels are reduced to between 
5-30% of normal  (Nichols et al,  1999;Neerman-Arbez et al,  1999).  ERGIC-53  recruits 
correctly folded FVIII through interactions with N-linked glycosylation in the B domain 
into the secretory vesicles of the ERGIC for trafficking to the golgi (Moussalli et al, 1999). 
However, mutations in ERGIC-53 do not account for all cases of the combined deficiency 
and recently another chaperone protein known as multiple coagulation factor deficiency 2 
has been implicated (Zhang et al, 2003).  There is also possibly a third protein involved in 
this  pathway.  FVIII  also  undergoes  further  processing  and  intracellular  proteolysis 
(Kaufman  et al,  1988),  in  which  the  B  domain  is  cleaved  at  the  motif Arg-X-X-Arg, 
resulting  in  two  cleavages  at  Arg  1313  and  1648.  These  cleavages  give  rise  to  the 
heterodimeric form of FVIII which circulates in plasma.
The dimeric form of FVIII is held in a stable conformation by a metal ion bridge, as the 
metal  ion  chelating  agent  ethylenediaminetetraacetic  acid  (EDTA)  causes  subunit 
dissociation (Eaton et al,  1987).  This has more recently being identified as a copper ion 
with  a  1   mol:mol  ratio  (Tagliavacca  et al,  1997).  The  copper  binding  site  has  been 
proposed  at  Cys  310,  with  His  99  also  being  important  for  the  A1-A3  interaction 
(Tagliavacca  et  al,  1997).  Copper  increases  the  intersubunit  affinity  by  a  100-fold, 
although calcium is necessary for FVIII activity (Wakabayashi et al, 2001).  Copper has an 
inhibitory effect on  the heavy chain,  whereas  on the  light chain  it  increases  the  rate of 
reconstitution  of  the  subunits  and  enhancement  in  the  reconstituted  FVIII  activity 
(Sudhakar & Fay, 1998).
1.1.5.3 Activation of FVIII
FVm circulates  in plasma  in the heterodimeric form  bound  to  the carrier protein VWF 
which protects against FVIII degradation.  FVm binds to VWF at two sites  in the  light
29chain, the acidic region a3 and in the C2 domain (Saenko & Scandella, 1997).  While FVIII 
is unactivated and bound to VWF it is unable to partake in the tenase complex.  In vitro 
FVffl  can  be  activated  by  both  factor  Xa  and  thrombin  by  cleavage  at  three  arginine 
residues 372, 740 and 1689.  However it would appear that thrombin is the main activator 
in  vivo  as  thrombin  activated  FVTIIa  has  a  higher  activity  than  that  formed  by  FXa 
activation (Neuenschwander & Jetsy, 1988;Parker etal, 1997).
1.1.5.3.1 Activation FVIII by FXa
FXa  can  activate  FVHI  causing  a  1.6  fold  increase  in coagulant  activity,  however this 
activation is inhibited by VWF (Koedam et al, 1990).  This is because the binding site for 
FXa overlaps that of the VWF binding site (Nogami et al,  1999).  Work has since shown 
that the C2 domain contains a FXa binding site between residues 2253-2270, whereas the 
FXa cleavage site is in the A3 domain (Hay, 1999).  In addition the PL binding site is also 
contained within the C2 domain (Scandella et al, 1995).  These findings, suggest that FVIII 
activation by FXa is unlikely to occur under normal haemostatic conditions.
1.1.5.3.2 Activation of FVHI by thrombin
Activation of FVIII by thrombin occurs by three further cleavages of the FVTQ dimer at 
Argenine 372, 740 and 1689.  Pitman et al demonstrated by amino acid subsitution that Arg 
740 did not appear to be necessary for FVIII activity, whereas Arg 372 was the main site 
for activity, and Arg  1689 was also necessary (Pittman & Kaufman,  1988).  Using snake 
venoms to cleave the heavy chain site, Arg 1689 was not required in the absence of VWF 
however, when VWF was present, cleavage in both heavy and light chain was necessary 
(Hill-Eubanks et al,  1989).  This would suggest that cleavages at Arg 372 and  1689 are 
required for full FVffl activity (Regan & Fay, 1995).  Cleavage at Arg 1689 appears to be 
the mechanism by which VWF disassociates from the FVIII molecule.  VWF promotes this 
cleavage by increasing the catalytic efficiency of thrombin cleavage by a factor of seven 
(Hill-Eubanks & Lollar, 1990).  Therefore, Arg 372 appears to be the limiting step in FVffl 
activation.  Cleavage at Arg 1689 cleaves the acidic region a3 from the light chain of FVffl 
which affects the conformation of the C2  domain.  This altered conformation  in the C2 
domain  then  allows  for VWF  dissociation  (Nogami  et al,  2000),  thereby  increasing the
30affinity of FVIII for PL by eight fold (Saenko et al, 1998).  The thrombin binding site for 
this cleavage is contained within the C2 domain, but is separate from VWF (Nogami et al,
2000)  and PL binding sites (Pratt et al,  1999).  There is however, overlap in the PL and 
VWF binding sites (Saenko etal, 1994) and FXa binding site (Nogami et al, 1999).
The fully activated FVTQ is in a trimeric form with the Al  and A3-C1-C2 domains held 
together by metal ions (Tagliavacca etal,  1997), the A2 domain is loosely associated with 
the complex by weak electrostatic charges (Lollar & Parker, 1990;Fay et al, 1991b).
1.1.5.4  Tenase complex
FVEQa acts as a cofactor in the tenase complex in which FX is activated to FXa by FIXa on 
a PL surface (Fig 1.4).  FVIIIa increases the catalytic efficiency of this complex by several 
orders  of magnitude  (Kane  &  Davie,  1988).  FVIIIa  binds  to  FIXa  in  a  1:1  complex 
(Lamphear & Fay, 1992) through the A2 and A3 domains (Mertens et al, 1999) to the EGF 
(Christophe et al, 1998) and protease domain (Bajaj etal, 1985) of FIXa.  The FVTQa-FIXa 
complex has high affinity with a 0.5nM dissociation constant (Jesty,  1990), which is also 
dependent upon calcium  (Duffy et al,  1992).  It appears  that the A2  domain  of FVIIIa 
modulates  FIXa  activity  (Jenkins  et al,  2002).  However,  the  other  components  of the 
complex also have important roles.  FX increases the affinity of FIXa for FVIIIa (Mathur et 
al, 1997).  Also it would seem that FVIIIa and FX increase the affinity of receptors on the 
surface of activated platelets for FIXa by five fold (Ahmad et al,  1989).  The PL surface 
also  has  two  functions  PS  and  PE  are  necessary  for FVIIIa  binding  to  the PL  surface 
(Gilbert & Arena, 1995), and the PL surface also contributes to the complex by increasing 
the catalytic efficiency by  1000 fold (Gilbert & Arena,  1996).  The binding of FIXa and 
FVTQa to PL membranes is a mechanism by which the local concentrations of the factors 
will be higher allowing for interaction between the two proteins.
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Fig 1.4 Interaction of  FVIIIa and FIXa.  FVIIIa and FIXa bind to a PL surface through the 
C2 and Gla domains respectively.  FVIIIa binds to FIXa through interactions with the A2 
and A3 domain of  FVIIIa and the EGF2 and Protease domain of  FIXa in a 1:1 ratio.
Metal  ions  are  also  key  components  of the  tenase  complex.  Magnesium  ions  facilitate 
efficient  FXa  generation  with  much  lower  amounts  of FVIIIa  than  those  with  calcium 
alone.  Ions also  potentiate the activation of FIX  by FXIa,  and also activation  of FX by 
FIXa (Sekiya et al, 1996).
1.1.5.5  Inactivation of FVIII
FVTQ  can  be  inactivated  by  a  number  of different  processes.  The  A2  subunit  of the 
heterotrimeric form is weakly associated  with the dimer, disassociation of the A2 subunit 
results in loss of FVIIIa activity (Lollar & Parker,  1991 ;Fay et al, 1991b).
FVIII is also inactivated by two further cleavages of the heterotrimer at Arg 336 and 562 by 
APC  (Fay et al,  1991c).  Protein  S acts as a co-factor in this  reaction  and  increases  the 
inactivation rate nine fold (Koedam et al, 1988), Factor V has also found to be a cofactor in 
this reaction (Shen et al, 1997).  In addition Arg 336 can also be cleaved by FIXa (O'Brien
32et al,  1992) (Lamphear & Fay,  1992)and FXa (Eaton et al,  1986).  However, APC is the 
main mechanism by which FVHI is inactivated.
FVIIIa is protected from inactivation by VWF (Rick et al, 1990), which protects FVIIIa by 
preventing APC-phospholipid interactions (Fay etal, 1991a), and also by directly inhibiting 
the APC binding site in a manner which is independent of phospholipids (Nogami et al, 
2002).
1.1.5.6 Clearance of FVTII
FVm  is  cleared  from  the  circulation  by  a  multifunctional  endocytic  receptor,  the  low 
density lipoprotein receptor-related protein (LRP).  LRP is widely expressed on a number 
of tissues and cell types, and recognises at least 30 different ligands, several of which are 
involved in haemostasis (Herz & Strickland, 2001).  FVIII interacts with LRP through the 
C2 (Lenting et al, 1999) and A3 domains of the light chain (Bovenschen et al, 2003), and 
also the A2 domain of the heavy chain (Saenko et al, 1999b).  Clearance of FVIII by LRP 
can be prevented by receptor associated protein (RAP) (Lenting et al,  1999; Saenko et al, 
1999b),  which  is  an  antagonist  for all  ligands  to  LRP.  Heparan  sulfate  proteoglycans 
(HSPGs)  also  facilitate  in  clearance  mediated  through  LRP,  and  also  in  a  non-LRP 
mediated clearance (Sarafanov etal, 2001).
1.1.6 Von WUIebrand Factor
1.1.6.1  Synthesis, secretion and storage
VWF  is  a  52  exon  gene  (Mancuso  et al,  1989)  which  is  located  on  chromosome  12 
(Ginsburg et al, 1985).  Synthesis of VWF occurs in two different cell types, in endothelial 
(Jaffe etal, 1973;Wagner etal, 1982) and in megakaryocytes (Nachman etal, 1977), which 
are the precursor cells to platelets.  VWF is stored within these cells in the Weibel-Palade 
bodies  of endothelial  cells  (Wagner et al,  1982;Wagner,  1993),  and  the  a-granules  of 
platelets (Cramer et al, 1985). VWF is secreted constitutively from endothelial cells giving 
rise to the plasma source of VWF.  Stored VWF is released as very high multimers (Spom 
et al, 1986) which are haemostatically more effective than low molecular weight multimers.
33VWF is synthesised as a large prepro-peptide, which is in total 2813 amino acids long, this 
consists of a signal peptide and 4 repeated domains A-D.  The signal peptide is cleaved 
during translocation into the ER, the resulting pro-VWF forms dimers through disulphide 
bridges  at the carboxy termini  (Voorberg et al,  1991).  Within the trans  Golgi  network 
sulphation occurs followed by multimerisation through the amino terminal and cleavage of 
the propeptide (Carew et al, 1990;Vischer & Wagner, 1994) which increases FVIII binding 
to VWF (Bendetowicz etal, 1998).  The propeptide is required for multimerisation of VWF 
and transport to the Weibel-Palade bodies (Joumet et al,  1993), which were shown to be 
independent of each other (Haberichter et al, 2000).
1.1.6.2 FVm-VWF complex
Theoretically VWF and FVIII can bind in a 1:1  ratio as there is  1   FVIII binding site per 
VWF monomer (Marti et al,  1987),  however,  in  plasma a 50:1  ratio has been observed 
(Vlot et al, 1995).  VWF stabilises FVIII in plasma and prolongs the half-life (Weiss et al, 
1977;Over et al,  1978), this is achieved by two mechanisms, firstly by preventing FVIII 
binding to PL before activation by thrombin (Saenko & Scandella, 1995;Hill-Eubanks et al, 
1989), and secondly by preventing inactivation by APC (Nogami et al, 2002).  The FVEI- 
VWF complex forms rapidly, with more than 95% of infused FVIII bound to VWF in  12 
seconds (Vlot et al, 1996).
1.1.6.3 VWF/Platelet interactions
VWF  interacts with two receptors on the surface of platelets, glycoprotein GPIba in the 
GPIb-IX-V complex and intergrin am,p3-   The GPIba is the most important interaction at 
high shear, at low shear this interaction is not necessary, and platelets are tethered though 
interaction  with collagen,  fibronectin,  and  fibrinogen/fibrin  (Savage et al,  1998).  VWF 
binding to GPIba  slows  platelets  down  and  allows  sufficient time for platelets  to make 
stable  interactions  through  other  receptors  (Savage et al,  1996).  At  high  shear  GPIba 
interaction with VWF may also be important for initiating platelet activation.
341.2  Haemophilia
Haemophilia  is  a  bleeding  disorder  resulting  from  a  congenital  deficiency  in  FVIH 
(Haemophilia A) or FIX (Haemophilia B).  The first written evidence of haemophilia is in 
the Talmud in the 5th century AD and in subsequent writings of the Rabbis.  It was advised 
that circumcision should not occur if two siblings had died from bleeding, it was also noted 
that this rule was to be followed even if the woman had more than one husband, which 
acknowledges  the  female  transmission  of  the  bleeding  disorders  (Rosner,  1969). 
Haemophilia A is a genetic disorder in which males are affected because the FVIII gene is 
carried on the X chromosome.  In some cases carriers may also be affected by low levels of 
FVffl.  From hereon in deficiency in FVffl will be termed haemophilia.
1.2.1  Genetic defect
Haemophilia  is  caused  by  a  mutation  in  the  FVffl  gene.  Mutations  causing  a  point 
mutation can have several outcomes, a mis  sense mutation in which a different amino acid is 
coded, a nonsense mutation in which a stop codon is produced leading to termination of the 
protein, or a mutation may affect the splicing sites between the exons.  The largest group of 
point  mutations  are  missense  which  account  for  81%  of this  group  (Kemball-Cook  & 
Tuddenham, 2003).  Patients with missense mutations can be cross reactive material (CRM) 
reduced or negative if the amount of FVffl antigen is reduced in proportion with the FVffl 
activity, or CRM +ve if the amount of FVTQ antigen is normal but the FVffl activity is 
reduced (Kemball-Cook & Tuddenham, 2003).  Patients who are CRM+ve have a normal 
expression of the FVffl protein, but presumably the mutation has affected interactions with 
the  other  coagulation  proteins.  Mutations  can  also  result  in  a  insertion  or deletion,  an 
increase or decrease in three bases maintains the reading frame, where as other deletions 
will  alter  die  reading  frame  and  a  stop  codon  will  be  produced  causing  a  premature 
termination  of the FVIII  protein.  The most common  mutation  in  severe  patients  is  the 
intron 22 inversion which accounts for around 50% of cases (Antomarakis, 1995).
351.2.2  Symptoms and FVIII level
The normal FVIII range is considered to be 50-150% .  Haemophilia patients have FVIII 
levels  less than 50% , these are divided into three categories depending upon their FVm 
level, which in general correlate with their clinical symptoms.
1.2.2.1  Elevated FVIII levels
There  is  some  evidence  that  high  levels  of FVIII  greater  than  150%  can  act  as  an 
independent risk factor for thrombosis, odds ratio of 4.8 after adjusting for blood group and 
VW F (Koster et al,  1995).  In an animal model Kawasaki et al demonstrated that elevated 
plasma FVm levels led to an increase in FVIII concentration within a thrombus, and that 
VW F  participated  in  this  accumulation  (Kawasaki  et al,  1999).  The  increase  in FVIII 
levels are due to an increase in protein secretion or in stability (O'Donnell et al, 1997), so 
far no genetic cause has been identified with screening of the promoter and the poly A site 
(Mansvelt et al, 1998).  There is a high heritability for FVHI and VW F, which is due in part 
to blood group, those with blood group O have lower FVIII and VW F concentrations (de 
Lange etal, 2001).
1.2.2.2  Reduced FVM levels
Mild haemophilias are classified according to the International Society of Thrombosis and 
Haemostasis (ISTH) as having 5-40% of normal, moderate as 1-5% and severe as having 
less  than  1%  of  normal,  100%  of  normal  is  equivlent  to  1   IU/ml  (Table  1.2). 
Mild/moderate haemophilia can be caused by a variety of genetic causes;  impaired FVM 
synthesis, processing or secretion, reduction of FVM binding to VWF, impaired thrombin 
activation,  impaired  FVM  stability  due  to  accelerated  dissociation  of the  A2  domain, 
missense mutations at PL binding surfaces, and altered interaction with FIXa (Jacquemin et 
al, 2003).
36Table 1.2 Classification of  haemophilia, taken from (Bolton-Maggs & Pasi, 2003).
Concentration of 
Fvm
Classification Clinical
<0.01 IU/ml Severe Spontaneous  joint  and  muscle 
bleeding;  bleeding  after  injuries, 
accidents and surgery
0.01 -0.05 IU/ml Moderate Bleeding  into joints  and  muscles 
after  minor  injuries;  excessive 
bleeding after surgery and  dental 
extractions
>0.05-0.4 IU/ml Mild Spontaneous  bleeding  does  not 
occur,  bleeding  after  surgery, 
dental extractions, and accidents
Those with haemophilias have a bleeding time which is the same as normal individuals, the 
bleeding tendency is therefore not due to a prolongation in the time taken to clot, rather 
bleeding  occurs  after  a  delay.  In  a  morphological  study  of haemophilic  clots  it  was 
observed that the fibrin plug was thinner than normals and contained red blood cells and 
leukocytes within the centre of the plug (Sixma & van den Berg, 1984).  This suggests, the 
defect in haemophilia is due to an inability to form stable fibrin clots.
The role of TAFI may be a key in the inability to form stable fibrin clots.  Monsnier et al 
demonstrated that at low TF concentrations, not enough thrombin is produced to activate 
TAFI, whereas at high TF concentrations enough thrombin was generated by the extrinsic 
pathway to activate TAFI independent of the intrinsic system (Mosnier et al, 2001).  This 
suggests  that  in  areas  with  low TF concentrations  the  clot may  be  more susceptible to 
fibrinolysis.  The amount of TF is low or absent in the skeletal muscle and in connective
37tissues at joints (Drake et al, 1989), which corresponds to those areas in which spontaneous 
bleeding occurs in severe haemophilia.  Additionally Carr et al have demonstrated that in 
FVffl deficient blood a decreased platelet contractile force is generated which is half that of 
normal plasma.  A consequence of this reduced force is a reduction in the elasticity of the 
clot,  which  is  another  mechanisms  by  which  haemophilic  clots  are  more  prone  to 
fibrinolysis (Carr, Jr. et al, 2002).
1.2.3  Inhibitors
Inhibitors are the main complication of haemophilila as an inhibitor is an antibody which 
neutralises  FV TTT  activity  by  preventing  interactions  with  VWF  (Saenko  &  Scandella,
1997), PL (Barrowcliffe et al,  1983), FIXa (Fijnvandraat et al,  1998;Zhong et al,  1998), 
thrombin (Precup et al,  1991), and FXa (Lollar et al, 1994;Foster et al,  1988).  Inhibitors 
can also cause proteolysis of FVIII (Lacroix-Desmazes etal, 1999;Lacroix-Desmazes etal,
2002).  Epitope mapping studies have shown that inhibitors tend to have restrictive binding 
sites, predominantly on the A2,  C2 and A3  domains on the FVffl molecule (Arai et al, 
1989;Lenting  et  al,  1996rZhong  et  al,  1998;Scandella  et  al,  1995;Scandella  et  al, 
1995Prescott et al,  1997). The highest inhibitor titres are found towards the light chain of 
FVffl (Scandella et al, 2001).  Moreover, recent studies have shown that some inhibitors 
are directed also towards the acidic -al, -a2 and -a3 regions (Barrow et al, 2000;van den 
Brink et al, 2000;Raut et al, 2003b).  It is well known that these acidic-regions are specific 
for proteolytic cleavages via thrombin or FXa and thus constitute important functional sites, 
particularly  in  the  activation  and  inactivation  of FVIII.  Furthermore,  various  models 
(Pemberton  et  al,  1997;Kembal 1-Cook  et  al,  1998;Stoilova-McPhie  et  al,  2002)  have 
predicted that these regions are exposed on the surface of the FVffl molecule and therefore 
may be open to a number of surface proteins.
Inhibitors to FVffl are measured using the Bethesda assay in which the sample plasma is 
incubated  with  an  equal  volume  of pooled  normal  plasma for two  hours  at 37°C.  The 
sample and normal plasma mixture as well as a control are assayed for FVIII as normal.  If 
an inhibitor is present then residual FVIII will be less than the control, a reduction of 50% 
in a two hour incubation period is the definition of one Bethesda unit (Kasper et al, 1975).
38In  haemophilic patients the rate of inhibitor development has been  linked to the type of 
genetic mutation and a higher incidence is found in those with null mutations.  Inhibitors 
affect  24-33%  of  severe-moderate  patients  (Bray  et  al,  1994;Addiego  et  al, 
1993;Ehrenforth etal, 1992).  Inhibitors can also arise in mild patients, although the risk is 
a quarter of those with severe haemophilia (Hay, 1998).  There is some evidence to suggest 
that  in  mild  haemophilias  inhibitors  can  develop  following  intense  FVIII  exposure 
(Sharathkumar et al, 2003).
Two inhibitor outbreaks have been documented following a change in the viral inactivation 
process  used  (Peerlinck et al,  1993;Rosendaal  et al,  1993;Peerlinck et al,  1997).  This 
product showed some unique characteristics,  increased thrombin proteolysis,  more rapid 
FXa generation and enhanced phospholipid binding (Barrowcliffe et al,  1993a;Raut et al,
1998).
Inhibitors  can  also  arise  in  patients  without a  genetic  defect,  which  is  termed  acquired 
haemophilia.  Acquired  haemophilia  is  idiopathic  in  around  60%  of cases,  but  can  be 
associated with malignancy, post partum and autoimmune disorders (Delgado et al, 2003). 
FVm antibodies have also been detected in 17% of normal healthy people (Algiman et al, 
1992;Moreau et al, 2000).  There are also studies which show that FVHI antibodies in both 
normal and haemophilia patients can be neutralised by anti-idiotypic antibodies(Sultan et 
al, 1984;Gilles & Saint-Remy, 1994;Gilles etal, 1996).
1.2.4  Treatment
1.2.4.1  FVIII replacement and prophylaxis
Treatment of haemophilia is by replacing the missing or dysfunctional FVIII.  In patients 
with  mild  or  moderate  haemophilia  this  would  be  after  injury  or  before  a  surgical 
procedure.  Severe  haemophilias  can  bleed  spontaneously  into  the  joints  so  require 
treatment  more  often.  Standard  treatment  used  is  on  demand  therapy  using  a  FVTII 
concentrate  as  required;  however,  prophylaxis  is  now  more  widespread,  especially  in
39children  and has several  advantages.  By maintaining FVTQ at a  low level  spontaneous 
bleeding into the joints can be avoided.  Which when started at a young age prevents the 
development of arthropathy (van den Berg et al, 2001 ;Astermark et al, 1999).  More details 
on FVIII concentrates are given in section 1.2.4.3
1.2.4.2  FVffl bypassing agents
A  major  challenge  to  the treatment of haemophilia  is  the development  of inhibitors  to 
FVm.  Treatment of inhibitor patients can be by immune tolerance in which large amounts 
of FVTTI are given to overcome the inhibitor.  Alternatively a product which bypasses FVIII 
can be given such as the prothrombin converting complex, FEIBA or Autoplex (Lusher, 
1994).  Despite the usage of these bypassing agents for more than 20 years the mode of 
action is unclear, although recent work using a purified system found that a combination of 
InM FXa and  35pM prothrombin  had  the  same  effect  in  vitro  and  in  vivo  as  FEIBA 
(Turecek et al,  1999).  This has been confirmed with a recombinant product showing that 
the previous finding was not due to contaminants (Himmelspach et al, 2002).
A more recent approach to FVHI inhibitors is the administration of high concentrations of 
recombinant FVTIa  (rFVIIa)  at  concentrations  much  higher than  in  normal  haemostasis 
(Seremetis,  1994).  Although the mechanism for FVTIa action is not understood there are 
suggested explanations.  Butenas et al demonstrated that in acquired haemophilia B  lOnM 
rFVIIa  with  an  elevated  number  of  platelets  and  5pM  TF  had  the  same  effect  on 
haemostasis as that of normal plasma (Butenas et al, 2003). This maybe because there is an 
increased amount of FXa generation  at the platelets surface with  elevated  rFVIIa  levels 
(Monroe et al,  1998).  rFVIIa also appears to decrease the permeability of the fibrin clot 
when FVIII or FIX is absent, this may make the clots of haemophilic plasmas resistant to 
premature fibrinolysis (He et al, 2003).
Porcine FVIII is another possibility, although the patient may develop an inhibitor to this as 
well. However, a complication of porcine FVIII is the theoretical transmission of zoonoses, 
and for this reason the manufacture is now discontinued.  A recombinant porcine FVHI is 
now  entering  clinical  trials.  A  conventional  FVHI  concentrate  high  in  VWF  may  be
40beneficial as it may protect FVIII from the antibodies in particular those against the light 
chain (Gensana et al, 2001).
1.2.4.3  Factor VIII concentrates
There  are  essentially  two  types  of  FVIII  concentrates,  plasma  derived  (PD)  and 
recombinant.
1.2.4.3.1  Plasma derived
Cryoprecipitate
Before the advent of cryoprecipitate, the only treatments available to patient were blood 
transfusions and fresh frozen plasma.  This was limiting due to the large volumes of plasma 
that  were  needed  to  cover  a  bleeding  event.  Cryoprecipitate  was  manufactured  by 
removing the plasma and rapidly freezing it, the plasma would then be slowly defrosted in a 
fridge, the precipitate was then isolated by centrifugation.  This process resulted in FVIII 
concentration increasing by 16-fold (Pool & Shannon, 1965).
Intermediate purity
Intermediate purity (IP) products are manufactured from  cryoprecipitate,  which are then 
further purified by heparin precipitation to remove fibrinogen and fibrinonectin.  The FVHI 
is then precipitated with glycine and sodium chloride and lyophilised, the product is then 
dry  heated  as  the  virucidal  step  (United  Kingdom  Haemophilia  Centre  Doctor's 
Organisation, 2003).  These products contain VWF.
High purity
Monoclonal-antibody purified
High  purity  (HP)  concentrates  are  also  made  from  cryoprecipitate.  Fibrinogen  and 
fibrinonectin are removed by centrifugation, and the remaining FVHI is then subjected to a 
solvent/detergent  treatment  to  remove  viruses.  The  product  is  then  applied  to 
immunoaffinity  column  and  the  solvent  and  detergent  are  removed  by  washing  before 
FVffl is eluted.  The eluate is then applied to an ion-exchange column.  The resulting FVffl
41product  contains  a  small  amount  of VWF.  Replenate  is  manufactured  by  the  same 
methodology  (United  Kingdom  Haemophilia  Centre  Doctor's  Organisation,  2003). 
Monoclate is purified by a similar method using an antibody against VWF.
Ion-exchange
The initial steps for this method are the same as for monoclonal-antibody purified.  After 
virus inactivation with solvent and detergent, the product is applied to an anion-exchange 
resin.  The  solvent and  detergent  are  removed  by  washing  steps,  FVIII  is  then  eluted 
(Schwinn et al, 1989).
1.2.4.3.2  Recombinant
Recombinant products are manufactured from cell  lines  which have had the FVIII gene 
inserted; FVIII  is then harvested  from the cell culture media.  These products therefore 
avoid reliance on plasma and in theory has an increased safety profile.
1st Generation
The first recombinant FVIII products to be manufactured were full-length products which 
were manufactured with proteins derived from animal and humans in both cell culture and 
in stabilisation of the final product.
Kogenate
The FVHI gene is inserted  into a baby hamster kidney cell  line.  The resulting FVIII  is 
subjected  to  a number of purification  steps  to  remove  the cell  culture  media and  cells. 
These steps  include,  anion  exchange,  immunoaffinity chromatography  and  gel  filtration. 
The original formulation of Kogenate contained albumin, however it is now manufactured 
without  additional  albumin  and  includes  a  solvent/detergent  viral  inactivation  step 
(Schwartz et al, 1990).
Recombinate
The  rFVin  is  expressed  in  Chinese  hamster  ovary  (CHO)  cell  line.  In  addition,  a 
recombinant VW F is inserted into the cell line to stabilise FVHI.  FVIII is purified from the
42cell  media by  filtration,  immunoaffinity  chromatography and  a two-stage  ion-exchange. 
The final product does not contain VWF (White et al, 1989).  The same FVHI is now also 
manufactured without albumin and is called Advate.
2nd Generation
A  refinement  of the  manufacture  process  was  to  eliminate  the  need  for  human  serum 
albumin  (HAS)  in the  final product, thereby reducing the possibility of transmission  of 
blood bome viruses.
B-domain deleted FVHI
An  improvement  to  the  full-length  recombinant  products  was  the  manufacture  of  a 
recombinant product which was the B-domain deleted (BDD), so called second generation 
recombinant FVIII.  The B-domain  is not thought to play a role  in haemostasis.  BDD 
allowed for a greater expression of FVHI in the cell culture system (Toole etal, 1986).
The BDD product is known commercially as Refacto- It is produced in a CHO cell line in 
which the modified 170 kDa FVIII is inserted as a single chain with a link between serine 
743  and glutamine  1638 (Bemtorp,  1997).  The FVHI is harvested from the cell culture 
medium and subjected to 5 chromotography steps and a solvent-detergent viral inactivation 
step (Eriksson et al, 2001).  Another advantageous property of the BDD deleted product is 
that it does not require stabilisation in the final product by HSA (Osterberg et al, 2001) 
(which is necessary for the full-length products), although HSA is present in the cell culture 
medium.
BDD FVIII  has  been  compared to  full-length  FVIII  in  several  studies  and  found to  be 
comparable (Pitman et al,  1993;Sandberg et al, 2001).  The first clinical study found that 
the recovery and  half-life of BDD  was the  same as a monoclonal  purified  PD  product, 
however,  the  volume  of distribution  and  clearance  were  statistically  higher  with  BDD 
(Fijnvandraat et al, 1997).
43Kogenate-SF
A further development of Kogenate was to manufacture this product without HSA in the 
final product.  However in this product animal proteins are present during the cell culture 
steps.
3rd Generation -Protein free recombinant FVHI
Advate
Manufacture  of  FVHI  without  the  use  of  any  human  plasma  products  is  the  latest 
development for FVIII concentrates which are called third generation.  The removal of all 
human and animal proteins from the manufacture of recombinant products should in theory 
remove  any  possible  transmission  of viruses  and  prion  diseases  such  as  new  variant 
Creutzfeldt Jackob  disease,  which  is  of particular concern due to the use of foetal  calf 
serum during cell culture.  Removal of all  proteins from the manufacture of the product 
Recombinate  led to  the development of the  latest FVIII  product Advate.  In addition,  a 
protein free version of  Refacto is also entering clinical trials.
1.2.4.4 Future developments of FVHI replacement
Due to the high cost and frequency of treatment, improvements such as extending the half- 
life of the FVm molecule are being investigated.  This could be done either by increasing 
the  stability  such  that  the  A2  subunit  cannot  dissociate  so  readily,  or  by  decreasing 
clearance of the FVIQ molecule through LRP mediated clearance.  Only about 20% of the 
global population of haemophilic patients are treated on a regular basis (Jones & Robillard,
2003),  due to the high cost of both  plasma and recombinant FVTQ  products.  Recently 
FVIQ has been expressed in the milk of transgenic pigs (Paleyanda et al,  1997), this could 
offer an approach by which FVQI could be  manufactured both  cheaply and on  a  larger 
scale.
1.2.4.5 Gene Therapy
A long-term goal of the haemophilia community has been gene therapy.  Haemophilia is a 
good  target  for gene therapy  as  there  is  a  large therapeutic  window,  and  only  a  small
44amount of FVIII,  as  in  prophylaxis  would  prevent those  with  severe  haemophilia  from 
spontaneous bleeding.  Gene therapy is the process by which the FVIII gene is administered 
in  a viral  vector which  is  then  able to  enter cells  and  express  FVIII  long-term.  Gene 
therapy has been successful in a number of animal models using adenovirus (Brown et al,
2004)  and adeno-associated virus (Scallan etal, 2003;Sarkar et al, 2004). However, to date 
gene therapy has only shown a small amount of promise in clinical trials (White, 2001).  A 
study of 13 patients with a retroviral vector found small increases in FVIII in nine patients 
with  greater  than  1%  FVIII,  these  levels  though  were  not  sustained.  An  increase  in 
pharmacokinetic  parameters  was  found  with  exogenous  FVIII  infusion,  which  would 
suggest  increased  endogenous  levels  and  five  patients  had  reduced  bleeding  tendency 
(Powell et al, 2003).  Another clinical trial for FVIII used a non-viral vector to transduce 
patient  fibroblasts;  these  were  then  expanded  and  given  back  to  the  patient  A  small 
increase in FVHI level (0.8-4% of normal) was observed in four of six patients (Roth et al,
2001).  These trials suggest that a small amount of FVHI is produced, however, it is very 
difficult to detect due to the sensitivity of FVHI assays.
An alternative approach  may  be to correct the mRNA using  splicesome-mediated RNA 
repair.  Chao et al corrected the haemophilia phenotype in F8 knockout mice by using a 
pre-trans-splicing  molecule  which  could  combine  endogenous  pre-mRNA  FVIII  of the 
mouse  to  form  a  repaired  FVHI  mRNA(Chao  et al,  2003).  The  disadvantage  of this 
technique is that treatment would need to be individualised to the mutation, which would be 
cumbersome in haemophilia as there is a wide range of mutations.
1.2.5  Measurement of FVIII
The level of FVHI must be obtained to diagnose and measure the severity of haemophilia, 
and to measure the potency of the replacement FVHI concentrate.  It is also necessary to 
measure the response to treatment,  pharmacokinetic  studies  and to  measure  response to 
gene therapy.  In addition  measurement of FVIII  is  also  important  in  diagnosis  of von 
Willebrand disease (VWD).
451.2.5.1 Qne-staee APTT assay
The one-stage APTT assay was developed in 1953 by Langdell et al (Langdell et al, 1953). 
The basis of this bio-assay is that of an APTT in which a sample is mixed with a source of 
phospholipid and a contact activator, after an incubation period, calcium is added to start 
the reaction and the time taken for a clot to develop is recorded.  For a FVIII assay various 
dilutions of a  standard and the sample are made in buffer and added to FVIII deficient 
plasma  and  then  tested.  By  plotting  on  a  graph  the  time  taken  to  clot  for  a  known 
(standard) amount of FVDI the amount of FVHI in the sample can be established.  This 
assay is the most commonly used in the clinical laboratory due to the relatively low cost 
and automation of the assay.
1.2.5.2 Two-staee assay
The two-stage assay was developed by Biggs et al in  1955 (Biggs et al,  1955).  The test 
method involves incubation of serum (to provide FX and FIXa), factor V, phospholipid, a 
dilution of the test or standard (which is absorbed first by aluminium hydroxide, to remove 
prothrombin).  Calcium  is  then  added  and  the  mixture  incubated  to  allow  FXa  to  be 
generated, at the end of the incubation period normal plasma (to provide prothrombin and 
fibrinogen) is added and the time required for the plasma to clot is recorded.  This method, 
however,  has  not  reached  widespread  use  as  it  is  difficult  to  standardise,  it  is  time 
consuming to perform and is not readily automated.
1.2.5.3 Chromogenic assay
The chromogenic assay is in effect a two-stage assay.  In the first step FVIII is activated by 
thrombin,  the  second  step  is  the  conversion  of FX  to  FXa  by  the  complex  of FVIIIa, 
phospholipid, FIXa and calcium.  FXa is then measured by colour change of a chromogenic 
substrate (van Dieijen et al, 1987).  The chromogenic assay has a greater precision than the 
one stage assay 2-7% coefficient of variation (CV) (Rosen et al,  1985;van Dieijen et al, 
1987),  as  compared to one-stage assays which  have an  inter-assay variability  of 7-10% 
(Raut et al, 2001).  The chromogenic assay is not widely used in the clinical setting due to 
the high cost of chromogenic substrates.  However, this test is used for the labelling of
46FVffl  concentrates,  particularly  in  Europe as  this  method  is  stipulated  in  the  European 
Pharmacopoeia, and is also recommended by the ISTH for measurement of concentrates.
1.2.6 Standards and units
FVffl assays are comparative in nature.  The clotting times obtained from dilutions of test 
samples are directly compared to those obtained from a standard with a known amount of 
FVIII.  Therefore, to measure the correct potency of a sample it must be assayed against a 
reference standard of known potency.  FVffl potency is measured  in International Units 
(IU),  1  IU is equivalent to 100% of normal.  There are two FVIII International Standards 
(IS),  one  for  plasma,  and  one  for FVIII  concentrates.  These  standards,  in  addition  to 
numerous other coagulation factor standards have been established by the World Health 
Organisation  (WHO),  and are made and  maintained by National Institute for Biological 
Standards and Control (NIBSC).  The IS must be maintained over several years, so it is 
impractical to use them in routine laboratories.  Instead the IS is used to calibrate a working 
standard (British Standard) which is then used to calibrate locally collected normal pools. 
Although not ideal, it is possible to use in clinical laboratories an uncalibrated large plasma 
pool with an arbitrarily assigned value of 100% for each coagulation factor.
1.2.7 Assay discrepancies
Discrepancies in FVIII levels obtained by the different assays and use of different standards 
have been noted for the last 25 years.
The discrepancies between assays have yet to be fully elucidated, and in fact the problem 
has become more complicated with the introduction of increasingly pure FVIII  products 
and  the  differences  in  measurement  by  manufacturers  (chromogenic)  and  that  used  by 
clinical laboratories (one-stage).
There are two FVIII standards in an attempt to overcome some of the assay discrepancies 
by  assaying  like  vs  like,  i.e.  patient  plasma  samples  against  a  plasma  standard,  and 
concentrates are measured against a concentrate standard.  This  makes though  a further 
complication by the range of FVIII concentrates available of differing purities, so that a
47true “like for like” standard is impractical.  The other issue is with post-infusion plasma, 
where it may be more accurate to think of as concentrate diluted in the patient's plasma, 
and therefore a concentrate standard diluted in FVIII deficient plasma may in theory led to 
a more accurate determination of the recovery values and minimise discrepancies.
1.2.7.1  Assays for FVIQ concentrates
When  assaying  very  high  purity  PD  concentrates  and  recombinant  products  a  large 
variation between laboratories was observed ranging from 19-100% (Barrowcliffe, 2003), 
the standard at that time was a concentrate standard derived from an intermediate purity 
product  This would suggest that an intermediate purity product is unsuitable for assays of 
high purity and recombinant products,  implying that separate standards for each type of 
concentrate would be required.  However, further research identified aspects of the assay in 
which  small  modifications  would  improve  the  reliability  with  high  purity  concentrates 
(Barrowcliffe,  1993b).  A  haemophilic  or  artificial  FVHI  deficient  plasma  containing 
normal levels of VWF was required in one-stage APTT assays (Barrowcliffe etal, 1993b). 
Inclusion of albumin in all buffers at a concentration of 1  % improved reproducibility.  Also 
all  concentrates  should  be  initially  diluted  to  approximately  1  IU/ml.  In  addition,  the 
choice of prediluent was shown to affect potency measurement.  With concentrates it was 
found  that  haemophilic  or  artificially  depleted  FVHI  deficient  plasma  was  required  to 
obtain the correct potency for all assay methods, for the one-stage assay higher potencies 
were obtained if FVHI deficient plasma was used (Lee etal, 1983).  However, a difference 
was not observed in the chromogenic assay, possibly due to the presence of bovine serum 
albumin  in  the  buffer  supplied  with  the  chromogenic  kit  (Mazurier et al,  1990).  This 
combined work led to recommendations by the Scientific and Standardisation Committee 
(SSC) of the ISTH (Barrowcliffe, 1993a) which were:
1)  The use of a concentrate standard for FVHI concentrate assays
2)  Test and standard should be pre-diluted in severe haemophilic plasma or artificially 
depleted plasma.
3)  All assay buffers should contain lOmg/ml albumin
4)  The chromogenic method as the reference method
48These  modifications  improved  the  inter-laboratory  variation  in  subsequent  collaborative 
studies,  and  this  led  to  the  adoption  of these  recommendations.  In  a  more  recent 
collaborative study for the 6th IS, the inter-laboratory variation was 7-10% for the one-stage 
and  6-9%  for  the  chromogenic  assays  for  assays  of recombinant  and  plasma-derived 
concentrates against a recombinant standard (Raut et al, 2001).  The 6th IS was the first 
time that a recombinant product had been used as a standard.  A subsequent study showed 
no differences between the use of a PD and recombinant standard (Albertengo et al, 2000).
1.2.7.2  Discrepancies between methods
The  use  of the  same  standard  should  ensure  that all  three FVIII  assays  give the  same 
potency.  However,  the  introduction  of  increasingly  pure  FVIII  products  has  led  to 
discrepancies  between  methods.  It  was  first  noted,  more  than  20  years  ago  in  a 
collaborative study that there  was a large disagreement between  laboratories.  This was 
thought to be mainly due to differences in reagents used.  There were however still some 
differences when the same reagents were used.  The two-stage assay detected more activity 
in a more highly purified  freeze dried preparation that was  tested  against a concentrate 
standard (Kirkwood et al, 1977).  A retrospective study at the same time found that the two- 
stage  assay  consistently  returned  values  which  were  higher  than  the  one-stage  when 
concentrates were assayed against the plasma standard (Kirkwood & Barrowcliffe,  1978). 
Since  these  studies  were  carried  out  changes  in  assay  design  have  occurred,  so  that 
concentrates are assayed against concentrate standards and the adoption of the other ISTH 
recommendations.
Adoption  of the  ISTH  recommendations,  however,  has  not  completely  overcome  assay 
discrepancies.  In a comparison of potency estimation of several concentrates by one-stage 
and two-stage assay, the two-stage assay gave lower results for several products (13-40% 
lower than one-stage).  This was statistically significant for several PD products of high 
purity (Barrowcliffe et al, 1990).  A more recent study between one-stage and chromogenic 
assays was done by Hubbard et al, in which the greatest discrepancy was observed in two 
monoclonal antibody purified products, in which the mean one-stage potency exceeded that
49of the chromogenic potency by 33 and 24%.  The BDD product was unique in this study in 
that the one-stage potency was 22% lower than the chromogenic (Hubbard et al, 2002a).  It 
is thought that the discrepancy between the one-stage and chromogenic assays for the PD 
intermediate products may be due to differences in activation (Hubbard et al, 2002b).  In a 
“field” study in which laboratories all analyse the same sample by their routine methods, 
differences were observed between the methods, these differences were less than 10 % for 
all  concentrates  apart  from  a  monoclonal  antibody  purified  concentrate,  although  this 
discrepancy was minimised by those laboratories which used pre-dilution in haemophilic 
plasma (Raut et al, 2003a).
The BDD product is unique in assay discrepancies in that the value obtained by the one- 
stage assay is lower than that of the chromogenic assay.  This difference can be as much as 
50% (Sandberg et al, 2001 ;Mikaelsson et al, 1998).  However, this large assay discrepancy 
was found to be due to the amount and type of phospholipid used in the one-stage assay, 
when  platelets  were used  in the one-stage assay discrepancies  between  the concentrates 
were eliminated (Mikaelsson etal, 1998).
1.2.7.3  Assays of post-infusion plasma and in vivo recovery
Discrepancies in the calculation of in vivo recovery are also a long standing problem.  In 
1979 Nilsson et al reported a 100% recovery with the APTT assay, whereas only 81% was 
recovered as measured by the two-stage assay when post-infusion plasmas were assayed 
against a plasma standard (Nilsson etal, 1979).
Due to the large variation between  laboratories and between assay methods the assay of 
FVm concentrates against a plasma standard has been avoided by the introduction of two 
standards.  However, it is not quite so straightforward in the case of post-infusion plasma as 
the concentrate administered has just been diluted  in the patient’s plasma, and  in theory 
may well not be equivalent to normal plasma FVIII.
Lower  or  higher than  expected  recovery  levels  suggest  that the  labelling  of the  FVIII 
concentrate may not be correct.  In a retrospective study to examine this, no evidence was
50found of any difference in in vivo recovery value between assays when concentrates were 
assigned potency with either a concentrate or plasma standard (Prowse, 1995).
Several pharmacokinetic studies have been performed to further address the issue of in vivo 
recovery.  A pharmacokinetic study with Hemojil-M found  large  discrepancies.  In this 
study the one-stage gave 26% higher potencies than the chromogenic on the concentrate. 
However,  the  recovery  was  17-28%  higher  by  chromogenic  assay  vs  one-stage  after 
correction for potency labelling (Lee et al, 1996a).  If the concentrate potency was assigned 
by chromogenic and post-infusion samples were assayed by one-stage, the recovery levels 
were higher than predicted by 11 -25%, and this is a situation that would arise routinely.  In 
another  study the  same  group  used  a  recombinant product  and  found  that significantly 
higher  recoveries  were  obtained  with  the  chromogenic  assay.  However,  the  use  of 
Recombinate  diluted  in  haemophilic  plasma  as  the  standard  eliminated  discrepancies 
between the two methods (Lee et al, 1999).
When  concentrate  potency  is  measured  by  chromogenic  assay,  the  recovery  values  are 
higher  when  measured  by  chromogenic  vs  one-stage  assay,  which  would  lead  to  an 
overestimated predicted recovery in a plasma derived product (Lee et al,  1996b), higher 
recovery  levels  have  also  been  demonstrated  for  recombinant  products  (Lee  et  al, 
1999^Lusher et al, 1998).
It has been found that assay discrepancies can be eliminated when a concentrate standard is 
used to assay post-infusion plasma samples (Lee et al,  1999;Mikaelsson & Oswaldsson, 
2002;Mikaelsson et al, 2001).  Traditionally the standard used has been a like vs like i.e. a 
plasma standard  for assays  on  patient samples  and  a concentrate standard  for assays  of 
concentrates.  In the case of post-infusion samples it may be more appropriate to think of 
post-infusion samples as concentrate diluted in the patient’s plasma, therefore a concentrate 
standard diluted in haemophilic plasma would be the more appropriate choice (Barrowcliffe 
etal, 1998).
51A product specific laboratory standard is available for Refacto.  In a comparison of one- 
stage  and  chromogenic  values  in  post-infusion  samples  using  the Refacto  standard  9% 
lower values were obtained with the one-stage assay, which the authors found acceptable 
for assays on post-infusion plasma samples (Sukhu et al, 2003).
Hubbard et al investigated the differences between the assays and found that plasma FVIII 
behaves differently in the chromogenic assay,  with more rapid thrombin generation, but 
slower FXa generation (Hubbard et al, 2001).  This study supports the use of a concentrate 
standard.
1.2.7.4  Assays discrepancies in mild/moderate haemophilia
There is a subgroup of patients with mild haemophilia in whom discordant assay results are 
reported between one-stage and two-stage assays. The one-stage assay is found to give 2-7 
fold more FVIII than is measured in the two-stage assay (Duncan et al,  1994).  Several 
different missense mutations have been reported all occurring in the Al, A2 or A3 domains 
(Rudzki et al, 1996;Mazurier et al, 1997Reeling et al, 1999;Schwaab et al, 2000).  Closer 
investigation of one of these mutations, Arg 531 His, revealed a higher dissociation rate of 
the  A2  subunit  from  the  activated  heterotrimer (Pipe et al,  1999)  and  this  most  likely 
accounts for the differences.
13 Thrombin generation test
1.3.1  Origin
The thrombin generation test (TGT) has been used for almost 50 years, and was originally 
developed by Macfarlane and Biggs (Macfarlane & Biggs,  1953) for use in whole blood 
and simultaneously by Pitney and Dacie for citrated plasma (Pitney & Dacie, 1953).  Both 
methods  were  similar  in  that  blood  or  plasma  was  placed  in  glass  tubes  with  saline, 
subsamples were removed into a fibrinogen solution and the time taken for the fibrinogen 
to clot was measured.
52In more recent years Hemker’s group has developed this assay further.  Initially this group 
used the chromogenic substrate S-2238 for measuring the amount of thrombin generated in 
each subsample.  The advantage of this method was that more subsamples could be taken 
than the limitations involved in performing the TGT on a coagulometer or by hand.  The 
disadvantage  of using  a  chromogenic  substrate  though  is  that  it  reacts  not  only  with 
thrombin  but  also  the  complex  of a2-macroglobulin-thrombin.  However,  this  can  be 
overcome by the use of a simple mathematical procedure applied to the raw data, to obtain 
the amount of free thrombin.  A further refinement of the chromogenic method was the use 
of a  slow  chromogenic  substrate,  this  allowed  the  development  of a  continuous  non­
subsampling system in which samples could be loaded onto a microtitre plate and read at 
regular intervals.  Again  a  correction  needs  to  be  made for a2-macroglobulin-thrombin 
complex.  The disadvantage of the continuous chromogenic method is that the plasma must 
be optically clear i.e. plasma must be defibrinated so that the clot does not interfere with the 
optical  density  (OD)  readings.  The  method  is  also  unsuitable  for measuring thrombin 
generation  in  platelet  rich  plasma  PRP,  which  must  be  performed  by  a  subsampling 
methodology.  The most recent advances  in the TGT has been the use of a fluorogenic 
substrate  (Hemker et al,  2000),  which  is  unaffected  by  the turbidity  of the  plasma and 
allows thrombin generation to be determined in plasma which is un-defibrinated, in PRP 
and also possibly in whole blood.
1.3.2  TGT in haemostasis
Although  the  TGT  has  never  reached  widespread  use  in  haemophilia  treatment,  a 
chromogenic  version  was  used  to  monitor  the  effect  of  DAAVP  infusion  in  mild 
haemophilia (Keularts et al, 2000), and has been used to study FVIII-inhibitor bypassing 
agents (Turecek et al, 2003 ;Barrowcliffe et al, 1983).  The TGT has  been used extensively 
in anticoagulant studies (Hemker, 1987;Hemker & Beguin, 2000;Lawrie etal, 2003) and is 
becoming more widespread since a commercial company was established in 2002 which 
provides the software necessary to convert a fluorescent signal into thrombin generation in 
real time (Hemker et al, 2003).
531.3.3  Other global tests for haemostasis
The increase in use of the thrombin generation test has been mirrored by increasing use of 
other  tests  which  measure  global  haemostasis.  The  first  of  these  was  the 
thromboelastogram (TEG), which although it has also been in use for almost 50 years, has 
been  used  principally  by  anaesthetists  to  measure  the  haemostatic  profile  during  liver 
operations (Vig et al, 2001).  Ingerslev et al have used the ro-TEG (which is a modified 
version which records the data electronically, which allows for post-test analysis) to study 
patients with haemophilia but have transformed the data in such a way that it resembles a 
thrombin generation curve, this method is now known as ROTEM [321 /id].  However, the 
parameters  measured  are  different  in  that  die  first  derivative  is  die  velocity  of clot 
formation;  therefore  the  ROTEM  only  provides  information  about  the  initiation  of 
coagulation.  The ROTEM at low TF  concentrations  clearly  shows  differences between 
normal  and  those  with  severe  haemophilia  A,  however,  at  high  TF  concentration  the 
velocity of clot development was similar (Sorensen et al, 2003).  The ROTEM has also 
been shown to be sensitive to FVIII levels less than 0.001 IU/ml when triggered with a low 
TF concentration.
He at al have developed an assay to determine the haemostatic potential of plasma (He et 
al, 2001).  This assay is based on the principal of adding a small amount of thrombin and t- 
PA to the plasma and monitoring aggregation of fibrin at 405nm. Thrombin converts the 
fibrinogen to fibrin and the t-PA produces plasmin, which is then able to break down the 
fibrin.  The area under the fibrin curve represents the overall haemostatic potential (OHP). 
In this assay, a commercial FVIII deficient plasma did not generate a detectable OHP (He 
et al, 2001).  With inclusion of platelets in the system FVIII <1% generated an OHP of less 
than  the  2.5  percentile  of the  normal  reference  range,  FVIII  of  1-5  and  6-15%  was 
distinguishable from the FVIII deficient plasma, and at 30% FVIII the OHP entered into the 
fifth percentile which was classified as a normal OHP (Antovic et al, 2003).  This method 
is also applicable to measurement of hypercoaguable situations and monitoring of heparin 
treatment (Antovic et al, 2002).
54Calatzis et al have developed a thrombin dynamics test (TDT) in which the dynamics of the 
initial  thrombin  formation  is  assessed.  This  method  was  able  to  distinguish  between 
different FVTO levels (Calatzis et al, 2003).
Carr et al developed a test for measuring the thrombin generation time, which is measured 
from the platelet contractile force.  Both FVIII and FIX deficiency resulted in a prolonged 
thrombin generation time.  Replacement of FVIII decreased the thrombin generation time 
to normal (Carr et al, 2003).
The PT and APTT clotting times are detected on automated coagulometers by changes in 
the  light  transmittance,  and  from  this  other  parameters  can  be  obtained  to  give  more 
detailed information on formation of the clot  The raw data can currently only be detected 
from one machine, the MDA 180 by Organon Teknika (Braun etal, 1997).  When clotting 
is  measured  by  the  APTT  a  biphasic  waveform  occurs  in  patients  with  disseminated 
intravascular coagulation (DIC) (Downey et al, 1997).  This is particularly valuable as the 
changes in the waveform are apparent before the standard laboratory tests can indicate DIC 
(Downey et al,  1998;Toh et al, 2002).  An abnormal waveform has also been observed in 
patients with anti-phospholipid antibodies when the PT is measured (Su et al, 2002).  This 
technique has also been applied to haemophilia and was able to differentiate between FVin 
concentrations down to 0.002 IU/ml (Shima etal, 2002).
1.4  Aims
The aim of this study was to use a more physiological approach to the TGT to investigate 
assay discrepancies.  This  was  to be by examination of thrombin generation  profiles  of 
various FVHI concentrates of differing purities under various assay conditions,  including 
the use of platelets.  In addition differences between concentrates were also to be examined 
using a purified FXa generating assay.  It was also planned to use the TGT to examine 
thrombin generation in haemophilic plasmas, to see if this assay would be more sensitive 
than  currently  used  assays,  and  also  to  examine thrombin  generation  profiles  at trough 
FVm levels in a group of patients on prophylaxis.
55CHAPTER 2 
MATERIALS AND METHODS
2.1 Plasma preparation
Haemophilic plasmas
Blood was collected into citrated tubes (Tri-sodium citrate 0.106 M).  Blood was spun at 
3000g for 15minutes at 4°C.  Plasma was removed and the centrifugation repeated.  Plasma 
was kept frozen in aliquots at -80°C.
Normal pooled plasma
Seven units of normal plasma were obtained from the National Blood Service (Colindale, 
London).  These  were  collected  by  conventional  venepuncture  into  citrate  phosphate 
dextrose-adenine (CPD-A) anticoagulant, containing 0.106 M total citrate, at a ratio of 6ml 
CPD-A to 450ml whole blood.  Each unit was centrifuged twice, and was buffered by the 
addition  of HEPES,  final  concentration  20mM.  The  units  were  pooled  and  frozen  in 
aliquots at -80°C.
22 FVIII assays
2.2.1 One-stage APTT assay 
Reagents
Glyoxaline:  50mM Imidazole,  lOOmM NaCl, 0.02%  sodium azide,  1   %
APTT reagent:
FVm deficient plasma: 
Deca coagulometer 
FVm standards
(v/v) HSA (Zenalb, BPL, Elstree, Herts) 
IL (Warrington, UK)
Technoclone (Dorking, Surrey)
Grifols (Barcelona, Spain)
20th British Standard for plasma
6  IS for FVIII concentrates
th
56Method
A standard and all test samples were diluted by 1 in 10, 1  in 30 and 1   in 100 in glyoxaline 
buffer. Samples were assayed in a reverse balanced order.  100pi of APTT reagent,  100pi 
of FVIII deficient plasma and lOOpl of test or standard dilution were warmed at 37°C for 5 
minutes on a Deca coagulometer.  lOOpl of Ca2+ was then added and the time taken for the 
mixture to clot was recorded by the Deca coagulometer, which detected clotting by means 
of a mechanical end point.
The FVIII concentration in the samples  was obtained by use of a parallel  line  software 
package (NIBSC  in-house software), comparing the unknown FVIII concentration in the 
test sample to the known amount of FVIII in the standard.
2.2.2 APTT blank time
lOOpl APTT lyophilised silica, lOOpl FVIII deficient plasma, 100pi glyoxaline buffer was 
incubated for 5  minutes at 37°C on Deca coagulometers, at which point lOOpl Ca2+ was 
added and the time taken for the clot to form was recorded.  Each plasma was measured in 
duplicate in a reverse balanced order.
2.2.3 Chromogenic FVIII assay 
Reagents
Coatest C/4 kit  Chromogenix (Quadratech, Epsom, Surrey)
FVm deficient plasma  Organon (Biomerieux, Basingstoke, Hampshire)
Method
FVffl was measured using a Coatest C/4 kit. The manufacture’s instructions were followed. 
FX/FIXa, PL and substrate were reconstituted.  The dilution buffer was made by diluting 
stock buffer 1  in 10 with water containing 1% HSA.
FVHI concentrates and standards were diluted to 6 IU/ml in FVIII deficient plasma, they 
were then further diluted to 1   IU/ml in buffer.  Test dilutions were then made in replicate 
with buffer to 1  in 50, 1  in  100 and 1  in 200.  Samples were loaded in a reverse balanced
57order on the ACL 3000 (IL) and the kit reagents added as required. Plasma samples were 
treated as above apart from no predilution and use of a plasma standard.  The ACL 3000 
was set up in the following manner.  25pi of sample was incubated with 75 pi of combined 
reagent for 300 seconds,  subsequently 50pl of chromogenic substrate was added,  OD at 
405nm was measured following a further 220 second incubation period.
FVIII concentration was established by parallel-line bioassay as describe in 2.1.1, using OD 
values instead of clotting times
2.2.4  FVUI:Ag binding assay (ELISA)
Reagents
Glycine buffered saline (GBS) pH 9.2:
Phosphate buffered saline (PBS) pH 7.4:
PBS-Tween (PBS-T):
PBS/HSA
Orthophenylenediamine (OPD)
Microtitre plate
Method
A 96-well microtitre plate was coated with  lOOpl  of a monoclonal  anti-FVIII  Ab F7B4 
(kind gift of Dr Saint-Remy) at a dilution of 1   in 1000 in GBS and incubated overnight at 
4°C.  The plate was then washed 4 times with PBS-T and blocked with PBS containing 5% 
HSA for 1   hr at room temperature (RT).  The plate was then washed again 3 times with 
PBS-T.  FVIII for the standard curve was diluted in PBS-T and  lOOpl was added to the 
plate, samples were added to the plate also and incubated for 2hours at RT.  The plate was 
once again washed 3  times with PBS-T and  lOOpl  of a  rabbit polyclonal  anti-FVm  Ab 
(Kind gift from Dr Ingerslev) was added at a dilution of 1  in 2000 in PBS-T and incubated 
for  1   hr at RT.  The  plate  was  washed  and  the  Tag  antibody  horseradish  peroxidase- 
conjugated Goat Anti-Rabbit immunoglobulins (DAKO)  lOOpl was added at  lin 2000 in 
PBS-T for lhr at RT.  After a final washing,  lOOpl of OPD substrate was added and the 
colour allowed  to  develop  for 30minutes  before termination  of the reaction  with  lOOpl
20mM glycine, 34mM NaCl
20mM  Na2 HP04,  67mM  KC1,  4.4mM
KH2 P04,140mMNaCl
PBS with 0.05% (v/v) Tween 20
PBS with 5% (v/v) human serum albumin
Dako (Ely, Cambridgeshire)
Maxisorp (Nunc, Sigma, Pool, UK)
580.5M  sulphuric  acid.  The  plate  was  read  at 490nm  in  a  Spectramax  250  plate  reader 
(Molecular Devices, Wokingham, Berkshire).
23 Thrombin generation tests
2.3.1  Clotting method 
Reagents
Tris buffered saline (TBS): 
TBS/HSA:
Saline:
Fibrinogen
FTXa
TF
PL
Thrombin
FVffl deficient plasmas
50mM Tris, 150mM NaCl, 0.02% NaN2 
TBS containing l%(v/v) human serum albumin 
154mM NaCl
Diagen bovine fibrinogen (Diagnostic Reagents,
Thame, Oxon)
11  IU/ml/  834nM  NIBSC  (97/572).  Derived  from 
recombinant  FIX,  which  was  then  activated  with  FXIa. 
Ampoules reconstituted with water and snap frozen. 
RecombiPlasTin  (IL).  Batches  were  calibrated  by  Steve 
Thomas  using  a  protrhombin  time  assay  against  NIBSC 
preparation  94/738,  which  had  previously  been  calibrated 
against American Diagnostica Lipidated Recombinant Tissue 
Factor  (Product  4500L,  Greenwich,  CT,  USA).  TF  was 
reconstituted with 1  Omls water and used within two weeks. 
Derived from bovine brain, consists of PC 24.7%, PE 38.9%, 
PS 28.5%, PI  5.7%,  SM 2.2% (as analysed by HPLC using 
Folch extracts by Bill Pickering).  lOmg/ml NIBSC (91/542), 
ampoule reconstituted in water and aliquots snap frozen 
100 IU/ml NIBSC (89/588)
Organon (Biomerieux, Basingstoke, Hampshire) 
Dade-Behring (Sysmex, Milton Keynes)
Technoclone (Dorking, Surrey)
Sigma (Poole, UK)
59Defibrination of plasma
Plasma was defibrinated with ancrod (55 IU/ml 74/581) final concentration 0.5 IU/ml for 
30 minutes at 37°C.  The clot was then removed by winding onto a wooden applicator stick. 
If plasma was not defibrinated before use in the TGT then die clot would develop during 
the course of the assay, at which point the clot was wound onto a wooden stick and all 
plasma squeezed out of the clot which was then left in the reaction.
Method
400pl plasma was incubated with 80pl FIXa (diluted 1  in 10) for 90 seconds at 37°C, after 
which 400pl PL (lOpg/ml) was then added.  Finally 400pi CaCh (25mM) was added at 2 
minutes to initiate thrombin generation.  Reaction mixture was mixed and placed in a pre­
warmed Eppendorf repeator pipette, at timed intervals of between 15-60 seconds 50pl was 
added to 200pi of fibrinogen, which was contained in a rotating cup on a Deca machine. 
The time taken for the clot to form was measured for 18 subsamples on two machines.  The 
amount of thrombin  in each subsample  was calculated from a thrombin  standard  curve, 
which was made from a range of thrombin 50-0.39 IU/ml.
Data analysis
To  calculate  the  amount  of thrombin  generated  at  each  time  point  clotting  times  were 
inputted into “tap” which was an in-house (NIBSC) programme.  Tap calculated thrombin 
in each sample from a thrombin standard curve, the programme plotted each point on a 
graph and calculated area under the curve (AUC).  Peak-height was determined from the 
transformed data.  Time-to-reach-half-peak-heigh (Ti/2m ax) was determined by reading from 
the graph the point at which half the peak height had been generated.
602.3.2  Fluarogenic method 
Reagents
A 1  OmM solution of Z-gly-gly-arg-AMC (Bachem, St Helens, UK) was prepared in 20mM 
Hepes,  150mM  NaCl,  60mg/ml  bovine  serum  albumin  (BSA,  Sigma)  and  10%  (v/v) 
DMSO.  This solution was aliquoted and stored at -40°C.
Method
40pi of un-defibrinated plasmas were loaded onto a black microtitre plate (Greiner, Sigma). 
The substrate mixture was prepared by combining all remaining reagents, 1  part substrate 
lOmM: 2.55 parts FIXa (97/572, diluted 1 in 10):  11.72 parts Ca2+  (25mM): 12.76 parts PL 
(91/542, lOpg/ml).  The mixture was warmed at 37°C and 80pl was added to each well on 
the  microtitre  plate.  In  each  well  the  plasma  was  diluted  by  two-thirds,  and  the  final 
concentrations were:  substrate 0.238mM, FIXa 5nM, Ca2+ 7mM, PL 3pg/ml.  The plate 
was placed in a Spectramax Gemini XS (Molecular Devices) at 37°C.  The plate was read 
at 30 seconds intervals for 1  hr, with excitation at 390nm and reading at 460nm.
Data analysis
The  data  was  exported  into  an  excel  file  and  the  amount  of thrombin  generated  was 
calculated according to the method by Hemker (Hemker & Beguin,  1999) (Table 2.1, Fig 
2.1).  This method was used by Hemker et al to determine the amount of free thrombin in a 
continuous  TGT  with  a  chromogenic  substrate,  and  also  with  a  fluorogenic  substrate 
(Hemker et al,  2000).  However,  recently this  group has developed  another method  for 
determination of thrombin in the fluorogenic TGT (Hemker et al, 2003).
61Table 2.1 Calculation of  free thrombin from relative fluorogenic units.  Subsampling times 
are entered into column B and corresponding RFU values are entered into column C.  In 
column E the amount of  product due to a2-macrogloubulin-thrombin activity is calculated. 
In column D the amount of  product due to the activity of  free thrombin is calculated using 
an assumed value ofk (cell $F$1).
A B C D E F
1
Time Data
Product from 
thrombin
Product from a2- 
macroglobulin
k
2 0.5 0 0 0 =sum(F112:F122)
3 1 =C3-E2 =E2+($F$1 *D3)
4 1.5 =C4-E3 =E3+($F$1 *D4) =(D4-D3)/0.5
5 2 =C5-E4 =E4+($F$1 *D5) =(D5-D4)/0.5
121 59.5 =C121-E120 =E120+($F$1*D121) =(D121-D120)/0.5
122 60 =C122-El 21 =E121+($F$1 *D122) =(D122-D121)/0.5
14000 
2   12000 
£  10000   data
8000
product from thrombin
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Fig 2.1 Calculation of  free thrombin
62Cell F2  is the sum of the last ten derivateives of thrombin generation  in column F, this 
value should be zero as free thrombin is assumed to have reached the zero level.  The value 
of K (Table 2.1) is set such that the sum (cell F2) is equal to, or close to zero.  However, in 
practice this was difficult to achieve due to the large variation in readings at the plateau.
This is the calculation that is performed in order to calculate the contribution by the a2- 
macroglobulin  which also combines with chromogenic and fluorogenic substrates.  This 
data calculation was developed by Hemker et al for the chromogenic substrate, but has also 
been used by them for fluorogenic calculation.  However, I have adapted this slightly for 
use with the fluorogenic system as the method for determination of k did not work on a 
practical  level, due to the large variation in values at the plateau phase due to the large 
number of units, so that a value close to zero was not possible in a vast number of cases, 
and even with the same plasma source the values of k varied widely.  In order to achieve 
comparable results k was set to 0.155 for all assays.  This allowed a thrombin generation 
curve to be obtained for all plasmas used and at all FVIII concentrations tested.  Using k at 
0.155 there was a similar CV between the final fluorogenic reading which is also a marker 
for endogenous thrombin potential (ETP) and the AUC, which after transformation of the 
data was 4.8 and 4.6% respectively, this was measured for normal plasma in 48 wells.  A 
comparison  between  the  ETP  and  AUC  for  different  FVIII  concentrations  was  also 
established  and  expressed  as  a  percentage  of normal  plasma,  with  comparable  results 
between the two parameters (Table 2.2).
Table 2.2 Comparison o f thrombin generation at different FVIII concentrations by ETP and 
AUC.
NP 100 50 25 12.5 6.25 3.1 1.58 0.78 BL
ETP 100 81.8 80.9 77.9 77.4 73.7 72.2 74.8 72.0 57.2
AUC 100 82.2 80.4 78.4 76.8 73.9 71.6 74.3 72.0 57.0
63A macro was established to calculate free thrombin.  From the free-thrombin data time-to- 
peak and peak-height were established (Table 2.3).  In addition AUC was calculated by the 
trapezium rule.
Table 2.3  Equations for the calculation ofpeak height and time to peak from free thrombin 
values.
A B C D
1 1 2 3
2 Time to peak =INDEX($A$6:$A$12533,1) =INDEX($  A$6: $  A$ 125,C3,1) =INDEX($A$6:$A$125,D3,1)
3 =M  ATCH(B436  125,0) =MATCH(C4,C6:C 125,0) =M  ATCH(D4,D6:D 125,0)
4 Peak height =MAX(B6:B125) =MAX(C6:C125) =MAX(D6:D125)
5 1 2 3
6 1 Data Data Data
7 1.5 Data Data Data
2.4  Factor Xa generation assay 
Reagents
Tris/EDTA  175mM NaCl, 50mM Tris, 7.5mM EDTA pH 8.4
S-2765  Chromogenix (Quadratech)
Human FXa  Haematologic Technologies (Pinewood Plaza, VT, USA)
Method
lOOpl of EDTA buffer was added to each well of a 96 well flat-bottomed micro-titre plate 
(Greiner).  300pl  hirudin  (Revasc,  23.3pg/ml),  300pl  phospholipid  (91/542,  50pg/ml), 
300pl FX (98/574  1   IU/ml),  300pl FIXa (97/562, 0.4 IU/ml) were heated together for 5 
minutes at 37°C.  Heated separately were FVIII (6 IU/ml) and CaCh (25mM).  At the end 
of incubation time, 300pl CaCh was added along with 300pl FVIII and reaction started.  At 
timed  intervals  50pl  subsamples  were  removed  into  the  EDTA  buffer  which  stop  any 
further  generation  of FXa.  In  some  experiments  FVIII  was  activated  with  thrombin 
(89/588,  NIBSC),  FVIII  was  incubated  wth  thrombin,  at  the  end  of this  step  further 
activation of FVHI was terminated by addition of hirudin, the remaining reagents were then 
added.  Once all subsamples were obtained, 50pi  1.5mM S2765 was added to each well, 
after 3 minutes the colour developing reaction was terminated with 50pl 50% acetic acid.
64The plate was read at 405nm, OD values were converted into FXa concentration using a 
FXa standard prepared with Human FXa.
2,5  Platelet Isolation 
Blood collection
Acid citrated dextrose-A (ACD-A)  70mM  sodium  citrate,  40mM  citric  acid,  120mM
glucose, pH 5.0).
Blood was collected from healthy volunteers that had not consumed any non-steroidal anti­
inflammatory agent for at least 7 days prior.  Blood was taken by venipuncture from the 
antecubital vein.  8.5 parts of blood was drawn into 1.5 parts into the citrate anti-coagulant 
ACD-A.
Platelet isolation
Whole blood was spun at 150g for 10 minutes and the PRP was removed.  PRP was mixed 
with 1/10 the PRP volume of ImM adenosine and incubated for 5 minutes at RT, 1/10 the 
volume of ACD-A was then added.
Albumin density gradient
A 50% albumin solution was prepared by adding  5  g of bovine serum albumin  (Sigma, 
A7906) to  10 mis  of water and  allowed to  dissolve undisturbed  at 4°C.  2mls  of 50% 
albumin was placed at the bottom of a centrifuge tube.  Layered on top of this was  1   ml 
each of 25,17,12 and 10% solutions diluted in Hepes buffer.
3 mis of the PRP prepared above was then layered onto the albumin density gradient and 
spun at 650g for  15  minutes.  The plasma and some of the albumin  was  removed,  the 
concentrated platelets at the interface of the 50% layer were carefully removed along with 
some of the albumin.
65Gel filtration
HEPES buffer- 137mM NaCl,  2.7mM KC1,  ImM MgCl2,  5.5mM glucose,  0.35% 
BSA, 3mM NaH2 P04 and 3.5mM HEPES, pH 7.3.
Preparation o f  column
Column was made up of a 60 ml monoject syringe for the column and at the bottom of the 
syringe a 25mm diameter stainless steel filter support (Millipore, XX3002510) on top of 
which was placed a 40 nm nylon mesh filter (25mm diameter) which was held in place by 
an O-ring.  Sepharose 2B (Amersham) was washed with 3  volumes of saline to remove 
storage  ethanol,  and  then  suspended  in  saline.  A  small  volume  of sepharose  2B  was 
pippetted into the bottom of the capped syringe, carefully avoiding air bubbles between the 
filter and the sepharose.  More sepharose was transferred into the column until 20mls was 
reached, at which point the syringe was uncapped and the buffer allowed to flow through 
the column, more sepharose was added until the final bed height was 50 mis.  The packed 
column was attached to a gravifax machine and washed through with 3 volumes of saline at 
a flow rate of lml/min.  Once prepared the column was stored at 4°C.  Before each use the 
column was brought to room temperature and then equibrilated with one bed volume of 
Hepes buffer with glucose and albumin.  After each use the column was washed through 
with 2 volumes of saline.
The albumin containing platelets was then carefully applied to the top of the column with a 
plastic Pasteur pipette.  The platelets were then eluted and collected in 1 ml fractions with 
Hepes buffer containing glucose and albumin at a rate of lml/min.  All  platelet fractions 
were pooled together and 1/10 of the volume of ACD-A was added, platelets were spun at 
lOOOg for 5  minutes,  the supernatant was  removed and  the platelets  resuspended  in  the 
residual  buffer.  Platelets  were  allowed  to  recover for  30  minutes  at room  temperature 
before being used in thrombin generation assay.
66CHAPTER 3 
STUDIES OF FVIII CONCENTRATES
3.1 Introduction
Discrepancies between chromogenic and one-stage APTT assays have led to an uncertainty 
about the  true  FVIII  level.  An  accurate  FVTH  level  is  critical  in  the  management  of 
haemophilia and should reflect the haemostatic effectiveness of FVIII concentrates so that 
patients  are  neither under or over-treated.  We have thus  applied  a more physiological 
approach by using the TGT to assess the potential haemostatic effectiveness of different 
FVIII therapeutic concentrates.
This chapter describes the studies of a wide range of FVTII concentrates using the clotting 
TGT and a FXa generating assay.
3.2 Initial investigations
The TGT method at NIBSC was  established by Barrowcliffe et al  in which  one part of 
plasma was incubated with one part PL and one part Ca2+ in glass tubes, subsamples were 
then taken into fibrinogen (Barrowcliffe et al, 1983).  A further modification was made to 
standardise activation with FIXa instead of glass (Barrowcliffe et al, 2002).  In this study, 
to  optimise  the  TGT  for  measurement  of  FVIII  concentrates  a  number  of  further 
modifications were made.  These included addition of various commercial FVIII deficient 
plasmas and investigation of optimal PL concentration, each one described below.
3.2.1  Choice o f FVIII deficient plasma
A FVm deficient plasma was required which would give minimal thrombin generation on 
its own, so that all thrombin generation would be due to the FVHI concentrate alone.
Three  different  FVHI  deficient  plasmas  were  examined:  Dade-Behring,  Immunads  and 
Organon.  Dade-Behring  and  Technoclone  plasma  were  depleted  by  FVIII  antibodies, 
whereas  Organon  was  depleted  by  a  chemical  method,  all  plasmas  contained  a  normal
67VWF  level.  Plasmas were first defibrinated by incubation with ancrod for 30 minutes at 
37°C.  Ancrod is a snake venom from the Malayan viper (iCalloselasma rhodostoma) which 
acts  as  a fibrinogen  activator,  acting on  the a-chain,  it  however,  has  no  effect on  FXIII 
(Hutton  &  Warrell,  1993).  Thrombin  generation  was  measured  in  duplicate  on  three 
occasions  by  incubating  400pl  defibrinated  plasma  with  80pl  FIXa  (84nM),  400pl  PL 
(50pg/ml)  and  400pl  Ca2+  (25mM).  All  the  FVIII  deficient  plasmas  produced  some 
thrombin (Fig 3.1).  The plasma from  Dade-Behring produced the most thrombin with an 
AUC  of 2156.1 ±690.5  IU.seconds,  Technoclone  produced  1496.3±378.2  IU.seconds  and 
Organon formed the least amount of thrombin, AUC  1358.3±682.5 IU.seconds.  Although 
these  differences  were  not  significant,  due  to  the  large  variation  in  these  experiments, 
Organon was chosen for subsequent use.
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Fig 3.1 Thrombin generation by three commercial FVIII deficient plasmas.
3.2.2  Phospholipid concentration
The next step was to establish the optimal concentration of PL.  A concentration of PL that 
would give minimal thrombin generation by the FVIII deficient plasma alone and maximal 
separation  between  different FVIII  concentrations  was  desired,  so  that  if there  were any 
differences between FVIII concentrates, they would be detected.
68Thrombin  generation  was  measured  in  Organon  FVIII  deficient  plasma  with  PL 
concentrations of between 50 and 5pg/ml (Fig 3.2) in duplicate samples.  There was almost 
no thrombin generation with the very low concentration of PL (5 pg/ml) and in the absence 
of PL.  However, a considerable amount of thrombin  was generated at 10 and 7.5pg/ml, 
and was greater than that generated by higher concentrations of PL 50 and 25 pg/ml.  This 
suggested that the optimal concentration for thrombin generation was between 5-10 pg/ml.
Time (seconds)
Fig 3.2 Thrombin generation with a range of PL concentrations (0-50 pg/ml) in Organon 
FVIII deficient plasma n =2.
Dose-response experiments were performed at PL concentrations of 5 fig/ml and  lOpg/ml 
using Replenate (a FVIII concentrate).  Replenate was added to the FVIII deficient plasma 
to give a FVTQ  concentration  in  plasma of 1, 0.5,  0.25  and 0.125  IU/ml.  The thrombin 
generation profiles were very similar and there was no discemable difference between 0.5 
and 0.25 IU/ml FVIII, T^max 134 and 129 seconds respectively (Fig 3.3 A).  Dose-response 
experiments  were  repeated  for  other  concentrations  of PL.  At  a  PL  concentration  of 
lOpg/ml there was maximal separation between FVHI concentrations (Fig 3.3 B), as with a 
difference  between  0.5  and  0.25  IU/ml  FVIII  of Ti/2m ax  79  and  94  seconds  respectively. 
lOpg/ml of PL was selected for subsequent experiments.
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Fig 3.3 Dose-response of thrombin generation to FVIII with two concentrations of PL. A) 
PL 5jug/ml, B) PL lOjug/ml., n=I
703.2.3  Summary o f TGT conditions
The final experimental conditions  were to activate 400pi defibrinated plasma with  80pi 
FIXa (84nM), to give a FIXa concentration in plasma of 14nM for 90 seconds, followed by 
400pl PL (lOpg/ml) and 400pi  Ca2+(25mM).  This  resulted  in final  reaction  mixture in
2 “h which  plasma  constituted  30%  of the  final  reaction  volume,  with  PL  3.1  pg/ml,  Ca 
7.8mM and FIXa 5.2 nM.  All samples analysed were tested in duplicate on three separate 
occasions.  These experimental conditions have been used throughout unless  mentioned 
otherwise.
33 Initial dose-response of Replenate
Once  the  initial  experimental  conditions  for  the  thrombin  generation  test  had  been 
established, the experimental conditions were examined more rigorously by performing a 
dose-response over a wider range of FVIII concentrations.  These were compared to the 
thrombin generation profile of pooled normal plasma (NP).
Replenate was spiked into artificial chemically depleted FVIII deficient plasma (Organon) 
over a range of FVIII concentrations from 0.005 to  1  IU/ml and the thrombin generation 
measured.
It was found that as the concentration of FVHI decreased from  1  to 0.005 IU/ml the lag 
time of the curves as represented by the Tv^ax lengthened from 64 to 165 seconds (Fig 3.4). 
At concentrations of 1  (T >/2  m ax 64±15  seconds) and 0.125  IU/ml  (Ti/2inax 87±4.2  seconds) 
thrombin was generated more rapidly than normal plasma (Ti/2inax  118±9 seconds), and a 
concentration  of 0.03  IU/ml  (T^ax  119±5  seconds)  had  a  similar  thrombin  generation 
profile to that of normal plasma.  A large amount of thrombin was generated at 0.005 IU/ml 
with a longer lag-time to 165±18.8 seconds.  An unexpected finding was that Replenate at 
0.125 IU/ml generated thrombin more rapidly than normal plasma (0.86 IU/ml).  The lag­
time with the concentrate was only comparable to normal plasma at a concentration of 0.03 
IU/ml.  This will be discussed more fully in section 3.6.
71However,  in  the  same  experiments,  peak  thrombin  was  unaffected,  and  only  a  small 
decrease in the AUC was observed.  Even at a FVTEI concentration of 0.005 IU/ml the AUC 
was only slightly lower than that of normal plasma,  6540±334 and 6728±328 IU.seconds 
respectively.
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Fig 3.4 Thrombin generation by Replenate at FVIII concentrations 0.005-1 IU/ml. Replente 
was added to Organon FVIII deficient plasma.
3.4  Reproducibility of TGT
The  reproducibility  of thrombin  generation  was  measured  by  repeated  measurement  of 
normal pooled plasma, and deficient plasma (Technoclone) with the addition of Replenate 
at 0.02 and 0.005 IU/ml.  Thrombin generation was performed as stated above.  The assays 
were run in duplicate on 5 different days (Table 3.1)
72Table 3.1  Reproducibility o f TGT parameters.  Normal plasma,  and Replenate added to 
Technoclone FVIII deficient plasma, n =5.
AUC
(IU/ml.seconds)
% T%  max
(seconds)
% Peak (IU/ml) %
Mean SD CV Mean SD CV Mean SD CV
NP 6069 410.5 6.8 122.5 13.1 10.7 37 4.6 12.3
0.02 IU/ml 6916 347 5 262.4 13.8 5.3 41.9 2.33 5.6
0.005 IU/ml 6372 586 9.2 361 35.4 9.8 35.7 4.16 11.7
The TGT  was  reproducible  with CVs of between  5  and  12.3%.  The  lowest CVs  were 
observed not at normal FVin concentrations, but at 0.02 IU/ml, in which the parameters 
varied by 5-6%, whereas in normal plasma this was 7-12%.  The lowest CVs were observed 
for AUC and the greatest variation was in the measurement of peak height.
3.5  Comparison of concentrates
Seven  different  FVIII  concentrates  including  both  plasma  derived  and  recombinant 
products  were  analysed  (Table  3.2).  All  products  were  ampouled  lyophilised  NIBSC 
preparations,  an  ampoules  was  reconstituted  with  1ml  water for each  experiment.  The 
experimental conditions used to measure TG were as described in 3.3 above with Organon 
FVni deficient plasma.
All concentrate potencies were assigned by chromogenic assay.  All concentrates at 1  IU/ml 
produced thrombin more rapidly, and in greater quantity, than normal plasma.  The Ty2  m ax 
of Refacto  (48±8  seconds) was  shorter than that of the other concentrates  (range  54±4- 
64±15 seconds); this difference was statistically significant, p<0.05 (Fig 3.5, Table 3.3).
There  was  no  difference  between  the  concentrates  in  terms  of peak  height  or  AUC. 
Therefore all the concentrates were capable of generating the same amount of thrombin 
with the only difference being in the time at which this occurred with Refacto being the 
most rapid.
73Table 3.2 Details of FVIII concentrates used in this study
Concentrate NIBSC code Fractionation VWF
Recombinant
Refacto B domain deleted 99/694 Recombinant None
Recombinate Full length recombinant 96/598 Recombinant,  ion 
and  immuno 
chromatography
exchange
affinity
None
Kogenate Full length recombinant 96/590 Recombinant,  ion 
and  immuno 
chromatography
exchange
affinity
None
Plasma derived
Replenate High  purity  monoclonal 96/574 Monoclonal  antibody  affinity VWF: Ag <FVIII:C
antibody purified chromatography
Hemoftl-M High  purity  monoclonal 95/640 Monoclonal  antibody  affinity VWF. Ag <FVHI:C
antibody purified chromatography
Octavi High purity ion-exchange 96/600 Ion exchange chromatography Contains VWF: Ag>FVIII:C
8Y Intermediate purity 96/576 Heparin/glycine precipitate Contains VWF: Ag>FVQI: C40
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Fig 3.5  Thrombin generation  by FVIII concentrates at  1  IU/ml.  FVIII concentrates were 
added to Organon FVIII deficient plasma.
Table 3.3.  Thrombin generation parameters of  FVIII concentrates at 1 IU/ml.  *=p<0.05
AUC (IU. seconds) T./2m ax (seconds) Peak (IU/ml)
Refacto 7888±758 48±8* 40±2
Recombinate 7514±649 57±8 39±2
Kogenate 7519±1496 64±6 38±3
Replenate 7789±997 63±8 40±3
Hemofil-M 7195±811 64±15 38±3
Octavi 7700±799 54±4 41 ±2
8Y 7246±815 64±9 40±2
NP 6174±735 118±9 38±3
75The same seven FVIII  concentrates were then  measured at a lower FVIII concentration  of 
0.03 IU/ml (Fig 3.6, Table 3.4, Fig 3.7).  There were no differences found in terms of peak 
height or AUC,  this  was  anticipated as  no  significant differences  had  been  observed  at  1  
IU/ml for these parameters.
There  was  however,  a  significant  variation  in  T >/2m ax  values  between  the  concentrates 
(ANOVA p<0.01) (Fig 3.7).  Refacto generated thrombin significantly fester than Kogenate, 
Replenate,  Hemofil-M  and  8Y  (t-test  p<0.05).  However,  the  T./2m ax  values  were  not 
significantly shorter for Refacto when compared to Recombinate or Octavi.  Kogenate was 
once again the concentrate to generate thrombin at the slowest rate.
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Fig 3.6 Thrombin generation by FVIII concentrates at 0.03 IU/m FVIII..
76Table 3.4 Ty,m ax valuesof thrombin generation for FVIII concentrates at 0.03 IU/ml FVIII.
T Vi max 
(seconds)
Refacto 107.7 ±8.6
Recombinate 120.0 ±11.4
Kogenate 126.3 ±1.9
Replenate 119.2 ±5.0
Hemofil-M 126.0±12.8
Octavi 112.2 ±5.8
8Y 122.6 ±9.79
Refacto  Recombinate  Kogenate  Replenate  Hemofil-M  Octavi  8Y
Fig 3.7 T > /im ax values of thrombin generation for FVIII concentrates at a concentration of  0.03 
IU/ml.
77All experiments above were performed on defibrinated plasma.  To see if there were any 
differences  between  the  concentrates  in  the  presence  of fibrinogen  or  fibrin,  thrombin 
generation was performed on un-defibrinated plasmas.  Thrombin generation was carried out 
as before, the clot formed during the course of the assay, was wound onto a wooden stick and 
the plasma removed by squeezing the clot against the side of the tube.  The clot itself was 
then left within the reaction mixture.
A dose-response was performed initially with Replenate with a PL concentration of lOpg/ml 
(Fig  3.8A).  However,  it  was  difficult  to  distinguish  differences  between  FVIII 
concentrations.  In addition,  a  greatly reduced amount of thrombin  was  generated  in  un- 
defibrinated plasma as compared to 3.3 above (these findings are explored in more detail in 
chapter 5).  To enhance the differences between FVIII concentrations the PL concentration 
was increased to 50pg/ml resulting in a clearer dose-response (Fig 3.8B), and more thrombin 
generation.
A small group of FVIII concentrates were compared in un-defibrinated plasma (Fig 3 .9) with 
a  PL  at  50pg/ml  and  FVIII  concentrations  of  1   and  0.03  IU/ml.  No  differences  were 
observed in AUC, T'/2 m ax ? and peak in un-defibrinated plasma.
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Fig 3.8 Dose-response of thrombin generation to FVIII in un-defibrinated plasma with two 
concentrations of  PL. A) PL lOpg/ml, B) PL 50pg/ml.  Replenate in Organon FVIII deficient 
plasma, n=2
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Fig 3.9 Ihrombin generation by FVIII concentrates in un-defibrinated plasma at two FVIII 
concentrations.. A-1 IU/ml B 0.03 IU/ml, n  1
803.6  Investigation of rapid thrombin eeneration  in Oreanon FVIII deficient plasma
It was noticed that adding FVIII concentrates to the commercial chemically depleted FVIII 
deficient plasma  (Organon)  caused thrombin  to be  generated  more  rapidly than  in normal 
plasma, even at much lower FVIII concentrations (Section 3.3, Fig 3.4).  The unusual finding 
may  be  because  the  plasma  has  been  activated,  during  manufacturing  and/or  the 
lyophylisation  process,  or  because  all  FVIII  concentrates  give  more  rapid  thrombin 
generation than normal plasma.  In an effort to  investigate the phenomenon further, normal 
plasma was diluted into the Organon FVIII deficient plasma to give final concentrations of 
12.5, 3  and 0.5% NP (Fig 3.10).  It was surprising to find that a dilution of 12.5% normal 
plasma  generated  thrombin  more  rapidly  than  undiluted  normal  plasma.  Equivalent 
thrombin generation was observed with only 3% of normal plasma diluted in Organon FVIII 
deficient plasma.  These findings suggest that the FVIII deficient plasma was the cause of 
rapid thrombin generation rather than the concentrates, enhancing thrombin generation at all 
FVIU levels, but having a profound effect on thrombin generation at low FVHI levels.
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Fig  3.10  Thrombin  generation  by normal plasma  in  Organon  FVIII deficient plasma. 
Normal plasma was diluted in Organon to give 12.5, 3 and 0.5% normal plasma..
81To further ascertain if these findings were due to the choice of FVIII deficient plasma a dose- 
response was carried out by diluting Replenate in severe haemophilic plasma obtained from a 
patient 91  hours post-infusion and compared to Organon FVIII deficient plasma (Fig 3.11 
Table 3.5).  Replenate in Organon plasma consistently generated thrombin more rapidly than 
the same concentration of Replenate in haemophilic plasma, as demonstrated by shorter time- 
to-peak.  These differences were significant between the time to reach peak-height at each 
FVIII concentration tested, p<0.001.  Furthermore, in the Organon plasma the same time to 
peak-height as in normal plasma, occurred at 0.03 IU/ml whereas in haemophilic plasma this 
occurred at 1 IU/ml.
The reduced lag-time of thrombin generation which was observed in Organon (Fig 3.10) was 
not observed when normal plasma was diluted in haemophilic plasma (data not shown), or 
when Replenate was used in a different commercial deficient plasma which was prepared by 
monoclonal antibody depletion (Section 5.3.1, Fig 5.1).
Table  3.5  Time-to-reach peak height (seconds)  by Replenate  in  Organon  or haemophilic 
plasma.
Replenate
NP 1  IU/ml 0.125 IU/ml 0.03 IU/ml 0.005 IU/ml
Organon 172.5±15.7 117.5±19.9 153±12.5 170±7.7 220±27.9
HP1 91 hours 180±10.6 190±22.5 220±18.2 262.5±22.7 420±21.2
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Fig 3.11.  Effect on thrombin generation of  different FVIII deficient plasmas over a range of 
FVIII concentrations.  Bold lines-Replenate  in  Organon FVIII deficient plasma.  Dashed 
lines-Replenate in severe haemophilic plasma.
These results suggest that the choice of FVIII deficient plasma is important in the TGT.  The 
anomalies  in  lag-time  with  Organon  plasma  may  be  due  to  the  way  in  which  it  was 
manufactured as this promotion of thrombin generation was not observed in haemophilic or 
in a commercial plasma prepared in a different manner.
3.7  Measurement of FXa generation
Thrombin  generation  curves  were  remarkably  similar  for  all  concentrates  tested.  From 
previous  studies  it  is  known  that there  are  major  differences  in  rate  and  amount  of FXa 
generated by different FVIII concentrates (Kemball-Cook et al,  1993).  The FXa assay was 
used  to  investigate  differences  between  the  FVIII  concentrates  used  in  this  study  and  to 
examine why these differences occur.
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83The FXa generation assay measures the ability of FVIII to partake in the tenase complex. 
FVHI is incubated with FX, PL, FEXa and Ca2+ to form the tenase complex.  Hirudin is also 
added to the system to inhibit any thrombin activation of FVTH, so that all FXa generation is 
due  to  activation  of FVIII  by  FXa.  The  same  method  was  used  as  that  developed  by 
Kemball-Cook et al (Kemball-Cook et aly  1993), with the inclusion of a modification.  This 
was to subsample into buffer containing EDTA which terminated any further FXa generation 
during the incubation of the subsample with the chromogenic substrate (see chapter 2.3)
The FXa generation profile was  measured  for all FVTH concentrates.  There was  a wide 
variation between the concentrates in the amount and time of FXa generation (Fig 3.12-3.14).
There were distinct differences  between the concentrates and the time at which FXa was 
generated.  As  the purity of the FVIII  concentrates  increased  so  did  the  amount of FXa 
generated.  Recombinant FVIII products all produced FXa at around the same time following 
a  lag-time  of 30  seconds,  followed  by  the high  purity  concentrates,  in  which  there  was 
considerable  difference  between  the  ion-exchange  and  monoclonal  antibody  purified 
products.  The  intermediate  purity  8Y produced  less  FXa  and  later  than  all  the  other 
concentrates (Fig 3.12), this was similar to previous findings.
Refacto generated FXa most rapidly (T./2m ax 61±4.3 seconds) followed by Kogenate (71±2.52 
seconds)  then  Recombinate  (79.2±6.3)  these  were  significantly  different  from  Refacto 
p<0.05, 0.001 respectively.  The difference in T./2m ax was also found to be significant between 
the  two  full-length  recombinant  products  p  <0.05.  There  were  significant  differences 
between all the other concentrates in the Ty2m ax (Fig 3.13) pO.001.
Despite these differences in the time at which FXa was generated amongst the recombinant 
products,  this was not translated  into differences  in the rate at  which FXa was generated 
(calculated from the linear portion of the curve) (Fig 3 .13). There was no difference between 
the recombinant products Refacto  11.5±1.3, Recombinate  11.6±2.1  and Kogenate  11.7±1.4 
nM/min.  There were however, significant differences between all the other concentrates in
84the  rate  at  which  FXa  was  generated,  Replenate  3.4±0.2,  Hemofil-M  2.6±0.2,  Octavi 
0.75±0.06 and 8Y 0.4±0.02 nM/min, P<0.001.
Refacto
Recombinate
Kogenate
Replenate
Hemofil-M
Octavi
8Y
12  i
10
10000 1000 100 10 1
Time (seconds)
Fig 3.12 FXa generation by FVIII concentrates at a concentration of 1 IU/ml FVIII.
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Fig 3.14 Rate of  FXa generation by FVIII concentrates at 1 IU/ml
863.7.1  Thrombin activation
The next step was to investigate the effect of thrombin activation on FVIII and the effect this 
has on FXa generation, as FVIII in vivo is activated predominantly by thrombin and not FXa.
For  these  experiments  two  FVIII  products  were  chosen;  one  full-length  recombinant 
(Kogenate) and on intermediate purity concentrate (8Y).  These two were chosen as Kogenate 
generated FXa rapidly when unactivated,  whereas 8Y was the slowest product to generate 
FXa.
In the first instance FVIII activation was initiated with increasing concentrations of thrombin 
(0.001 - 0. llU/ml).  Thrombin activation was then terminated after 30 seconds by addition of 
hirudin  to  the  reaction  mixture.  Both  concentrates  reached  maximal  activation  with  0.1 
IU/ml thrombin (Fig 3.15).  The results were more interesting however, at lower thrombin 
concentrations.  Whereas  8Y  was  sensitive  to  levels  of 0.001  IU/ml,  Kogenate  lacked 
sensitivity until levels of0.004 IU/ml were used.
The effect of incubation time (30seconds-10minutes) was then studied using a concentration 
of 0.004 IU/ml thrombin (Fig 3.16).  Maximal thrombin activation occurred at 4 minutes for 
Kogenate and 6  minutes for 8Y.  Again  8Y was more  sensitive than Kogenate to  shorter 
incubation times with just 15 seconds reducing the lag-time for FXa generation.
The final stage of these experiments was to study all concentrates with 0.004 and 0.1  IU/ml 
thrombin activation, to see if this reduced the differences between the concentrates in Ti/2m ax 
and rate of FXa generation (Fig 3.17-3.19, Table 3.6, Table 3.7).  A concentration of 0.004 
IU/ml did not overcome the differences in FXa generation as there were still differences in 
both time and rate of FXa generation between the different types of concentrates, although 
the differences were reduced  in comparison to no thrombin (Fig 3.12).  The recombinant 
products reacted differently to the PD concentrates, in that at maximal thrombin activation 
although a significant reduction was observed in T > /2m ax p<0.001, there were no differences in 
the rate of FXa generation.  The PD concentrates all produced a significant increase in FXa 
generation and a significant reduction in Ti/2m ax values for both 0.004 and 0.1 IU/ml thrombin
87activation, P<0.001.  However even at maximal thrombin activation despite the reduction of 
the differences between the concentrates there was still variation between the concentrates in 
Tvim ax and  in the rate of FXa generation (ANOVA p<0.001  and <0.01  respectively).  The 
shortest time to  T./2m ax  was  observed  for the plasma derived  concentrates Hemofil-M and 
Replenate, whilst the greatest amount of FXa generation was observed for the recombinant 
Refacto and the PD 8Y and Octavi.
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Fig  3.15  Effect  of thrombin  concentration  on  FVIII activation.  FVIII  (6  IU/ml)  was 
activated by thrombin (0-0.1 IU/ml) for 30 seconds at 37°C.  The activated  FVIII was then 
added to  hirudin,  then  to  remaining  reagents.  A-  Thrombin  activation  of Kogenate  B- 
Thrombin activation of  8Y.
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Fig  3.16  Factor Xa generation following  activation  by  thrombin.  FVIII  (6 IU/ml)  was 
activated by thrombin (0.004 IU/ml) for between 15 seconds and 10 minutes, FVIII was then 
added  to  hirudin,  then  remaining  reagents.  A-  Thrombin  activation  of Kogenate,  B- 
Thrombin activation of  8Y.
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Fig 3.17 FXa generation of FVIII concentrates following activation  by thrombin. A- FXa 
generation following activation by 0.004 IU/ml thrombin for 30 seconds.  B- FXa generation 
following activation by 0.1 IU/ml thrombin for 30 seconds.
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Fig 3.19, Rate of  FXa generation following thrombin activation
92Table  3.6  Tyimax of FXa generation by FVIII concentrates following activation with 
thrombin
I '/imax  (sC C O Ild s)
No thrombin 0.004 IU/ml 0.1 IU/ml
Refacto 61.4±4.3 58.6±3.4 30.3±3.9
Recombinate 79.3±6.2 75.1±5.8 33.4±3.6
Kogenate 71.0±2.5 69.2±6.6 24.1 ±1.9
Hemofil-M 207.8±12.0 164.9±8.7 24.3±2.3
Replenate 177.4±5.2 93.6±5.6 25.1±3.3
Octavi 426.9±54.3 125.8±12.6 28.4±2.2
8Y 622.9±47.8 192.8±7.9 33.8±4.3
Table 3.7 Rate ofFXa generation o f  FVIII concentrates following activation with thrombin
Rate of FXa generation nM/minute
No thrombin 0.004 IU/ml 0.1 IU/ml
Refacto 11,54±1.4 12.7±0.8 12.8±1.2
Recombinate 11.6±2.1 10.6±1.0 11.3±0.7
Kogenate 11.7±1.4 10.7±1.8 10.6±0.6
Hemofil-M 2.7±0.2 5.1±1.1 10.5±1.0
Replenate 3.4±0.2 6.1 ±0.6 10.9±0.8
Octavi 0.8±0.06 4.2±0.7 12.4±0.8
8Y 0.4±0.02 1.4±0.07 12.6±1.8
933.7.2 Effect o f VWF
It is thought that the amount of VWF in FVHI concentrates may affect the amount and rate of 
FXa generation,  as VWF  may  interfere  with FVm activation.  This  may explain  why  in 
earlier  experiments  8Y  which  contains  VWF  is  always  slower  and  produces  less  FXa 
compared with more highly purified FVIII products.
In  this  experiment,  PD  VWF  (kind  gift  of Prof Mazurier,  LFB,  Lille,  France)  which 
contained VWF:Ag 200 IU/ml was added to the recombinant concentrate Kogenate.  For this 
experiment Kogenate,  which  was  from  a  product  vial,  reconstituted  and  snap  frozen  in 
aliquots, was used as opposed to the ampuoled NIBSC material.  This change in Kogenate 
was  necessary,  as  a higher concentration  was needed  in  order to  test a number of VWF 
concentrations.  VWF was added to FVIII for 5 minutes at 37°C before addition to remaining
^  I
FXa reagents  (PL, FX, FTXa,  hirudin,  Ca  ), and the assay was  carried out as previously 
described.  The results showed (Fig 3.20) a prolongation in the time for FXa to be generated 
and a decrease in the amount of FXa formed when increasing VWF was present.  For the 
curves of 8Y and Kogenate to have a similar lag-time for FXa generation, VWF was required 
at a ratio of 10:1, this is far in excess of the amount of VWF found in 8Y which is present at a 
ratio of 3:1 (Raut et aly  1999).
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Fig 3.20 Effect of VWF on FXa generation by Kogenate, ratio ofVWF.Ag toFVIILc.  8Y was 
included  for comparison (3:1),  n  1.
Subsequent experiments  were  performed  with  a  range  of FVHI  concentrates  of differing 
purity and adding VWF to these concentrates at a ratio of 4:1  (Fig 3.21).  It was found that in 
these  experiments  a  ratio  of 4:1  VWF  when  added  to  Kogenate  caused  equivalent  FXa 
generation  compared  to  8Y,  there  was  no  significant  differences  between  the  two 
concentrates in Tv^nax  (Fig 3.22) or in rate of FXa generation (Fig 3.23).  However, the other 
concentrates  (Refacto,  Recombinate,  and  Replenate)  generated  FXa  more  rapidly,  with 
shorter  Ty^ax  values,  this  was  found  to  be  significantly  different  from  8Y and  Kogenate 
p<0.01.  These concentrates also generated FXa more rapidly with Refacto and Recombinate 
generating FXa at a rate twice that of 8Y and Kogenate.  Refacto, Recombinate and Replenate 
were also found to generate FXa at a significantly faster rate than 8Y and Kogenate p<0.01.
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Fig 3.21.  FXa generation of  FVIII concentrates with the addition of VWF to a ratio of 4:1, 
no additional VWF added to 8Y.
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Fig 3.23 Rate  of FXa generation following addition  of VWF to FVIII concentrates  (4:1) 
except 8Y.
973.8  Discussion
At 1   IU/ml all FVIH concentrates tested behaved similarly in the thrombin generation test, 
with the exception of Refacto which produced thrombin significantly more rapidly (P<0.05) 
than the other concentrates.  It was interesting that the wide range of FVIII concentrates, 
from  a  plasma  derived  intermediate  purity  concentrate  to  highly  purified  recombinants 
products should produce thrombin at the same rate.  This suggests that the potencies obtained 
by chromogenic assays using high dilutions give a good prediction of their ability to generate 
thrombin  at physiological  concentrations,  and  hence possibly  of their haemostatic  effect. 
Refacto  was  the  only  concentrate  to  be  significantly  different  in  the  rate  of thrombin 
generation at 1   IU/ml.  Refacto is a high purity recombinant concentrate and is structurally 
different from other recombinant concentrates in that the B domain is absent.  Other studies 
have  found  BDD  FVHI  to  be  functionally  comparable  to  full  length  FVIII  products 
(Sandberg  et  al,  2001)  except  in  the  ability  to  bind  to  phospholipids.  This  difference 
however, is reduced with the use of a physiological source of phospholipid such as platelets 
(Mikaelsson et al, 1998). Despite the differences observed between concentrates at 1 IU/ml, 
no other substantial differences were observed at a lower concentration of 0.03 IU/ml or in 
un-defibrinated plasma.
The results from the experiments looking at the addition of normal plasma to the artificially 
depleted plasma indicate that the more rapid thrombin generation seen with the concentrates 
compared to normal plasma is an artefact of the particular deficient plasma used.  Chemical 
depletion  with EDTA followed by addition of Factor V is  a well established method for 
production of FVDI deficient plasma with normal VWF levels (Chantarangkul eta l,  1978), 
and  such  plasmas  are  widely  used  as  substrates  in  one-stage  FVIII  assays.  The  same 
phenomenon was not observed with immuno-depleted and haemophilic plasmas.  However, 
the total amount of thrombin generated at low levels was still high with these plasmas, which 
would suggest that this finding was not an artefact of the chemically depleted FVIII deficient 
plasma.
There were large differences between the concentrates  in the ability to generate FXa in a 
purified system.  FXa was generated most rapidly by the recombinant products, and slowest
98by the intermediate purity product 8Y.  These results are in agreement with those found by 
Kemball-Cook et al in a similar FXa generating assay (Kemball-Cook et al, 1993), although 
they attributed the differences between the concentrates to the presence of FVIIIa.  We have 
however, demonstrated that differences in the rate of FXa generation are due to the VWF 
content of the concentrates, as the addition of VWF to the concentrates caused a delay and 
decreased the amount of FXa generated.  This effect of VWF has also been  observed by 
Koppelman et al in which VWF was found to inhibit FXa generation, if present at the start of 
the reaction (Koppelman et al, 1994).  These findings may be explained by the observation 
that VWF  inhibits  cleavage  of FVIII  by FXa  (Koedam et al,  1990).  Furthermore,  they 
suggest that in a purified system, FVIII in complex with VWF is less able to support FXa 
generation following activation by FXa.  It has also been suggested that VWF prevents FVIII 
from  binding to PL prematurely  (Saenko et al,  1999a) and this  may also account for the 
increased lag-time when VWF is present, as without FVIII binding to PL the tenase complex 
is unable to form.  This corresponds to our findings in which FXa generation was delayed 
and a smaller amount produced in those concentrates containing VWF.  However, addition of 
an equal amount of VWF to a range of highly purified FVIII concentrates did not result in the 
same FXa generation profile as that of the intermediate purity product 8Y, and would suggest 
that although the majority of the differences in FXa generation is due to VWF, this does not 
account for all variation.
Differences  in generation of FXa were observed between the concentrates upon treatment 
with thrombin, with a concentrate containing VWF showing increased FXa generation with a 
low concentration of thrombin, whereas the same concentration of thrombin had no effect on 
a recombinant product.  Other work has shown that thrombin cleavage of FVIII is enhanced 
by the presence of VWF which increases cleavage in the light chain of FVHI (Arg 1689) by 
eight-fold (Hill-Eubanks & Lollar,  1990).  This would explain our findings  in that at low 
concentrations  of thrombin  or  with  short  incubation  times  concentrates  containing  high 
amounts of VWF show a dramatic response.  This is most likely due to VWF increasing the 
cleavage of FVIII,  so that a greater proportion of the FVIII present is  in  the active form 
before the termination of the thrombin activation step by hirudin, and is thus able to generate
99FXa more rapidly.  However, following activation with low concentrations of thrombin, FXa 
generation is still more rapid in concentrates which do not contain VWF.
Upon full thrombin activation of the FVIII concentrates there were still small differences in 
the time and rate of FXa generation.  However, these differences do not seem to discemibly 
affect  thrombin  generation  as  the  only  difference  observed  was  the  decreased  time  for 
thrombin generation to occur for Re  facto, even though FXa was not more rapid than any 
other recombinant concentrate when fully activated by thrombin.  The differences between 
the  FXa  assay  and  the  TGT  and  differences  between  concentrates  are  because  they  are 
measuring different things.  The FXa assay is measuring one component in the pathway to 
thrombin  generation.  Only  a  small  amount  of  FXa  is  required  for  full  prothrombin 
activation.  In addition, large amounts of thrombin are generated in the TGT which is much 
greater than the concentration required for full activity in the FXa generating assay, which 
will produce full and rapid activation of FVIII in the TGT.  Also differences in VWF content 
are equalled out in the TGT by use of FVIII deficient plasma containing normal VWF levels.
3.9  Summary
Differences  were observed between the concentrates  in a FXa generating assay,  with  the 
most rapid FXa generation by recombinant products and the slowest FXa generation by an 
intermediate  purity  product.  These  differences  were  mainly  due  to  the  different  VWF 
content  of the  concentrates  and  there  was  no  difference  in  FXa  generation  when  the 
concentrates were fully activated by thrombin.  Despite the differences in FXa generation the 
only difference observed in thrombin generation was that Refacto generated thrombin more 
rapidly than the other concentrates at 1  IU/ml.
100CHAPTER 4 
STUDIES AT LOW FVIH LEVELS
4.1 Introduction
Findings from the previous chapter demonstrated a surprisingly large amount of thrombin 
generation even at FVIII concentrations of 0.005 IU/ml.  This was an unanticipated finding 
as die sensitivity of the one-stage APTT and chromogenic assays are generally 0.01  IU/ml. 
A concentration of FVIII <0.01  IU/ml is associated with a severe clinical profile in which 
spontaneous  bleeding occurs,  thus  a much  reduced  thrombin  generation profile  would be 
anticipated at these severe FVm levels.  The experiments in this chapter further investigate 
the sensitivity of the TGT to FVIII.
Another avenue that is explored in this chapter is the protection of FVIII against anti-FVin 
antibodies  by  a  complex  of FIXa  and  PL.  Previous  work  by  Barrowcliffe  et  al  had 
demonstrated protection of FVHI by FIXa and PL, although this protection was mostly due to 
the action of PL (Barrowcliffe et al,  1983).  In light of our findings, i.e. a large amount of 
thrombin generated by small amounts of FVIII it was decided to re-investigate the role of 
FIXa in protecting FVIII from antibodies.
42 Results with haemophilic plasma
It was observed that some variation was occurring in the  amount of thrombin generated by 
the commercial FVIII deficient plasma (Organon) between batches.  Also, as the concentrates 
had  been  tested  in  a  commercial  plasma  it  was  desirable  to  test the  findings  in  severe 
haemophilic plasma.  Commercial plasma is preserved by lyophilisation and may therefore 
be unphysiological.
4.2.1 Thrombin generation in two severe haemophilic plasmas
Initially thrombin generation was measured in two severe haemophilic patients.  The plasma 
was obtained from HP1  at 37 hours post-infusion, the sample taken from HP2 was obtained 
at 72hours post-infusion.  These plasmas generated a large amount of thrombin (Fig 4.1) with
101AUC  almost  two  thirds  that  of  normal  plasma  (HP1  4532±753,  HP2  4765±339,  NP 
6934±749  IU/ml.s).  This  finding was  unexpected as  both plasmas  had been  measured by 
one-stage APTT assay and found to contain less than 0.01 IU/ml FVIII.  More plasma was 
obtained  from  HP1  at  61  and  91  hours  post-infusion,  these  generated  considerably  less 
thrombin  (AUC  331±253  IU/ml.s  at  61  hours  1414.4±260.6  IU/ml.s  at  91  hours  post­
infusion) than at the earlier time point.  As all samples contained less than 0.01  IU/ml FVIII, 
this suggests that thrombin is generated by FVDI below this level.  The reduction in thrombin 
generation from patient HP1  with plasma taken at a longer duration post-infrision suggests 
that more FVDI was present in the original sample,  due to the presence of residual FVIII 
concentrate.  This is in contrast to patient HP2 in which the original sample was taken at 72 
hours  post-infusion and  suggests that thrombin  generation  in this patient may  be due to  a 
small amount of endogenous FVDI.
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Fig  4.1.  Thrombin generation  by normal plasma and  two  haemophilic patients.  Three 
samples were obtained from one patient (HP1) at 37,  61 and 91 hours post-injiision,  and 
patient 2(HP2) at 72 hours.
102To confirm that the large amount of thrombin generated by HP1  at 37 hours post-infusion 
was  due  to  FVIII,  the  plasma  was  incubated  with  a  polyclonal  anti-FVUI  antibody  (Ab) 
overnight (Fig 4.2).  If thrombin generation was not due to residual FVIII in the plasma then 
no difference in the amount of thrombin generated by control  and anti-FVIH  Ab would be 
observed.
To test this  a rabbit polyclonal anti-FVHI  Ab was added to normal and HP1  37hours  at a 
dilution of 1  in 1000 for the FVIII Ab and at lOpg/ml for the control Ab (Gammabulin).  The 
plasma and antibody mixtures were incubated at 37°C overnight.  The thrombin generation 
test was then carried out as before.
Treatment  with  anti-FVHI  Ab  abolished  thrombin  generation  in  both  normal  (AUC 
5514.75±551.5  IU/ml.s  for  control  to  329.3±110.0  IU/ml.s  for  anti-FVIII  Ab)  and  the 
haemophilic  plasma  (AUC  3655.4±661.3  to  146.4±38  IU/ml.s  for  anti-FVHI  Ab  treated), 
which was significant for both  plasmas,  t-test p<0.001.  These findings suggest that FVIII 
<0.01  IU/ml is indeed being detected by the thrombin generation test and that if all FVHI is 
removed no thrombin is generated
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Fig  4.2.  Thrombin  generation  of normal  and  haemophilic  plasma following  overnight 
incubation at 37 °C with polyclonal rabbit anti-FVIII antibody or control (gammabulin).
1034.2.2  Prophylaxis study
Due to the high sensitivity of the thrombin generation test it was decided to use the TGT in a 
clinical  setting  by  examining  the  thrombin  generation  profile  of  a  group  of  severe 
haemophilic  children  on  prophylaxis  regimes.  The  children  were  6-14  years  old  and  all 
received  prophylaxis  treatment  three  times  a  week  with  500  or  1000  U  of Refacto  or 
Kogenate.
Samples  were  obtained  from  8  children  that  attended  clinic  during  a  five  month  period. 
Samples were measured for thrombin generation using the clotting method with a high FIXa 
concentration  to  start  the  reaction.  The  samples  were  collected  at  54-128  hours  post- 
infusion.  The FVm  level  of the  samples  was  measured  by  one-stage  assay  on  the  ACL 
10,000 at the Royal Free Hospital by Dr Dale Owens.
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Fig 4.3  Thrombin generation by severe haemophilic patients at trough FVIII levels during 
prophylaxis treatment (n=l)
104Table  4.1  Thrombin  generation  parameters  of prophylaxis  samples  as  a percentage  of 
normal plasma (m  l)
Sample ID 401161 401162 401164 401182 401192 401193 401229 401303
FVm IU/dl 0.4 3.0 0.6 2.7 0.4 0.6 1.0 0.8
%  of 
NP
AUC 43.23 2.53 73.08 85.26 44.92 64.19 57.65 82.41
Peak 21.86 - 59.54 83.74 22.10 48.85 58.12 67.52
Time to 
peak
323.08 261.54 123.08 353.85 215.38 169.23 184.62
There was a wide variation in the amount of thrombin generated (Fig 4.3 Table 4.1) between 
the samples which ranged from <0.4-3.0 IU/dl FVIII.  In particular one sample generated 
absolutely no thrombin during the 20 min duration of the assay.  This was an unexpected 
finding as this plasma was found to contain 3 IU/dl FVHI.  However, this child had a central 
line.  Although the line was flushed before the sample was taken it is possible that heparin 
contaminated the  sample.  If this  was  the  case then  the TGT  is  much  more  sensitive to 
heparin than the one-stage assay.
More  thrombin  was  generated,  and  a decrease  in  lag-time  was  observed  with  increasing 
FVIII levels.  The peak and time-to-peak were significantly correlated with the FVIII level in 
this  experiment,  peak  ^=0.58,  p<0.05,  time to peak  r2=0.58  p<0.05  after removal  of the 
outlier.  These samples were also run with the fluorogenic method and discussed in section
5.9.2
43 Commercial FVlll deficient plasma
During the course of experiments  it had been observed that variable amounts of thrombin 
were being generated by different batches of commercial FVDI deficient plasma containing 
less than 0.01  IU/ml FVDI.  It was decided to investigate this more fully by investigating 
Organon and a range of commercial FVIII deficient plasmas.
105The five  most  widely  used  commercial  plasmas  were  selected  from  a UK NEQAS  study 
(April  2001).  These  were:  Dade,  Technoclone,  Sigma  ,  IL  and  Organon.  Organon  is 
manufactured  by  a  chemical  process,  the  other  plasmas  are  produced  using  an  lmmuno- 
depletion method with antibodies against FVIII or VWF.  Organon, Technoclone and Dade 
all contain normal levels of VWF, whereas the plasmas by Sigma and IL are also deficient in 
VWF.  All plasmas were assayed for FVIII in a chromogenic assay and all contained < 0.01 
IU/ml FVm.  There was a wide range in the amount of thrombin generated and the lag-time 
(T‘ /jinax) of the commercial plasmas (Fig 4.4, Table 4.2).
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Fig  4.4.  Thrombin generation  by commercial FVIII deficient plasmas containing  <  0.01 
IU/ml FVIII.
106There was a wide range in the amount of thrombin produced both between manufacturers and 
with Organon, between batches.  The greatest amount of thrombin (AUC) was generated by 
Organon,  which  was  100%  of normal  plasma.  The  least  amount  was  33%  which  was 
generated  by  Technoclone.  This  is  still  considerably  higher  than  that  generated  by 
haemophilic  plasma  at  91  hours  post-infusion  which  generated  23%  of normal  plasma. 
Although a considerable amount of thrombin is generated in FVIII deficient plasmas the lag­
time  in  all  cases  was  prolonged  when  compared  with  normal  plasma,  and  markedly 
prolonged in those FVIII deficient plasmas with a peak height of <7 IU/ml thrombin.  There 
was no difference in the amount of thrombin generated by those plasmas which contained 
VWF (Organon, Technoclone, and Dade) and those which did not (Sigma and IL).
APTT blank times were measured for all the deficient plasmas, apart from Technoclone.  The 
APTT blank time (Table 4.2) showed a large variation in the clotting times from 65.7 -107.5 
seconds, with shorter clotting times  correlating with a larger AUC, which was  significant 
(Pearson correlation coefficient ^=0.81, p<0.05).
Table 4.2.  Parameters o f thrombin generation and APTT blank time o f commercial FVIII 
deficient plasma
FVm deficient plasma Batch AUC (IU.s) T X A max (s) APTT blank time 
(seconds)
Organon 112078 6102.5±627.1 342.1±62.3 65.7
Organon 111028 5673.4±584.8 280.0±21.0 72.2
EL N0324258 4853.4±333.4 407.5±43.4 93.9
Organon 111101 3391.0±223.0 368.0±36.4 90.1
Dade 503875 2625.4±211.4 383±23.0 107.5
Technoclone 489400D 2116±164.5 476.5±87.8 -
Sigma 051K6030 2111.8±203.9 363.8±58.8 106.9
Technoclone 482200D 2019.3±69 574.8±72.8 106.4
NP 6069.0±410.5 118±9.0 -
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Fig 4.5  Area under the curve and peak height of FVIII deficient plasmas expressed as a 
percentage of  normal plasma.
To establish if the observed thrombin generation was due to the presence of FVIII, normal 
plasma  and  commercial  FVIII  deficient  plasmas  were  incubated  overnight  with  a  rabbit 
polyclonal anti-human FVDI  Ab or a rabbit polyclonal anti-human growth hormone Ab as 
control.  Plasma was incubated with polyclonal rabbit anti-FVIII antibody serum (kind gift of 
Dr Ingerslev) at a dilution of 1  in  1000 or polyclonal rabbit anti-human growth factor (kind 
gift of Dr Raferty, NIBSC) at a dilution of 1   in  1000.  Samples were incubated overnight at 
37°C, following incubation the plasma was defibrinated and thrombin generation measured 
as previously described.
Incubation with anti-FVIII Ab mostly abolished thrombin generation in all plasmas (Fig 4.6, 
Table  4.2).  Thrombin  generation  was  reduced  in  normal  and  haemophilic  plasmas  with 
lower AUC after treatment than in the commercial FVTQ deficient plasmas.  The reduction in 
AUC after treatment with FVIII Ab was not significant for Dade or the haemophilic plasma, 
but was significant for the other plasmas paired t-test p<0.01.
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Fig 4.6.  Thrombin generation of FVIII deficient plasmas after treatment with polyclonal 
anti-FVIII Ab or polyclonal growth hormone Ab following  overnight incubation.
Table 4.3  AUC of FVIII deficient plasmas after treatment with polyclonal control Ab or 
polyclonal rabbit anti-FVIII Ab.
HP 91 Dade Organon Technoclone NP
Control Ab 1055±210.1 2706.7±301 3553.7±301 3012.1±1249.6 5134.5±624
Anti-FVHI
Ab
315.9±271.9 760T876 811±26.2 1294.6±1344 218.94±97.7
As thrombin generation is reduced following treatment with an anti-FVHI antibody in all the 
plasmas tested, this would suggest that a small amount of FVIII is present in all commercial 
FVIII deficient plasmas.
1094.4  Dose-response at very low concentrations of FVIII
As  it  was  observed  that  a  large  amount  of  thrombin  was  generated  at  low  FVIII 
concentrations, it was decided to investigate even lower concentrations of FVIII to establish 
the sensitivity of the assay to FVIII.
Replenate  or  TBS/HSA  was  added  to  haemophilic  plasma  (HP1  91 hours).  The  initial 
dilution  of Replenate  was  such  that  the  final  concentration  in  the  plasma  would  be 0.01 
IU/ml, subsequent 1   in  10 dilutions were made with TBS/HSA.  Thrombin generation was 
performed as previous.
More thrombin was generated than the deficient plasma at 10'5IU/ml both in peak-height and 
AUC  (Fig  4.7,  Table  4.4).  Increases  in  peak-height  and  AUC  were  observed  at  all 
concentrations.  However, these differences were only significant from blank at 0.001 IU/ml,
p<0.01.
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Fig 4.7.  Thrombin generation test with very low levels of FVIII.  Replenate or buffer was 
added to haemophilic plasma (HP  1 91  hours), triggered with high FIXa, PL and Ca2+.
110Table 4.4 AUC and peak-height at low FVIII concentrations, only significantly different from 
blank at lx l0  3 IU/ml.  *=p<0.01
10*2 IU/ml \0'3 IU/ml 1  O'4 IU/ml 10° IU/ml 0 IU/ml
AUC
(IU.s)
6860.9±801.7 * 4089±915.7 * 3600.5±1174.7 2322.8±364.7 1700±541.6
Peak
(IU/ml)
30.4±4.2 * 13.35±3.5 * 11.6±3.5 6.4±1.1 4.1±1.6
4.5  Effect of FIXa
The large amount of thrombin generated even at very low FVIII was an unexpected finding, 
especially due to the severe bleeding tendency of patients with <0.01  IU/ml FVIII.  This 
would suggest that the assay may not represent what is occurring in  vivo.  This calls into 
question the concentration of FIXa used to trigger activation of the plasma.  Therefore it was 
decided to see if the amount of thrombin generated at low FVIII levels was related to the 
amount of FIXa used to initiate the reaction.  The concentration of FIXa used was originally 
chosen as this had been used previously  within the  group,  as  it gave the  same  thrombin 
generation  profile  as  glass  contact  activation.  To  confirm  that  this  was  still  the  same 
experiments were performed to reconfirm these findings with the modified TGT method.
4.5.1  Contact activation
To see if the large amount of thrombin generated at low FVIII by the FIXa concentration 
would  also  be  generated  by  contact  activation  the  following  experiment  was  performed. 
Thrombin generation in a normal and haemophilic sample were trigged by incubating 400pi 
plasma in a glass tube for 2 minutes followed by the addition of 400pi PL and 400pl Ca2+, 
the rest of the reaction was carried out in the glass tubes.
Following contact activation the amount and time of thrombin generation was similar to that 
obtained with FIXa activation  (Fig 4.8) in both plasmas.  These findings suggest that the
111amount of FIXa used to initiate the reaction is comparable to that obtained ffom activation 
via the intrinsic pathway.
Fig 4.8  Comparison of thrombin generation by contact or FIXa activation for nomal and 
haemophilic plasma, n=l
4.5.2  Effect of decreasing concentration of FIXa on thrombin generation 
As the concentration of FIXa used was comparable to that of contact activation the amount of 
FIXa  was  reduced  to  see  what  effect  this  had  on  thrombin  generation  at  low  FVIII 
concentrations.
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Fig 4.9 Thrombin generation at different concentrations of  FIXa.  A- Normal plasma B-FVIII 
deficient plasma (Organon) n=l.
The concentration of FIXa was attenuated (Fig 4.9) in order to check the influence of FIXa 
on thrombin generation at very low FVIII  concentrations.  Decreasing FIXa concentration 
from  14nM progressively prolonged  the  lag-time of normal  plasma (Ti/2inax  114  seconds  at 
14nM to 226  seconds at 0.2nM)  but caused  no  change  in peak-height  or AUC  (at 0.2nM 
AUC 98% of 14nM).  In contrast to results with FIXa concentration of 14nM, at 0.2nM in
113haemophilic plasma, virtually no thrombin was generated.  The thrombin generation test is 
therefore sensitive to the low amounts of FVIII but is dependent also on the concentration of 
FIXa.  In  the  absence  of FIXa  to  activate  plasma,  thrombin  is  still  generated  in  normal 
plasma, however, there is a considerable delay in the thrombin generation.
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Fig 4.10.  Effect of FIXa concentration on thrombin generation.  Thrombin generation was 
triggered with FIXa 14 or 0.2nM in normal and haemophilic plasma.
4.5.3  Dose-response of FVIII at low FIXa concentration
To establish the effect of a lower concentration of FIXa thrombin generation was measured 
by  the  addition  of Replenate  to  haemophilic  plasma  (HP1  37hours)  to  give  final  FVIII 
concentrations of 1-0.03 IU/ml.  Thrombin generation was carried out as before using 0.2nM 
FIXa.
As FVin  concentration decreased,  AUC  and  peak-height also  decreased,  and  the  lag-time 
increased (as was observed previouslyXFig 4.11).  In contrast to the high FIXa concentration 
peak-height and AUC remained abnormal, and were only normalised by much higher FVIII 
concentrations.  The effect on thrombin generation with increasing FVTQ was more marked 
at a lower FIXa concentration.
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Fig 4.11.  Dose-response of Replenate  in haemophilic plasma at low FIXa concentration 
(0.2nM).
4.5.4  Comparison of FVIII concentrates with low FIXa
It was thought that the lower concentration of FIXa might enhance any differences between 
the  FVDI  concentrates  that  could  not  be  readily  observed  between  the  concentrates  as 
measured  previously.  Thrombin  generation  was  measured  for  five  different  FVin 
concentrates at a concentration of 1  IU/ml in haemophilic plasma (HP1 37hours).
The thrombin generation between the concentrates (Fig 4.12) was more variable than at the 
higher FIXa concentration (see section 3.6).  Refacto, Replenate, Octavi and 8Y all generated 
thrombin  at  around  the  same  time  with  no  difference  in  the  T% m ax  (ANOVA  p=0.45). 
However,  Kogenate  was  significantly  slower  to  generate  thrombin  than  the  other 
concentrates  (ANOVA  p  <0.001).  With  the  exception  of Kogenate,  all  concentrates 
generated thrombin more rapidly than normal plasma.
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Fig 4.12  Thrombin generated by FVIII concentrates at 1 IU/ml with  low FIXa activation 
concentration (0.2nM).
4.6  Protection from FVIII inhibitors bv FIXa and PL
Previous  experiments  by  Barrowcliffe  et al  (Barrowcliffe  et al,  1983;Barrowcliffe  et al,
1984)  had demonstrated that incubation  of FVIII  with PL and  FIXa protected FVIII  from 
neutralisation by a high titre inhibitor plasma.  The authors attributed this protection to the 
action of PL as FIXa excluded from the reaction mixture produced almost as much thrombin 
as when it was present.  Since our results had shown that the FIXa concentration used has a 
marked effect on thrombin generation, it was decided to see if incubation of FVIII with FIXa 
had an additional protective effect to the use of PL alone.  Our study differed in methodology 
to Barrowcliffe et al as they used a higher concentration of PL (25pg/ml) and undefibrinated 
inhibitor plasma.
Experiments were conducted by incubating 50pi Hemofil-M with one or more of the other 
reagents: 400pl PL (10 pg/ml), 400pl Ca 2+, 80pl FIXa (84nM), the complex was incubated 
for 5  minutes at 37°C, this was followed  by a 30  min  incubation  with  50pl  of polyclonal 
rabbit anti-FVin antibody (01/460 20BU/ml) or 50pl of buffer.  At the end of the incubation,
116300fil FVHI deficient plasma (Technoclone) and the remaining reagents were added and the 
TGT carried out as before.
Initially,  the  same  concentration  of  FIXa  was  used  as  in  earlier  thrombin  generation 
experiments with  low concentrations  of FVIII,  this  was equivalent to  14.8 pmol FIXa per 
IU/ml  FVm.  Incubation  of FVTH  with  the  rabbit  polyclonal  anti-FVIII  antibody  did  not 
abolish  thrombin  generation,  however,  thrombin  generation  was  delayed  (peak-height 
occurred  at  165  seconds  with  antibody,  120  seconds  without  antibody),  and  as  shown 
previously lag-time is a marker of reduced FVHI levels.  FVHI was then pre-incubated with 
various components of the thrombin generation system  1) FVDI and FIXa, 2) FVHI, FIXa 
and  PL,  3)  FVHI  and  PL  before  the  mixture  was  incubated  with  the  FVHI  antibody. 
Preincubation of FVTH with FIXa did not protect FVHI from the actions of the antibody (Fig 
4.13), as there was a slightly longer lag-time than FVIH alone.  When FVIII was in complex 
with PL or PL combined with FIXa then thrombin was generated more rapidly than  in the 
absence of the antibody i.e. thrombin generation was enhanced if FVHI was in complex with 
PL or PL and FIXa.
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Fig  4.13  Protection  of FVIII from  a  polyclonal  anti-FVIII  antibody  by  a  30  min 
preincubation of  FVIII with FIXa, and PL.
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To  establish  if the concentration  of FIXa used was  not optimal,  further experiments  were 
carried out with  increasing concentrations of FIXa (14.8. 41.7 and 80.7 pmols.IU'1   FVIII). 
The same pattern was observed as previously i.e. that a more rapid thrombin generation was 
observed with the combined complex of FIXa and phospholipid.
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Fig 4.14  Pre-incubation of FVIII with increasing concentrations of FIXa.  FIXa 14.8, 41.7 
and 80.7 pmol per IU FVIII and 8.9pg PL per TU FVIII were incubated with FVIII for 5 
minutes at 37°C before a further incubation with anti-FVIII Ab for 30 min a 37°C, at which 
point FVIII deficient plasma and Ca2+ were added to complete the reaction and thrombin 
generation was carried out as normal. n=l
The highest concentration of FIXa (80.7pmol.IU’1   FVIII) was  selected  for a more detailed 
look at the complex, as this concentration had the most rapid thrombin generation.  In this 
experiment  (Fig  4.15),  when  FVDI  was  incubated  with  FEXa  before  the  addition  of the 
antibody, thrombin generation was much slower than the antibody alone.  This would suggest 
that at this concentration FEXa is inactivating FVIII.  The combined complex of FIXa and 
phospholipid did offer more protection from the antibody than PL alone, although this was 
not a marked finding.
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Fig 4.15  Pre-incubation of FVIII with a  very high concentration of FIXa  (80.7pmol.IU1  
FVIII) n=l.
Experiments with high concentration of FIXa had shown only a small additional affect on 
FVIH protection, and in addition, an inactivation of FVHI by FIXa (also shown in Fig 4.17). 
It  was  decided  to  look  at  the  effect  that  a  lower  concentration  of FIXa  may  have.  The 
concentration  that  produced  minimal  thrombin  generation  in  FVffl  deficient  plasma  was 
chosen.  In addition calcium was also added to the various complexes to assess what affect 
this may have on thrombin generation (Fig 4.16).
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Fig 4.16  Protection of FVIII by PL, IXa and Ca2 \   FVIII was incubated with PL, IXa or 
Ca2  before a 30 min incubation with rabbit polyclonal anti-FVIII antibody.  The remaining 
reagents for thrombin generation  were added at the end of the  incubation  and thrombin 
generation measured.  A) Protection by High IXa (14.8pmol.IU1 FVIII) B Protection by low 
IXa (0.23pmol.IUJ  FVIII).
120Table 4.5 Protection o f FVIIIfrom a polyclonal Ab by pre-incubation with PL, FIXa or Ca2*-thrombin generation parameters. High IXa 
(I4.8pmol.IU1FVIII, low IXa (0.23pmo.lU' FVIII).
Control Ca"+ PL PL Ca"+ PL FIXa Ca"+ PL FIXa
High
IXa
AUC 7605.1±706 6752.8±154.5 7818.3±1172.6 6857.0±302.1 6890.3±155.3 7402.3±658.5
Peak 40.0±2.0 36.5±4.1 41.6±2.74 34.7±3.93 38.3±0.43 40.0±1.72
Time 260±31.2 200±8.66 125±18.7 190±43.3 180±15 116.3±28.4
Low
IXa
AUC 3130.1±2087.6 6249.9±664.5 6994.3±70.0 6679.4±590.5 6655.0±99.3 6901.9±230.2
Peak 20.1±13.7 34.0±3.25 41.3±2.0 38.1±2.5 37.9±3.1 42.0±0.5
Time 440±62.4 380±62.4 235±8.66 230±31.2 200±34.6 270±15Incubation of FVHI with the polyclonal antibody did not abolish thrombin generation even at 
this low FIXa concentration, as the incubation period was not long enough to achieve this. 
However, the lag-time was  increased at both concentrations of FIXa.  Incubation of FVIII 
with Ca2 +  alone did offer some protection from the antibody with a reduction in the lag-time. 
However, this finding was not significant for either concentration of FIXa (p=0.07 and 0.3, 
for high and low concentrations respectively).  Maximum protection was observed with the 
high FIXa concentration with PL; PL, IXa; and PL, Ca2+.  The combined complex of FVIII, 
PL, IXa and Ca2+ was significantly less effective than the complex without Ca2+  (p< 0.05). 
This was in contrast to the findings with the lower FIXa concentration  in which the most 
effective  protection  of  FVDI  from  Ab  was  by  PL,  IXa  and  Ca2+,  although  in  these 
experiments this was not significantly different from PL and IXa (p= 0.06).
The results above suggested that the high FIXa concentration was producing a detrimental 
effect  on FVIH  compared  to  the  lower FIXa  concentration  in  which  FIXa  increased  the 
protective effect against the FVDI antibody.  To clarify this Hemofil-M was incubated with 
either  concentration  of FIXa  for  30  minutes  or  with  no  pre-incubation  and  thrombin 
generation  carried  out  as  normal  (i.e.  in  the  absence  of  antibody).  The  high  FIXa 
concentration caused a delay  in thrombin generation when FVIH was  incubated with this 
concentration for 30 minutes (Fig 4.17).  A delay in the lag-time was not observed with the 
lower  concentration  of  FIXa  and  suggests  that  the  higher  concentration  is  causing 
inactivation of FVDI.
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Fig 4.17 Effect of incubation time on thrombin generation following incubation of  FVIII with 
FIXa.  High  FIXa  (I4.8pmol.IU‘FVUI)  low  FIXa
4.7  Discussion
With  a high  FIXa concentration  the TGT  was  found to be very  sensitive to  low levels of 
FVDI.  A large amount of thrombin  was generated when FVIII  levels  were less than 0.01 
IU/ml in both an artificial situation in which FVHI concentrate was added to FVHI deficient 
plasma, and in two severe haemophilic plasmas. Early work on the TGT found that only very 
small amounts of thrombin could be detected  in haemophilic plasma,  however,  only small 
additions of normal plasma were required to improve the thrombin generation.  Macfarlane 
and  Biggs  in  their  plasma  studies  showed  that  an  addition  of  0.5%  normal  blood  to 
haemophilic blood caused  detectable  thrombin  generation,  although,  it was  prolonged  and 
was only one third of the average peak height of the normal samples (Macfarlane & Biggs, 
1953).  Pitney  and  Dacie  found  that  addition  of  1%  normal  plasma  improved  thrombin 
generation, but that 20% or more was required to bring the thrombin generation within the
123normal limits (Pitney & Dacie, 1953).  The use of a FVm antibody on a haemophilic sample 
demonstrated that thrombin generated below 0.01  IU/ml was due to FVHI. A repeat sample 
from this patient was taken after a longer duration post-infusion and generated hardly any 
thrombin,  suggesting  that  the  thrombin  generated  from  the  original  sample  was  due  to 
residual FVIII from the infusion.  Plasma from another patient was collected at 72 hours 
post-infusion and the thrombin generated is unlikely to be due to the infusion.  The APTT 
clot waveform analysis in a recent study has also shown detectable FVIII in  some severe 
haemophilic  patients  with  levels  measured  between  0.002  and  0.01  IU/ml  (Shima  et al, 
2002).  As this low level of FVDI can be measured it has implications for the frequency of 
prophylaxis.  We  have  demonstrated  considerable  thrombin  generation  at  less  than  0.01 
IU/ml, and there is some evidence to suggest that with trough levels of less than 0.01 IU/ml 
joint bleeds are still rare (Petrini, 2001).  Although it is generally accepted that prophylaxis 
should be maintained above this level, it has not been proven that this leads to an improved 
clinical outcome (van den Berg et al, 2001).
The sensitivity of the TGT to low levels of FVHI may be explained by the amount of FIXa 
used  in the assay to  initiate  coagulation.  It  was  found  that the FIXa  concentration  was 
important in the ability of low concentrations of FVIH to generate thrombin, but this effect 
was minimised as levels of FVHI normalised.  The high FIXa concentration was originally 
chosen  as  it  produced  the  same  thrombin  generation  profile  as  intrinsic  glass  contact 
activation.  The amount of thrombin generated in plasma is controlled by the amount of FIX 
present  as  well  as  FVIH.  At  low  TF  concentrations,  FIX  is  activated  by  the  FVIIa-TF 
complex,  which  explains  the  role  of the  anti-haemophilic  factors  in  thrombin  generation 
(Osterud  &  Rapaport,  1977;Bauer,  1997;Keularts  et  al,  2001b).  In  addition,  at  low 
concentrations of TF,  less than  1% of total plasma FIX  is  activated,  which  would give a 
plasma FIXa concentration of 0.9nM (Lawson et al, 1994).  The low FIXa concentration of 
0.2nM that has been used  in these experiments  is therefore  lower than this,  but could be 
considered to be a physiological  concentration present during initiation of the coagulation 
cascade.  The  higher  FIXa  concentration  of  14nM  used  to  trigger  thrombin  generation, 
although similar to contact activation, would perhaps appear to be higher than physiological, 
although local concentrations of FIXa following injury may be higher than 0.9nM  Other
124work  has  used  FLXa  concentrations  of 0.1 nM  to  1.5nM  in  the  TGT  (Hoffman  et  al, 
1996;Jetsy,  1991 ;Kumar  et  al,  1994;Sekiya  et  al,  1996).  It  may  be  that  at  high  FIXa 
concentrations  when  assaying  low  concentrations  of FVffl  the  FIXa  protects  what  little 
FVIIIa is produced by the haemophilic plasma from degrading (Lenting et al,  1998), and at 
much higher FIXa concentrations FIXa can enhance FVIII activity (Rick, 1982).  These high 
FIXa  conditions  in  the  TGT  maybe  artificial,  but could  be  useful  in  practical  terms  for 
detecting low levels of FVIII, for example in gene therapy.
In gene therapy clinical trials to date, there have been some individuals with a reduced need 
for FVIH despite no observed increase in FVIII  levels  (White, 2001).  The TGT may be 
better suited to detecting small  increases  in FVIII  levels under these circumstances.  The 
TGT may also be able to shed light into a minority of patients (10-15%) with FVIH of less 
than 0.01  IU/ml but with a clinical status that is better than the FVIII level suggests.  It has 
been suggested that the most common prothrombotic mutation, factor V L eid e n   with a carrier 
rate of 8.8% in Europeans (Rees etal, 1995) and 6% in white North Americans (Ridker etal, 
1995), may account for those with a less severe clinical phenotype among patients with the 
same  FVIII  mutation  (Nichols  et  al,  1996),  and  children  with  prothrombotic  mutations 
develop their first bleed significantly later than those without (Ettingshausen et al, 2001).  An 
in vitro model has also shown increased thrombin formation with the factor VLeiden mutation 
(van't Veer et al, 1997).  However, most haemophilic patients with factor VLeiden still have a 
severe clinical outcome (Lee etal, 2000).
At lower concentrations of FIXa, the dose-response produced by a high-purity concentrate 
was more marked.  Under these conditions all the parameters of the TGT were affected.  As 
concentration of FVTtl decreased, T./2m ax increased as for the high FIXa concentration, but in 
contrast the peak height and the  AUC  decreased  at the  lower FIXa  concentration.  This 
version of the TGT may therefore be more useful  for monitoring patients’  response after 
infusion of concentrates.
The  clotting  method  has  shown  a  great  sensitivity  towards  FVIII  with  the  ability  to 
distinguish levels less than 0.01 IU/ml.  This was an unexpected finding as the detection limit
125of the  chromogenic  and  one-stage  APTT  FVIII  assays  are  carried  out,  in  general  on 
automated machines, which have a higher precision than manual methods.  The TGT could 
be readily used by laboratories which do not have expensive machinery as it is performed on 
a relatively simple machine which records the time to clot.  The TGT can also be performed 
by hand with tubes in a water bath.  The other advantage of the TGT as a valuable technique 
for laboratories in developing countries is the cost of reagents which are also low.
The sensitivity of the TGT to  low levels of FVIII could be useful  in the measurement of 
prophylaxis.  We did examine a small cohort of children receiving prophylaxis treatment. 
There was no significant correlation between the AUC, peak-height or time-to-peak and the 
measured FVIII level.  However, the TGT does provide additional information that the FVIH 
level alone cannot provide.  The peak-height and time-to-peak are important parameters, in 
that, the rate at which thrombin is generated is probably more important than the total amount 
of thrombin produced.  One sample generated no thrombin despite a measured FVIH level of 
3 IU/ml, near normal thrombin generation would have been expected with this FVIH level. 
This therefore suggests contamination of the sample, as the patient had a central line, heparin 
would be the most likely cause.
The  TGT  may  also  be  a  useful  tool  for  shedding  light  on  those  patients  with  different 
phenotypes.  It has been known for some time that there is a subset of severe patients  in 
whom  spontaneous  bleeding  is  less  common.  As  the  current diagnostic  assays  are  only 
sensitive to 0.01  IU/ml, this level is the definition for severe haemophilia.  However, some 
patients may have a very small amount of endogenous FVIH, which is not detected by the 
current  assays.  Recent  work  has  demonstrated  that  there  are  patients  with  severe 
haemophilia who fell  into two distinct groups.  By measuring the clot waveform analysis 
Shima et al demonstrated that two thirds of patients had FVIH  levels between 0.002-0.01 
IU/ml, while the remaining patients had levels less than 0.002 IU/ml (Shima et al, 2002).  In 
addition Ingerslev et al have shown that severe patients have two different types of ro-TEG 
profiles.  They also  found a difference  in the amount of FVIH  required to normalise the 
velocity of coagulation, with some patients requiring 0.05 IU/ml, whilst for others an order of 
magnitude  greater was  required  (Ingerslev et al,  2003).  The differences  between  those
126severe haemophilacs which regularly bleed “severe severe” and those that do not “moderate 
severe” is currently being investigated by the SSC of the ISTH.  The results presented here 
would also suggest that the TGT triggered with the high FIXa concentration may also be able 
to  differentiate  between  the  two  different  types  of  patient.  However,  despite  recent 
developments in assays which are more sensitive to low levels of FVIII the current ISTH 
definition  for  severe  haemophilia  (<0.01  IU/ml)  is  not  being  adhered  to  and  there  is 
widespread  misunderstanding amongst  clinical  laboratories  in  diagnosis  and  in  ability  to 
reliably measure samples containing <0.01 IU/ml (Preston et al, 2004).  This would suggest 
that further definitions would not be practical at this time.
Studies described above with FVHI deficient plasmas have shown a wide variation in the 
amount  of thrombin  generated  and  a  considerable  variation  between  the  batches  of one 
product.  Great care must be used to find an appropriate FVHI deficient plasma for use in the 
TGT.  The choice of FVHI deficient plasma may also have a bearing on the one-stage APTT 
assay  as  there  is  a  reliance  on  deficient  plasma  in  this  method.  In  particular the  large 
amounts of thrombin generated by some plasmas, may limit the sensitivity of the assay to 
low levels of FVHI.  The choice of FVIII deficient plasma was also shown to be important in 
the Bethesda assay for measuring FVHI inhibitors (Verbruggen et al, 2001).  This study also 
found that chemically depleted plasma contained FVa, leading to over estimation of inhibitor 
titres.  It would seem likely that the rapid generation of thrombin which occurred in our assay 
with chemically depleted plasma was due to the presence of FVa, as FVa can increase the 
rate of thrombin formation by 12,900 fold (Philippou etal, 1996).
Previous  work has  shown  that PL  can  protect FVIII  from  inhibitors  (Barrowcliffe  et al, 
1983).  These authors also looked briefly at FIXa in the complex but at a FIXa concentration 
of 1  pg/ml to  1   IU/ml FVm, FIXa did not improve the protection by PL alone.  This is in 
agreement with the results presented here as the concentration used by Barrowcliffe et al is 
approximately 15pmol FIXa.IU'1  FVHI.  We investigated if FIXa would add to this affect as 
thrombin generation is increased by FIXa.  High concentrations of FIXa were initially used, 
but this was found to be detrimental to FVIH, presumably by inactivation of FVHI by FIXa 
(O'Brien et al, 1992).  The most effective concentration of FIXa for protection of FVIH was
127found to be a much lower concentration of O^pmol.IU^FVHI (0.2nM), which was the same 
concentration  that  gave  minimal  thrombin  generation  in  FVIII  deficient  plasma.  This 
concentration of FIXa was most effective when Ca2+ was included in the complex, although 
this was not a significant improvement on the complex without calcium.  In addition calcium 
also offered some protection from die polyclonal  antibody on  its own.  Calcium  ions  are 
known to stabilise FVIII (Mikaelsson et al, 1983) and this may be occurring, or the calcium 
ions may be preventing the antibodies from binding to FVIII by blocking binding sites or 
altering the conformation.  The protection of FVIII against inhibitors by calcium ions has 
also been observed  in a clinical trial,  when patients  were  infused  with  calcium before or 
during FVIH replacement a greater reduction in inhibitor titre was observed (Muhleman etal,
1985).  This combined approach could be a significant finding, as an inhibitor to FVHI is a 
major hindrance to treatment and quality of life.
4.8  Summary
This chapter presents results in which it is demonstrated that the thrombin generation test is 
very effective at measuring low FVHI levels < 0.01 IU/ml which is below the detection limit 
of conventional FVIH assays.  The TGT has also  shown great versatility in measurement 
both at high and low FVIH concentrations, which has not been previously demonstrated.
The amount of thrombin that is generated by these low FVIH levels  is potentiated by the 
FIXa  concentration  used  to  initiate  thrombin  generation.  With  the  original  FIXa 
concentration  large amounts of thrombin  (two-thirds  of normal  plasma)  can be generated 
even by severe haemophilic plasmas, however if the level of FIXa is attenuated, the amount 
of thrombin generated is also reduced.  The sensitivity  of the thrombin generation test has 
several implications for management of haemophilic patients.  The thrombin generation test 
could  be  a  useful  tool  for  monitoring  low  FVIH  levels,  for  example  in  prophylaxis, 
phenotype monitoring and for measuring gene therapy.
128CHAPTER 5 FLUOROGENIC THROMBIN 
GENERATION TEST
5.1  Introduction
This section describes results obtained with the fluorogenic TGT.  This method was chosen 
for  several  reasons:  reduced  sample  volume;  the  fluorogenic  substrate  is  unaffected  by 
turbidity,  therefore  platelets  can  be  added  to  un-defibrinated  plasma  for  a  closer 
approximation  to  the  in  vivo  situation;  also  it  is  a  method  which  does  not  require 
subsampling.
There  are  several  methods  by  which  thrombin  generation  can  be  measured,  clotting  of 
fibrinogen, subsampling into a chromogenic substrate and continuous measurement using a 
slow chromogenic or fluorogenic  substrate.  The  continuous  fluorogenic  substrate  method 
has been developed by Hemker’s group (Hemker et al, 2000) to overcome the limitations of 
chromogenic methods.  The chromogenic methods are affected by the turbidity of the plasma 
samples and as a consequence, samples must first be defibrinated, and PRP must be studied 
by a labour intensive subsampling methodology.  Defibrinated samples  are thought to be 
unphysiological, as it has been postulated that the presence of fibrin  in PRP may activate 
platelets  (Beguin  &  Kumar,  1997).  Therefore,  the  fluorogenic  method  allows  thrombin 
generation  to  be  determined  in  a  more  physiological  system  and  without  the  need  for 
subsampling to be hindered by removal of the developing clot.  An additional advantage of 
continuous thrombin generation is that the method can be carried out in a microtitre plate 
minimising the volume of plasma required, and allowing more TGTs to be performed.
The  main  disadvantage  of the  continuous  registration  of thrombin  with  a  fluorogenic  or 
chromogenic substrate is that a2-macroblobulin forms a complex with thrombin which also 
cleaves the substrate.  The a2-macroglobulin-thrombin contribution can be subtracted with 
the use of a mathematical equation  (Hemker et al,  1993),  as  detailed  in  the  material and 
methods section (2.3.2).  Another disadvantage is that thrombin generation is measured in 
terms  of relative  flouresence  units  (RFU),  as  opposed  to  the  other  tests  which  can  be
129converted  to  thrombin.  Hemker’s  group  has  more  recently  developed  a  calibrator  for 
conversion of the RFU to thrombin (Hemker et al, 2003).
5.2 Reproducibility of fluorogenic assay
Initial  experiments  were  performed  with  this  method  to  test  the  reproducibility  and  to 
establish if any wells needed to be excluded on the microtitre plate.  Normal plasma was 
added to each well of the microtitre plate and thrombin generation performed as described in 
the methods section (2.2.3). In brief, 40pl of non-defibrinated plasma was placed in a well of 
a black microtitre plate.  To this was added 80pi of the remaining reagents FIXa, PL, Ca2+ 
and the substrate Z-gly-gly-arg-pro.  Final reaction concentrations were plasma 33%, FIXa 
5nM,  PL  3 pg/ml,  Ca2+   7mM,  Z-gly-gly-arg-pro  0.234  nM.  Thrombin  generation  was 
measured by excitation at 390nm and emission at 460nm at 30 second intervals for one hour. 
These experimental conditions were used throughout unless mentioned otherwise,  samples 
were run in each assay in duplicate and assays were repeated three times (unless otherwise 
stated)
The fluorogenic assay used here was designed to be similar to the clotting method i.e. plasma 
constituted a similar proportion of the reaction mixture and reagents were also utilised at a 
similar final concentration (Table 5.1).  The similar design between the two methods would 
allow for some comparisons between the methods.
Table 5.1 Comparison o f  final reagent concentrations in both TGT methods.
Clotting Fluorogenic
Plasma 30% 33%
PL 3.1pg/ml 3 pg/ml
Ca2+ 7.8 mM 7mM
FIXa 5.2 nM 5nM
Z-gly-gly-arg-pro - 0.234 nM
130The intra-assay variability gave a CV of between 3.8 and 9.5% (Table 5.2).  The data was 
analysed by Mr Peter Rigsby (NIB SC) and all surrounding wells were excluded as was row F 
due  to  high  varability  in  these  wells.  Exclusion  of these  wells  reduced  the  intra-assay 
variability to  1.7-3.8% (Table 5.3).  All subsequent experiments were performed excluding 
the use of these wells  for samples,  with  the  inclusion of buffer in all empty  surrounding 
wells.
Table  5.2.  Reproducibility o f AUC.  Normal plasma  was  assayed  in  each  well o f a  96 
microtitre plate n 4 .
1 2 3 4
Mean 45583.53 43939.88 45182.81 44913.07
SD 2403.428 4178.102 1813.33 1706.15
CV 5.3 9.5 4.0 3.8
Table 5.3.  Reproducibility o f  AUC with exclusion o f wells.  Columns 1 and 12 and rows A, 
F and G o f  a 96-well microtitre platewere excludedfrom data in table 5.2 n=4.
1 2 3 4
Mean 47279.95 46265.91 46597.91 46186.5
SD 1755.2 1745.6 772.9 830.2
CV 3.8 3.8 1.7 1.8
The  inter-assay  variability  was  also  assessed  for  normal  pooled  plasma  and  Replenate 
dilutions  in  Technoclone  FVIII  deficient  plasma  (Table  5.4).  The  largest  variation  was 
observed for peak-height, which ranged from 8.7-14.1%.  The least variable parameter was 
the time-to-peak which  varied  by  4.4-8.8%.  In  addition,  thrombin  generation  by  normal 
plasma was more variable (6.4-14.1%) than that produced by the low FVIII concentrations, 
for example the FVIII deficient plasma varied by 4.3-8.7%.
131Table  5.4.  Reproducibility fluorogenic  TGT with different FVIII concentrations.  Normal 
plasma, Technoclone and dilutions o f normal plasma in Technoclone were assayed, n = 5.
AUC (RFU) % Peak (RFU) %
Time to peak 
(min) %
Mean SD CV Mean SD CV Mean SD CV
NP 43615.3 5674.2 13 3125.7 441.8 14.1 10.15 0.65 6.4
0.03 IU/ml 37673.0 785.1 2.1 2891.0 213.2 7.4 11.85 1.0 8.8
0.008 IU/ml 36142.8 2133.7 5.9 2721.2 329.4 12.1 13 1.0 7.4
Technoclone29490.9 1269.2 4.3 1485.6 129.9 8.7 22.0 1.0 4.4
S3 Effect of fibrinogen
A comparison  was carried out between the fluorogenic and clotting methods of thrombin 
generation  at  different  FVIII  concentrations  in  both  defibrinated  and  non-defibrinated 
plasmas.
To remove the fibrinogen, plasmas were treated with ancrod (0.5 IU/ml) for 30 minutes at 
37°C.  The  plasmas  were  prepared  at  the  same  time  and  measured  by  each  method 
simultaneously.  In the clotting method, in samples which were not defibrinated the clot was 
removed by winding the clot onto a wooden stick as it formed, the stick was then pressed 
against the side of the tube in order to remove the plasma from the clot.  The wooden stick 
with the fibrin attached was left in the reaction mixture.
5.3.1  Clotting method
In  the  clotting  method  the  AUC  was  higher  when  the  samples  were  defibrinated 
9032.1±653.5  IU/ml.s  compared to  5225.2±638  in non-defibrinated plasma,  (p<0.05)  (Fig 
5.1,  Table 5.5).  The peak-height was also significantly higher in defibrinated plasma for
132normal  plasma 25.5±2.6  IU/ml  compared  to  48.3±2.1  IU/ml  in  non-defibrinated  plasma, 
(p<0.05).  However, removal of fibrinogen did not have any effect on the time to peak height 
(185±34.6 seconds  in non-defibrinated plasma,  172.5±22.5  seconds  in defibrinated normal 
plasma).  These differences were also found both in deficient plasma and with an addition of 
3% normal plasma to FVIII deficient plasma (Technoclone).
Table  5.5.  Comparison  o f TGT parameters  with  and  without fibrinogen  in  the  clotting 
system.  NP, the addition o f 3%NP to Technoclone, and Technoclone alone.
Non-defibrinated Defibrinated
NP 3% Technoclone NP 3% Technoclone
AUC
(IU/ml.s)
Mean 5225.2 6071.6 1134.8 9032.1 9721.9 4355.4
SD 638.0 182.7 79.5 653.5 715.9 1341.4
Peak
(IU/ml)
Mean 25.5 28.0 3.0 48.3 48.1 11.6
SD 2.6 1.6 0.5 2.1 4.3 3.0
Time
(s)
Mean 185 375 890 172.5 320 670
SD 34.6 54.1 121.2 22.5 31.2 45.8
From  the  graph  (Fig  5.1)  it  can  also  be  seen  that  the  peak  of thrombin  generation  is 
maintained for a longer duration in the non-defibrinated samples compared to defibrinated 
plasma.
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Fig 5.1.  Effect of  fibrinogen on thrombin generation in the clotting assay.  Comparison of 
NP, 3% NP and Technoclone, all with and without defibrination.
5.3.2  Fluorogenic method
With the fluorogenic method, a significantly higher AUC was also obtained  in defibrinated 
normal  plasma  (Fig  5.2,  Table  5.6),  32565±  3617  compared  with  non-defibrinated 
40405±4369 RFU.min (p<0.05).  However, the increase in AUC was not due to an increase 
in peak-height, but due to sustained thrombin generation as the curves did not return to the 
baseline.  The  differences  in  peak-height between  non-defibrinated  and  defibrinated  were 
only significant with 3% normal plasma which would suggest a trend towards reduced peak. 
The  fibrinogen  did  not  affect  the  time-to-peak  for  the  samples  when  measured  with  the 
fluorogenic method.
134Table 5.6.  Comparison of TGT parameters with and without fibrinogen in the fluorogenic 
assay.  NP, the addition of 3% NP to Technoclone, and Technoclone alone.
Non-defibrinated Defibrinated
NP 3% Tech NP 3% Tech
AUC
(RFU.min)
Mean 32564.5 26711.0 16469.6 40405.2 36881.1 19201.7
SD 3616.5 3425.5 1842.8 4369.4 4536.7 1927.5
Peak
(RFU)
Mean 2565.9 2488.5 962.6 2095.0 2102.8 751.0
SD 259.8 284.0 163.2 277.9 281.2 76.6
Time (min)
Mean 7.0 9.5 20.8 7.9 9 19.6
SD 0.8 0.4 1.5 0.4 0.3 1.5
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Fig 5.2.  Effect offibrinogen on thrombin generation in the fluorogenic assay.
To determine if the differences in the thrombin generation profile were due to the absence of 
fibrin,  plasma  was  treated  with  the  peptide gly-pro-arg-pro  (4mg/ml  plasma)  which  is  an
135inhibitor of fibrin  polymerisation  (Pratt  et al,  1997;Laudano  &  Doolittle,  1980).  Plasma 
treated with the peptide (AUC 56580 RFU.min) behaved in the same way as ancrod treated 
plasma  (AUC  54952  RFU.min),  whereas  untreated  plasma  had  a  lower  AUC  of 41626 
RFU.min (Fig 5.3).  This would  suggest that the absence of polymerised fibrin  caused the 
increase in thrombin generation.
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Fig 5.3.  Comparison of thrombin generation by different clot inhibition treatments.  Normal 
plasma was treated with ancrod (0.5 IU/ml) and fibrinogen removed,  or gly-pro-arg-pro(4 
mg/ml), n  1
5.3.3  Comparison of methods
From the curves of normal plasma (Fig 5.4) it can be seen with the fluorogenic method that 
the lag-time was the same for both non-defibrinated and defibrinated plasma, although the 
peak-height  was  lower and  the decline  in  thrombin  generation  was  more  gradual.  In  the 
clotting  method  the  lag-time  was  also  the  same,  however,  the  peak  was  half  that  of 
defibrinated plasmas.  The peak of the curve was also maintained for a longer duration than 
in defibrinated plasma.  The difference in AUC was greatest with the clotting method with 
AUC in non-defibrinated plasma around 60% of that in defibrinated plasma, however in the 
flurorogenic method this was 80%.  The biggest differences between methods is in the lag­
time which occurs considerably later in the fluorogenic method.
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Fig  5.4  Comparison  of Normal plasma  whole  and  defibrinated  in  the  two  thrombin 
generation assays .  Dashed lines represent assays in  the fluorogenic system,  solid lines 
represent thrombin generation in the clotting system.
Table  5.7.  Comparison  of thrombin  generation  methods  at  two  FVIII  concentrations. 
Parameters of 3% NP and  Technoclone plasma and are given  as percentage  of normal 
plasma.
Fluorogenic Clotting
Non-defibrinated Defibrinated Non-defibrinated Defibrinated
3% 0% 3% 0% 3% 0% 3% 0%
AUC
Mean 82.0 50.6 91.3 47.6 117.1 23.2 108.3 48.3
SD 3.2 1.1 6.9 3.1 10.9 0.3 14.5 14.8
Peak
Mean 96.9 37.6 100.4 36.0 110.9 12.5 99.9 24.2
SD 3.4 6.0 2.1 1.5 15.9 2.5 11.4 6.9
Time
Mean 134.9 296.0 113.8 247.8 206.3 487.7 186.4 390.6
SD 11.7 44.4 4.1 23.5 42.7 82.7 15.7 26.3
137To  establish  how the  fluorogenic  and  clotting  methods  compared,  TGT  parameters  were 
measured at concentrations of 3% and 0% (Technoclone).  The results were calculated as a 
percentage of NP (Table 5.7).  In non-defibrinated plasma more thrombin is generated in the 
clotting system at 3% FVHI, whereas in the absence of FVIII more thrombin is generated in 
the  fluorogenic  assay.  These  differences  were  significant  (3%  FVHI  p<0.05,  0%  FVHI 
<0.01).  In addition, there was a significant difference between the methods  in the peak- 
height of 0% FVIH (peak-height 38% in fluorogenic versus 12.5% with the clotting method 
(P<0.01)).
When plasma was defibrinated there were no differences between the two methods in terms 
of AUC or peak-height  There were however, significant differences between methods  in 
time-to-peak, with the clotting method taking longer to reach peak, Technoclone p<0.05, 3% 
p<0.05.
The relative amounts of thrombin generated in defibrinated plasma were the same for both 
methods.  There were differences though with non-defibrinated plasma, and this is likely to 
be due to the technical differences in thrombin measurement  In the fluorogenic system, the 
clot was not disturbed once it had formed and thrombin that was attached to the fibrin could 
still be detected.  In contrast in the clotting system the clot must have been disturbed, in order 
for the  subsample to  be  obtained  and although  plasma  was  removed  from  the clot some 
thrombin would have remained attached to the fibrin network.
5.4  Dose-response
A dose-response was carried out to further characterise the fluorogenic method over a range 
of FVHI concentrations.  The dose-response was measured with different concentrations of 
Replenate  in  Technoclone  FVIH  deficient  plasma,  for  both  high  (5nM)  and  low  FIXa 
(0.08nM) trigger concentrations which are comparable to final concentrations in the clotting 
method (Fig 5.5, Table 5.8).  The TGT parameters were then compared to NP.
138High FIXa (5nM
At the high FIXa concentration, similar results were observed to the clotting method i.e. very 
little  change  in  AUC  (92.1—   83.0  %  of NP)  with  FVIII  from  1   IU/ml  to  0.008  IU/ml 
respectively and for peak-height (96.7-86.4 % of NP).  As  in the clotting assay there were 
more differences in time-to-peak, which varied by 97.5-133 .3 % of NP. The deficient plasma 
(Technoclone) alone generated a considerable amount of thrombin, AUC 59.4±17.3 % of NP, 
this  was  a greater proportion than  in  the  clotting  assay  despite the  same concentration  of 
FIXa.
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Fig 5.5.  Dose-response with Replenate and a high FIXa trigger concentration.  Thrombin 
generation  was  measured from  0.008-1  IU/ml Replenate  in  Technoclone  FVIII deficient 
plasm, FIXa 5nM.
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139Low FIXa (0.08nMl
With  the  low FIXa  concentration  (0.08nM) to  trigger thrombin  generation  (Fig  5.6, Table 
5.8) there was  a greater range of response to FVIII  in the AUC  (103±7.8-62.7±0.9%) and 
peak  height  (113.8±5.2-55.4±7.1%).  There  was  also  a  reduced  amount  of  thrombin 
generated  in the deficient plasma  in  which  AUC  was  6.2±1.4% of that in normal  plasma. 
There was also longer time to reach peak-height 96.0-202.9 % of NP.  These results mirror 
those with the clotting assay.
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Fig 5.6.  Dose-response with Replenate using 0.08nM FIXa to trigger thrombin generation. 
Thrombin  generation  was  measured from  0.008-1  IU/ml  FVIII  in  Technoclone  FVIII 
deficient plasm, FIXa 5nM.
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140Table 5.8  Thrombin generation parameters over a range o f FVIII concentrations.  Values are expressed as a percentage o f normal plasmas 
following activation with either high or low FIXa.
FVIII concentration IU/ml
1 0.5 0.25 0.13 0.063 0.03 0.016 0.008 0
High
IXa
AUC 92.1±3.7 90.6±3.4 89±2.0 88.8±2.4 86.5±3.0 84.0±4.0 85.0±3.6 83.0±4.4 59.4±17.3
Peak 96.7±7.5 96.0±8.1 95.7±7.9 94.8±6.9 92.9±8.6 89.2±8.3 88.6±6.6 86.4±8.6 47.9±8.5
Time 97.5±6.6 100.8±6.3 102.5±5 105.0±5.0 110.0±6.6 119.2±7.6 126.7±3.8 133.3±9.5 217.5±4.3
Low
IXa
AUC 103.0±7.8 101.5±6.3 99.4±7.3 96.9±8.6 95.H7.5 88.7±5.5 81.1±1.8 62.7±0.94 6.2±1.44
Peak 113.8±5.2 112.0±5.4 107.0±10.3 106.0±2.9 101.5±3.2 92.8±3.05 78.3±4.7 55.4±7.1 4.33±0.7
Time 96.0±2.0 101.3±5.0 106.8±3.1 118.1±5.3 133.0±3.7 147.7±7.0 176.0±8.1 202.9±12.1 378.4±8.8As a large amount of  thrombin was generated in commercial FVIII deficient plasma , TGT 
was repeated with severe haemophilic plasma (HP1  91 hours) which was found to give the 
lowest levels of thrombin generation with the clotting method.  However, HP1  91 hours still 
generated a large amount of thrombin (Fig 5.7), AUC 46.3 % of normal plasma although 
this was less than the amount of thrombin generated by Technoclone.
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Fig 5.7 Thrombin generation in fluorogenic assay by severe haemophilic plasma.
To ensure that the large amount of thrombin generated by FVIII deficient plasmas was due 
to residual FVIII, as  in the clotting system, a haemophilic plasma was  incubated  with an 
anti-FVm antibody.  90pl severe haemophilic plasma (HP1  91  hours) was incubated with 
lOpl  rabbit  anti-FVTII  Ab  (NIBSC,  01/460)  or  with  lOp.1  rabbit  anti-human  growth 
hormone serum (diluted 1   in 1000) for 5 hours at 37°C.
This treatment of the plasma abolished thrombin generation (Fig 5.8)  in the haemophilic 
plasma  treated  with  the  anti-FVTII  Ab  (AUC  922  RFU.min)  as  opposed  to  the  control 
treated plasma (10351 RFU.min).
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Fig 5.8 Thrombin generation is abolished by anti-FVUI Ab.  HP I 91 hours was incubated 
with TBS, anti-FVUI Ab or anti-growth hormone as control  for 5 hours at 37°C,  n  1
5.5  Comparison of triggers in the fluorogenic TGT
In the clotting TGT, FIXa was used to activate the reaction.  The fluorogenic test has been 
adapted to use similar dilutions and similar final concentrations of reagents.  TF is however 
the most widely used trigger in TGTs and it has been suggested that a concentration of 5pM 
TF is akin to the in vivo situation (Lawson et al, 1994;Cawthem et al, 1998).  In these sets 
of experiments a range of FVIII concentrations from 0-1 IU/ml was made by the addition of 
Replenate to a commercial FVIII deficient plasma (Technoclone).  The same concentration 
of PL, Ca  and substrate were used, whilst variations were made with the trigger.
High FIXa. 5nM
Using the high FIXa concentration as a trigger the AUC increases (Fig 5.9a, 5.10) as FVHI 
concentration  increases.  This was however only a small  increase and the AUC was only 
significantly lower than 1   IU/ml for deficient plasma alone, p<0.05  The similarity in AUC 
at all FVIII levels was reflected in the peak-height which plateaus at 0.01 IU/ml.  The time-
143to-peak decreases  with increasing FVIII concentration, although there was no difference 
between 1  and 0.1 IU/ml and 0.1 and 0.001 IU/ml.
Low FIXa. 0.08nM
At the lower concentration of FIXa, the amount of thrombin generated by deficient plasma 
alone was much lower than at 5nM FIXa p<0.01.  Increasing FVIII concentration increases 
AUC, this was a significant difference between all FVHI levels apart from 1  and 0.1 IU/ml 
p<0.05 AUC (Fig 5.9b, 5.10).  The differences in AUC were also reflected in peak-height 
which was significantly different for all FVHI concentration p<0.05 apart from  1  and 0.1 
IU/ml.  The  time-to-peak  decreases  with  increasing  FVHI  concentration  which  was 
significant for all FVIII levels apart from 0 and 0.001 IU/ml p<0.05.
Tissue Factor. 5oM
With TF (RecombiPlasTin™, reconstituted in water, IL)  to activate thrombin generation 
there was no difference in AUC or peak-height between 1  and 0.1 IU/ml, and 0.001  and 0 
IU/ml.  The differences between the other FVIII concentrations however were significant 
p<0.01.  Time-to-peak was significantly different between all FVHI concentrations p<0.05.
Overall there was no difference in peak-height or amount of thrombin generated at 1   and 
0.1  IU/ml  FVffl  between  the  different  triggers.  In  terms  of the  AUC  there  was  no 
difference  between  0.08nM  FIXa  and  5pM  FIXa  apart  from  at  0.01  IU/ml,  at  this 
concentration the low FIXa trigger generates significantly more thrombin than TF (p<0.05). 
There were significant differences in time-to-peak between all methods.
To summarise, the amount of thrombin generated at low FVIII concentrations is affected by 
the type and  concentration  of trigger used.  The  low FIXa  concentration gave a greater 
differences  in  lag-time between  the  FVIII concentrates  and  the  concomitant changes  in 
peak height and AUC.  The difference in the amount of thrombin generated at 0.01  IU/ml 
by the different methods is crucial, as this is the level that defines severe haemophilia.  The 
sensitivity  and  reproducibility  of the  assay  at  low  FVIII  levels  (0.001-0.1 IU/ml)  was 
greater  when  using  the  low  FIXa  as  the  trigger.  For  all  studies  hereonin  with  the 
fluorogenic  method  the  low  FIXa  concentration  was  used,  unless  otherwise  stated.
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Fig 5.9 Comparisons of Triggers for thrombin generation.  A- High IXa, B- Low IXa, C- TF 
5pM. FVIII concentration I -OlU/ml.
145A
60000
50000 High  IXa
n  Low IXa 40000
5
g  30000 
2
•5  20000
10000
0.01  0.001 
FVIII concentration (IU/ml)
B
4500
■ High IXa
3000
□ Low IXa
|   2500
|  2000
£  1000
0.1  0.01  0.001 
FVIII concentration (IU/ml)
50
45
40
35
30
25
20
15
1 0
5
0
■  TF
■  High IXa 
□  Low IXa
0.1  0.01
FVIII concentration (IU/ml)
0.001
rh
Fig 5. JO Comparison of thrombin generation parameters A-AUC, B- Peak height C- Time- 
to-peak.
1465.6  Comparison of FVIII concentrates
The  thrombin  generation  profiles  were  assessed  in  the  fluorogenic  assay  for all  FVIII 
concentrates.  The same concentrates were tested as for the clotting method, except that for 
Re  facto, Recombinate and Kogenate in which ampouled material was no longer avaliable, 
instead a vial of material was reconstituted and snap frozen in aliquots.  In addition another 
concentrate had become available “Kogenate-SF’ this product is manufactured without the 
addition of albumin to stabilise the final product.  To compare the two different FVIII assay 
methods, potencies were measured for each FVIII concentrate by one-stage APTT and by 
chromogenic assay against the 6th IS  (NIBSC)(Table 5.9).  FVHI concentrates were then 
diluted in FVIII deficient plasma (Technoclone) to achieve a concentration of 0.3  IU/ml 
according to potency.  Thrombin generation was then triggered with low FIXa and other 
reagents for the fluorogenic method as previously described.
Table  5.9.  FVIII concentrate potencies obtained by  one-stage and chromogenic  assays 
n=3.
One-stage (IU/ml) Chromogenic (IU/ml)
Refacto 123.2 188.7
Recombinate 82.2 77.6
Kogenate 92.3 84.9
Kogenate-SF 24.1 19.3
Replenate 11.6 8.9
Hemofil-M 9.4 7.1
Octavi 7.9 7.2
8Y 7.8 8.8
Thrombin  generation  was  compared  for  concentrates  at  0.3  IU/ml  as  assigned  by 
chromogenic or one-stage assay (Fig 5.11, Fig 5.12).  More thrombin was generated when 
chromogenic potencies were used, this was also true for peak-height.  These differences 
though were not statistically significant.  In general there was a wider spread in time-to- 
peak with the one-stage assay compared to chromogenic.  Time-to-peak was slightly longer
147in  the  one-stage  than  the  chromogenic,  but  this  was  again  not  significant.  The  one 
concentrate that did not generate thrombin more slowly in the one-stage assay was Refacto 
which had time-to-peak of 110% in chromogenic compared to 102.5% of NP with the one- 
stage potency.
With  the  one-stage  potency,  Refacto  generated  thrombin  more  rapidly  that  other 
concentrates, this though was not statistically significant from all other concentrates.  There 
were  statistical  differences  between  the  concentrates  in  time-to-peak  as  measured  by 
ANOVA p<0.001.
In  the chromogenic assay, time-to-peak  is more closely clustered with the exception  of 
Kogenate-SF.  The variation between all concentrates was significant (ANOVA p<0.05), 
however, this could be attributed to Kogenate-SF as removal of this from ANOVA analysis 
resulted in no significant differences between the remaining concentrates p=0.35.
Overall there was no difference in the amount of thrombin generated by the concentrates 
when  potencies  were  measured  with  either  assay.  When  potencies  were  measured  by 
chromogenic assay it resulted in thrombin generation profiles which were most similar, and 
would  suggest  that  chromogenic  assay  potencies  correlate  more  closely  with  thrombin 
potential.
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Fig 5.11  Thrombin generation  by all FVIII concentrates at 0.3 IU/ml,  FIXa  0.08nM. A- 
potency measured by one-stage assay B-potency measured by chromogenic assay n=4.
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1505.7  Platelets
In vivo phospholipid required for thrombin generation is provided by activated platelets.  A 
purified source of PL has been used in experiments so far as this has been more convenient, 
as use of platelets with the clotting TGT was not practical due to the large volumes used. 
The development of the fluorogenic assay allowed platelets to be readily used due to the 
smaller volumes required in the assay, and also the developing clot is not disturbed as in 
other  TGT  methods.  In  addition  to  providing  a  PL  surface,  platelets  also  support 
interactions with VWF and fibrin which are important for thrombin generation (Beguin & 
Kumar,  1997).  As haemophilic PRP could not be used, a method was required to isolate 
platelets from normal donor PRP and remove FVIII while avoiding platelet activation.
5.7.1 Isolation o f  platelets
Initial  experiments  with  a  centrifugation  washing  method  proved  unsuccessfiil  as  four 
washes were required to remove FVIII, and this led to visible aggregation of the platelets. 
Gel filtration was then considered but work by Grignani et al  (Grignani et al, 1977b) and 
Timmons and Hawgier (Timmons & Hawiger, 1978) had demonstrated that FVIII-VWF is 
not removed by gel-filtration alone.  Addition of a discontinuous albumin gradient though, 
enabled platelets to be obtained which did not contain FVIII-VWF (Timmons & Hawiger, 
1978;Grignani etal, 1977a).
Platelets  were  isolated  by a  combined  method  of albumin  gradient and  gel-filtration  to 
remove FVIII from the platelet preparation.  Platelets were eluted at fractions  10-30 (Fig 
5.13),  however,  this  did  depend  upon  the  volume  of platelet  rich  albumin  which  was 
applied to the Sepharose 2B column.  The platelet containing fractions, which were visibly 
distinct by their opaque nature, were collected.
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Fig 5.13 A typical elution profileofplatelets  from a sepharose 2B column.
All fractions eluted were measured for protein by OD at 280nm.  Platelets are eluted before 
most of the proteins  (Fig  5.13).  To  make sure  that FVIII  was  not eluted  in the platelet 
containing fractions a FVIII ELISA was carried out.  In the example presented here fraction 
1-54 were analysed (Fig 5.14).  All fractions contained FVHI less than  1   IU/dl, and all but 
one of the platelet fractions contained less than 0.3 IU/dl.  This fraction is most probably an 
aberrant reading as fractions either side were much lower.
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Fig 5.14 FVIII ELISA of gel filtration fractions.  A- Standard curve B- FVIII content of 
fractions.  Results from one experiment.
The pooled platelet preparation was also tested and found to contain 0.02 IU/dl FVIII.  This 
method of isolating platelets was therefore found to contain minimal FVIII.
153To  ensure that the  platelets  were not  activated  by  the  process they  were  tested  in  three 
different  assays  by  Bill  Pickering  at  NIBSC.  These  were  a  FXa  generating  assay, 
measurement of prothrombinase complex, and a thrombin generation test
Factor Xa generating assay
Factor Xa generation was measured by a similar method to that described  in section 2.4 
Briefly,  160pl  of platelets  were added  to  800pl  of combined  FX,  FIXa  and  FVIII,  FXa 
generation was then initiated by 160pi Ca2+.  25pl of this mixture was removed and added 
to 50pl “stopping buffer”, FXa was then measured by the addition of lOOpl 3mM S-2756, 
this reaction was terminated at 3  minutes with 50% acetic acid.  The amount of FXa was 
determined from a standard curve.
FXa  was  measured  in  the  absence  of  platelets,  unactivated  platelets  and  by  platelets 
activated  with calcium  ionophore (A23187  lOgM,  Sigma).  The gel-filtered  platelets  did 
not produce FXa during the time course of the experiment (Fig 5.15), this was comparable 
to the absence of platelets, which would suggest that the platelets were unactivated and not 
exposing  procoagulant  PLs.  Treatment  with  calcium  ionophore  did  generate  FXa,  this 
suggests that they can expose PL.
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Fig  5.15  FXa  generation  by platelets.  FXa  generation:  Effect  of calcium  ionophore 
(A23187) on gel-filtered platelets at a concentration of 100xl(f/L
154Prothrombinase complex
The  ability  of the  platelets  to  partake  in  the  prothrombinase  complex  was  measured  by 
incubating  158pl  of platelets  for  3  minutes  with  5pl  Ca2+,  25pl  FXa  (3mM),  and  FVa 
(6mM,  Hematologic  Technologies  Inc).  Prothrombin  60pl  was  added  to  reach  a  final 
concentration of 4pM.  5pi of reaction mixture was removed at timed intervals into 200pi 
“stopping buffer”.  The amount of thrombin generated was determined by addition of 50pl 
S-2238  (Chromogenix)  for 3  minutes,  subsequently colour reaction  was  terminated  with 
50pl 50% acetic acid.
Gel-filtered  platelets  only  started  to  produce  thrombin  after  350  seconds  (Fig  5.16). 
Whereas in ionophore-treated platelets maximal thrombin was produced within 75 seconds. 
This  demonstrates  that without activation  the gel-filtered platelets  are  much  less  able to 
provide the necessary phospholipid surface for the prothrombinase complex.
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Fig  5.16  Measurement  of  prothrombinase  complex  with  gel-filtered  platelets. 
Prothrombinase activity: Effect of  calcium ionophore (A23187) on gel-filtered platelets at a 
concentration of 100x1 if  /L.
155Thrombin generation
Thrombin generation in plasma was also measured in a chromogenic assay.  80pl FLXa (1.1 
IU/ml) and 400pl defibrinated normal pooled plasma were mixed,  lOOpl of platelets were
-  74.
then  added,  thrombin  generation  was  initiated  with  50pl  Ca  (90mM),  lOpl  subsamples 
were taken at intervals into 140pl stopping buffer.  Thrombin was detected by adding 50jil 
S-2238 (1 2mM) for 3 minutes, then terminating with 80pl 50% acetic acid.
A small amount of thrombin was generated by the unactivated platelets by 30 minutes (Fig 
5.17).  This  is  in  contrast  to  the  ionophore-treated  platelets  which  reached  maximal 
thrombin generation at 390 seconds.
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Fig 5.17  Thrombin generation in normal plasma by gel  filtered platelets.
These  experiments  demonstrated  that  the  platelets,  following  albumin  gradient  and  gel 
filtration were  in  an unactivated  state.  They  were  considerably slower to partake  in  the 
prothrombinase complex and  thrombin generation,  and no FXa was generated during the
156time-course of this experiment.  Therefore gel-filtered platelets contained minimal FVIII 
and remained in an unactivated state.
5.7.2 FVIII concentrates with platelets
Four different concentrates (.Refacto, Kogenate, Repienate and 8Y) were compared at 0.3 
and 0.03 IU/ml with unactivated platelets to establish if there was any difference between 
the types of concentrates in their ability to generate thrombin in the presence of platelets.
Thrombin  generation  was  measured  with  40gl  HP  91 hours  plasma,  with  40pl  platelets 
(200x106/ml),  thrombin  generation  was  initiated  by  the  addition  of 40pi  substrate  mix 
(substrate 0.7nM, FTXa 0.23nM, Ca2+21 mM).
At  a  concentration  of 0.3  IU/ml  (Fig  5.18,  Fig  5.19)  no  significant  differences  were 
observed  between  the  concentrates  in  terms  of  AUC,  peak  or  time-to-peak  height. 
Kogenate  did  generate  thrombin  more  slowly  than  the  other  concentrates,  but  this 
difference was not significant.  All  concentrates  had thrombin  generation  with  a higher 
peak and more rapid thrombin generation than normal plasma (0.86 IU/ml).  At a lower 
concentration  of 0.03  IU/ml  again  thrombin  generation  was  slower  with Kogenate,  but 
again this difference was not significant (ANOVA, p=0.35).
An  unexpected  finding  was that the concentrates  generated thrombin more  rapidly than 
normal  plasma  despite  the  much  lower  FVIII  concentration  (0.3  IU/ml),  this  was 
significantly  different  for  Refacto  and  Repienate  p<0.05.  This  would  suggest  that 
concentrates  can  produce  thrombin  more  rapidly  than  FVIII  in  normal  plasma  when 
platelets are present, regardless of the purity of the product.
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Fig 5.18.  Thrombin generation by FVIII concentrates (0.3 IU/ml) triggered with low FIXa 
and with platelets.
158A
ex
<4-1
o
160
140
120
100
80
60
40
20
0
I
□ AUC
■ Peak-height
□ Time-to-peak
Refacto Kogenate Repienate 8Y
B
CL
£
<4-1
o
200
180
160
140
120
100
80
60
40
20
0
□ AUC
■ Peak-height
□ Time-to-peak
Refacto Kogenate  Repienate 8Y
Fig  5.19  Thrombin  generation  parameters  of FVIII  concentrate  with  platelets  A- 
Concentrates 0.3 IU/ml B- Concentrates 0.03 IU/ml.
159Just to make sure that there was no difference between concentrates, thrombin generation 
was also measured with 5pM TF as the trigger (Fig 5.20).  Again no significant differences 
were observed between the different concentrates at 0.3  and 0.03  IU/ml.  A larger peak- 
height was generated by the FVHI concentrates compared to normal plasma, as was found 
with a low FIXa concentration as the trigger.  With TF, Kogenate was not slower than the 
other concentrates to generate thrombin.  In addition, thrombin generation occurred at the 
same time for concentrates at 0.3 IU/ml as normal plasma.
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Fig 5.20.  Thrombin generation of  FVIII concentrates (0.3 IU/ml), with platelets, triggered 
with 5pM TF.
5.8  Concentrates with VWF/ different deficient plasmas
It is known that the absence of VWF from plasma can affect potencies, in particular with 
the  one-stage  assay.  Thrombin  generation  was  measured  in  four  different  concentrates 
(.Refacto, Kogenate, Repienate, 8Y).  Of these concentrates tested only 8Y, an intermediate 
purity  product contains  a  large  amount of VWF,  which  contains  VWF:Ag:FVHI:c 2.9:1 
whereas Repienate contains 0.013:1  (Raut et al, 1999), the recombinant products of course 
do not contain any VWF.
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160Thrombin  generation  was  measured  for  the  four  concentrates  in  three  different  FVIII 
deficient plasmas.  The plasma from Sigma was specifically chosen as VWF is removed 
during the manufacture.  The other commercial plasma,  Technoclone,  contained normal 
VWF levels.  They were both compared to severe haemophilic plasma which also contained 
normal  VWF  levels.  Thrombin  generation  was  measured  by  incubating  40gl 
plasma/concentrate with 40pl PL and 40pl substrate/Ca2+/FIXa mixture.
The FVTTT deficient plasmas were assessed for VWF content by Lynne Weller (NIBSC). 
The plasma manufactured by Sigma contained no VWF, Technoclone contained 0.62 IU/ml 
and  the haemophilic  plasma  HP1  91 hours  contained  1.2  IU/ml  VWF  (normal  range  of 
VWF: 0.5-2.0 IU/ml).
At 1   IU/ml FVm, no differences were observed between the concentrates in AUC or peak- 
height, or between the different FVIII deficient plasmas (Fig 5.21).  However, there were 
differences in lag-time between concentrates and FVIII deficient plasmas.  Thrombin was 
generated more rapidly for all concentrates in the Sigma plasma, followed by Technoclone, 
then HP1  91 hours.  This finding was consistent and statistically significant.  For example 
for Repienate when Sigma was used it was significantly more rapid than Technoclone and 
HP1  91hours  (p  <0.05,  <0.01  respectively).  Despite  the  shorter  time-to-peak  between 
Technoclone and HP1 91 hours this was not significant.
The  only  difference  between  concentrates  was  observed  for Refacto,  Kogenate  and  8Y 
where the two high purity products generated thrombin significantly more rapidly than 8Y 
(p <0.01, <0.05, respectively) in the Sigma plasma.  These differences were not observed in 
the  other  FVIII  deficient  plasmas.  In  HP1  91 hours  thrombin  was  generated  at 
approximately the same time for all concentrates.  These results suggest that the absence of 
VWF causes thrombin to be generated more rapidly.
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Fig 5.21.  Thrombin generation parameters for FVIII concentrates (I IU/ml) in different
FVIII deficient plasmas. A-AUC B-Peak-height C-Time-to-peak
162Thrombin generation was also studied at a lower concentration of 0.03 IU/ml (Fig 5.22).  A 
lower AUC and peak-height was obtained with concentrates in HP1 91 hr plasma, compared 
to the commercial plasmas, this was however only significant for Kogenate (p< 0.05).  In 
contrast to 1  IU/ml at the lower FVHI concentration there was in general no difference in 
time-to-peak between the two  commercial  FVIII  deficient  plasmas,  the exception being 
again  with  Kogenate  which  was  significant  (p<0.05).  Thrombin  was  generated 
considerably more slowly in the haemophilic plasma compared to the commercial plasmas 
for 8Y, Refacto and Kogenate (p<0.01).  The time-to-peak was not significantly different 
for Repienate  between HP1  91 hours and Technoclone and was no significant difference 
between Sigma and Technoclone, unlike that found in 1 IU/ml.
In contrast to the results at 1 IU/ml, no difference between 8Y and the recombinant products 
was observed in the Sigma plasma.  However, a longer time-to-peak height was observed 
for Refacto and Kogenate in haemophilic plasma which was significantly different from 8Y 
(p<0.05 for both).
To summarise, there were differences in the time at which peak thrombin is reached in the 
different plasmas.  There were significant differences between the two plasmas containing 
normal VWF levels.  This suggests that there are other factors, apart from VWF, which 
affect the lag-time in thrombin generation.
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164To  assess  the  direct  influence  of VWF  on  thrombin  generation,  purified  VWF  (1st  IS 
00/514) was added to Sigma (which did not contain VWF) to concentrations of 0.1  and 1  
IU/ml  VWF.  This  allowed  comparison  without the  confounding  variables  of different 
deficient plasmas.
At 1 IU/ml FVIII there was no difference between the absence or presence of VWF on the 
AUC or peak height (Fig 5.23).  The greatest difference however was observed in the time- 
to-peak,  as  was  observed  previously  with  different  plasmas.  Increasing  VWF 
concentration,  increased die time-to-peak for Repienate, Refacto and Kogenate, although 
the difference between 0 and 1   IU/ml VWF was only significant for Refacto (p <0.05) and 
Kogenate (p <0.05). 8Y generated thrombin at die same time for all VWF concentrations. 
There was no difference in the time at which 8Y generated thrombin with additional VWF. 
With no VWF present Refacto and Kogenate produced thrombin significantly quicker than 
8Y  (p<0.01  and  0.05  respectively).  At  0.1  IU/ml  VWF  Refacto  was  still  producing 
thrombin more rapidly than 8Y (p<0.05), this was also significantly different from Refacto 
in the absence of VWF (p<0.05).  At 1   IU/ml VWF with Refacto thrombin was generated 
more rapidly, but this was not significandy different from 8Y.  For Kogenate an addition of 
0.1  IU/ml VWF to the FVIII deficient plasma increased the time-to-peak, to that of 8Y, a 
further increase in the VWF concentration to  1   IU/ml  prolonged the time-to-peak height 
further which  was significandy  longer than 8Y (p< 0.05).  At  1  IU/ml VWF, Kogenate 
generated thrombin significandy more slowly than with 0.1 IU/ml VWF (p<0.05).
In contrast to findings with 1  IU/ml FVIII, at 0.3 IU/ml there were differences in the peak- 
height and AUC with different VWF levels (Fig 5.24).  Differences in the AUC and peak- 
height were only observed  for the  recombinant products Refacto and Kogenate.  In  the 
absence  of VWF these  concentrates  both  produced  significantly  less  thrombin  than  8Y 
{Refacto p<0.01, Kogenate p<0.05).  Increasing VWF concentrations resulted in increased 
thrombin  generation.  At  1  IU/ml  VWF,  significandy  more  thrombin  was  produced 
compared to 0 IU/ml for Refacto (p<0.05) and Kogenate (p<0.05).  These findings were 
also mirrored in the findings with the peak-height  An unexpected finding was that at the 
lower FVIII concentration time-to-peak was unaffected by increasing VWF levels.
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1675.9  Low FVIII concentrations
Thrombin  generation  was  assessed  at  low  concentrations  of FVTQ  with  the  fluorogenic 
method as was done with the clotting method (section 4.3) to establish how sensitive this 
method was to low FVIII concentrations.
5.9.I  Low FVIII dose-response
A range of FVIII concentrations (10"5to 10'1  IU/ml) was produced by diluting Repienate in 
FVIII  deficient  plasma  (HP1  91hrs)  and  thrombin  generation  measured  (Fig  5.25).  An 
addition  of  10"4  IU/ml  FVIII  slightly  increased  thrombin  generation  from  the  baseline 
(Table  5.10),  this  increase  however  was  not  significant.  Further  increases  in  FVIII 
concentration  increased  both  the  AUC  and  peak-height  and  these  were  significantly 
different from the baseline for FVIII concentrations  of 10'3IU/ml  and upward  (p<0.001). 
These  findings  demonstrate  that  the  fluorogenic  method  is  as  sensitive  as  the  clotting 
method in distinguishing low levels of FVIII.
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Fig 5.25.  Thrombin generation at low concentrations of  FVIII.
168Table 5.10.  AUC and peak height o f low  levels o f FVIII in  the fluorogenic assay with a 
high FIXa concentration.  *p< 0.001
lO’IU/ml lO^IU/ml 10"3IU/ml lO^IU/ml 10  IU/ml 0 IU/ml
AUC
RFU.min
28130*946* 28080*721* 25827*1371* 21400*2063 19634*1377 19593*985
Peak
(RFU)
2532*111* 2480*143* 1936*98* 1349*167 1202*87 1199*80
5.9.2  Prophylaxis samples
The prophylaxis  samples  (section 4.2.2)  were also  measured by the fluorogenic method 
using both high and low concentrations of FIXa and PL.
The high FIXa concentration (Fig 5.26a) produced a large amount of thrombin in all the 
plasmas except 401162, which did not produce thrombin at all, which was in agreement 
with results obtained with the clotting method.
The low FIXa trigger produced much less thrombin than the high FIXa concentration, there 
was  a  greater  correlation  between  AUC  and  FVIII  levels,  and  this  association  was 
statistically significant (p<0.01).  There were also significant correlations between peak- 
height (p<0.01) and time-to-peak (p<0.05).  This suggests that the fluorogenic assay could 
be useful in a clinical setting for determining treatment.
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170Table 5.11  Thrombin generation parameters of  prophylaxis samples expressed as a percentage of normal plasma.
Sample ID 401161 401162 401164 401182 401192 401193 401229 401303 Correlation
FVIII IU/dl 0.4 3.0 0.6 2.7 0.4 0.6 1.0 0.8 R2 P
High IXa 
(% of 
NP)
AUC 70.29 1.51 107.84 103.80 57.09 80.89 97.41 104.82 0.25 n.s
Peak 50.62 0.82 87.42 90.55 32.78 68.93 86.68 100.35 0.24 n.s
Time 218.92 - 162.16 121.62 254.05 151.35 145.95 154.05 0.42 n.s
Low IXa 
(% of 
NP)
Auc 5.1 1.6 16.3 81.1 19.1 37.3 22.5 31.4 0.85 <0.01
Peak 2.9 1.2 9.7 59.3 11.4 22.6 14.6 21.1 0.89 <0.01
Time 458.3 - 387.5 210.4 397.9 316.7 364.5 354.2 0.72 <0.055,10  Discussion
The results presented in this chapter demonstrate the reliability of the fluorogenic method 
and  that  results  are  comparable  to  the  clotting  based  method.  However,  there  are 
differences between the methods in the presence or absence of fibrinogen.  In defibrinated 
plasma a larger AUC, but smaller peak-height is observed in the fluorogenic method, than 
in  the  clotting  based  method.  These findings  have also  been  observed by  others  in  the 
fluorogenic  system  (Hemker  et  al,  2003)  and  with  subsampling  chromogenic  methods 
(Kumar et al,  1994;de Bosch et al, 2002).  However, in their study defibrinated plasma in 
the fluorogenic assay did not return to the baseline as was observed in Fig 5.4, instead the 
thrombin  level  plateaued  at  approximately  half peak-height.  The  differences  in  results 
between  the  two  different  fluorogenic  methods  may  be  due  to  the  different  amount  of 
plasma in the system, in the method used by Hemker et al plasma constitutes two-thirds of 
the reaction mixture, whereas in our method plasma only makes up one-third of the reaction 
mixture.  In a chromogenic subsampling TGT, previous work has shown that in fibrinogen 
depleted  plasma,  thrombin  generation  onset  is  quicker  than  that  of  untreated  plasma 
(Kumar et al, 1994;de Bosch et al, 2002).  This was not found in our subsampling method, 
but may be due to the differences in subsampling into a chromogenic substrate, as opposed 
to fibnnogen.
Another  experiment  was  performed  by  treating  plasma  with  the  peptide  gly-pro-arg-pro 
(GPRP),  this  peptide prevents  fibrin  polymerisation  by binding to the A and B chains of 
fibrin  (Laudano  &  Doolittle,  1980),  thus  causing  a  conformational  change  (Pratt  et al, 
1997).  Plasma treated with GPRP behaved in the same way as defibrinated plasma, which 
suggests that the  increase  in thrombin  generation  was  due to the absence of polymerised 
fibrin.  It has been shown that thrombin contained within a clot is able to activate FV, FVIII 
(Kumar et al,  1994), and FXI (von dem Borne et al,  1995).  Also fibrin alone can activate 
platelets  (Kumar  et  al,  1994),  this  is  mediated  through  the  GPIb  receptor  on  platelets 
(Beguin et al, 1999).
The dose-response to FVIII was measured in the fluorogenic system for both concentrations 
of the FIXa trigger.  The same findings were found as  for the clotting system at the high
172FIXa  concentration  i.e.  large  amounts  of  thrombin  are  observed  even  at  very  low 
concentrations  of  FVIII,  peak-height  and  AUC  were  similar  to  normal  plasma  which 
contained 0.87 IU/ml FVIII.  However, the deficient plasma generated a larger amount of 
thrombin, AUC 60% of normal plasma, compared to 35% in the clotting system.  Thrombin 
generation  could  be  abolished  in  deficient  plasma  by treatment  with  a  polyclonal  rabbit 
anti-FVIIl antibody.  This would suggest that the fluorogenic TGT is also sensitive to very 
low levels of FVIII.  With a lower concentration of FIXa as the trigger,  peak-height and 
AUC  increased  with  increasing  FVTII,  while  the  time-to-peak  height  decreased.  These 
results mirror those observed m the clotting system.
The thrombin generation profiles were compared for both concentrations of FIXa and also 
5pM  TF.  It has been suggested by several  different groups that this concentration of TF 
may be a closer approximation to the in vivo situation as at this concentration of TF, FVIII, 
FIX and FXI  are required for normal haemostasis (von dem Borne et al,  1995;Keularts et 
al, 2001a).  In general 5pM TF generated similar thrombin generation profiles to that of the 
low FIXa concentration, however, there was a large difference in the amount of thrombin 
generated at 0.01  IU/ml.  At this concentration the peak and AUC were much smaller than 
that caused by the low FIXa concentration.  This was an interesting finding as this level of 
FVni determines the classification of severe haemophilia, and our results suggest that more 
thrombin is generated if triggered by the intrinsic pathway (FIXa) versus the extrinsic (TF).
The  range  of  FVIII  concentrates  were  compared  at  a  concentration  of  0.3  IU/ml  for 
potencies  obtained  by  both  the  one-stage  APTT  and  chromogenic  assay.  The  product 
Kogenate  -SF.  which  was  manufactured  without  albumin,  showed  consistently  slower 
thrombin generation for potencies obtained with both methods  Overall, time-to-peak was 
most  similar  if potencies  had  been  established  by  the  chromogenic  method,  this  would 
suggest that this assay is able to give a better reflection on the haemostatic effectiveness of 
concentrates.  This  is  interesting  because  the  one-stage  assay  is  thought  to  be  more 
physiological than the chromogenic (Lollar, 2003).
173Once  it had been established that the new TGT  system behaved in  the  same  way as the 
clotting  method,  unactivated  platelets  were  added  to  the  system  as  the  source  of PL. 
Platelets were added to determine if there were any differences between the concentrates in 
ability to generate thrombin  in a system that more closely resembled the in vivo situation. 
Haemophilic platelets could not be obtained, therefore platelets were obtained from normal 
donors  and  the  endogenous  plasma  containing  FVIII  removed.  The  removal  of plasma 
from  platelets  was  not straightforward  as  it  was  important  to  remove  all  FVIII  without 
activating platelets.  A combined procedure of discontinuous albumin gradients followed by 
gel-filtration  was  effective  in  removing  FVIII  from  platelets,  whilst  leaving  them 
unactivated.  The absence of FVIII was demonstrated by our findings with a FVIII ELISA. 
We also demonstrated that the platelets were unactivated by gel filtration as shown by the 
absence of FXa generation  by unactivated  platelets.  However,  treatment of the platelets 
with  calcium  ionophore,  which  causes  the  inner  leaflet procoagulant phospholipids to  be 
exposed (Bevers et al, 1982), showed that when the platelets were activated they were able 
to take part fully in PL dependent reactions.  The fluorogenic assay  is  comparable to the 
clotting method, although there is a longer duration until the peak is obtained.  This is most 
likely due to the decreased availability of thrombin due to thrombin being sequestered by 
the  substrate,  and  therefore  unable  to  partake  in  feedback  activation.  A  slower  rate  of 
thrombin generation has also been observed with the continuous chromogenic method.
The addition of platelets to the TGT was to make the test more physiological, Beguin and 
Kumar had demonstrated the important  link between thrombin,  fibrin,  VWF and platelets 
(Beguin & Kumar,  1997).  It was thought that the concentrates may behave differently due 
to the different levels of VWF.  However, no difference was observed when four different 
concentrates with differing VWF concentrations were compared.  This would suggest that 
assay  discrepancies  are  not  due  to  the  differing  purities  of the  concentrates.  All  FVIII 
concentrates tested at 0.3 IU/ml generated thrombin more rapidly than normal plasma (0.86 
IU/ml), this  is  in  contrast to the results  with  PL in  which thrombin  was generated after a 
slightly  longer delay as  would  be expected  with a  lower FVTII  concentration.  However, 
when  the  reaction  was  triggered  with  5pM  TF  the  FVIII  concentrates  did  not  generate
174thrombin more rapidly than normal plasma.  In addition there were no differences between 
the concentrates when trigged with TF.
To further study the effect of VWF, FVIII concentrates were tested in a commercial FVIII 
deficient plasma  which  was  also  deficient  in  VWF.  This  demonstrated  that the  lack  of 
VWF  had  an  effect  on  lag-time;  and  was  confirmed  by  increasing  VWF  concentration, 
which  increased  lag-time  for  some  of the  concentrates.  Refacto  and  Recombinate  had 
shorter lag-times than 8Y, which contains VWF in the ratio  1:4 (IU/ml).  Addition of VWF 
to the deficient plasma minimised differences  between  the  recombinant products and 8Y. 
Kogenate,  however had a significantly  longer  time-to-peak  with  a normal  VWF  content 
than  8Y.  This  was  in  agreement  with  other  TGT  experiments  in  which  Kogenate  was 
consistently  slower  to  generate  thrombin,  although  this  was  often  not  a  significant 
difference.  The studies do highlight, though the importance of normal VWF content, and 
discrepancies may occur if potencies are assessed in VWF deficient plasmas (Barrowcliffe 
etal,  1993b).  This confirms previous studies which have shown the importance of VWF in 
the deficient plasma to minimise discrepancies.
5.11  Summary
The fluorogenic test has been demonstrated to be reproducible and comparable to that of 
the clotting method.  The results presented  in this chapter have shown that the method is 
sensitive to FVIII concentrations as low as 0.001  IU/ml
Potencies  as  measured  by  one-stage  APTT  assay  gave  more  variable  lag-times  than  the 
chromogenic potencies, suggesting that chromogenic assay gives truer values.  VWF was 
found to influence the lag-time.  However, no effect was observed with IP products when 
assayed  in plasma with normal  VWF content.  This  suggests that in  vivo the haemostatic 
effects will be the same for all  concentrates.  In addition  when platelets were included in 
the  assay  no  differences  were  observed  between  products  of  different  purity.
175CHAPTER 6 
GENERAL DISCUSSION AND CONCLUSION
Issues in the measurement of FVIII have been a long standing problem, with discrepancies 
between assay methods and with the type of standard used.  This project has not aimed to 
study the effect of which standard is used, but rather to use a different approach to try and 
understand  the  discrepancies  between  different  FVIII  concentrates.  Previous  studies  as 
detailed  in  section  1.2.7  have  demonstrated  that  discrepancies  between  methods  can  be 
overcome with the use of the correct standard i.e. like vs like (Barrowcliffe,  1993b).  The 
type  of deficient  plasma  used  is  also  a  crucial  component  and  must  contain  VWF.  In 
addition,  other work has  shown  that more  physiological  forms  of PL  can  also  eliminate 
discrepancies  between  one-stage  and  chromogenic  assays  in  potency  measurement  of 
recombinant products in particular Rejacto.
Thrombin  generation was measured for a range  of different FVIII concentrates  in both  a 
clotting based version and  m a fluorogenic adaptation of the assay.  In the clotting based 
assay, Rejacto was found to generate thrombin more rapidly than the other concentrates at 1  
IU/ml.  However, Refacto was not found to generate thrombin more rapidly than the other 
concentrates at other concentrations in the clotting system.  In addition, in the fluorogenic 
system Refacto was not found to generate thrombin more rapidly than other concentrates. 
Together these  findings  suggest that  the  presence  or absence  of the B  domain  does  not 
affect the way in which thrombin is generated.
For all FVIII concentrates used throughout these studies, potency had been established by 
chromogenic  assay.  It  was  confirmed  by  TGT  that  the  chromogenic  assay  does  give  a 
reliable measure of potency  between  the concentrates.  A  direct comparison  of thrombin 
generation  following  potency  measurement  by  both  one-stage  and  chromogenic  assay 
demonstrated  lag-times  more  closely  associated  together  when  potency  was  assessed  by 
chromogenic.  There  was  no  significant  difference  in  time-to-peak  between  Rejacto,
176Recombinate, Kogenate, Replenate, Hemofil-M, Octavi or 57.  These results  suggest that 
the chromogenic assay is more accurate in determining haemostatic potential in vivo than 
the one-stage for FVIII concentrates.  It is unclear if the chromogenic assay would also be 
more accurate for plasma samples.  The results suggest that all FVTII concentrate potencies 
should be determined by chromogenic assay.  In addition, Refacto was found to have the 
same thrombin generation profiles with the chromogenic potency, suggesting that Refacto 
can be accurately assayed alongside other concentrates.
The FXa generating assay demonstrated large differences between the concentrates in time 
and quantity of FXa generated.  However, these large differences resolved upon thrombin 
activation, so that, although there were differences between concentrates these were small. 
This matches findings in the TGT,  in that any differences between concentrates are small 
and  unlikely  to  result  in  different  haemostatic  responses  in  vivo.  In  unactivated 
concentrates the differences  were due largely to the VWF  content,  with those containing 
most  VWF  generating  least  FXa  and  more  slowly.  However,  there  were  still  some 
differences between  concentrates  when  the same amount of VWF  was  added,  suggesting 
possible dilferences in the FVIII:VWF complex, or maybe there are slight variations in the 
ratio  of FVIITVWF,  which  could  be  accounted  for  because  of  variation  in  potency 
assignment.
VWF was shown to be an important constituent of thrombin generation when experiments 
were performed with and without VWF.  In the absence of VWF, thrombin generation was 
quicker, although there was no difference in the amount of thrombin generated overall.  Of 
the  concentrates  tested,  8Y  was  unaffected  by  the  addition  of VWF  to  VWF  deficient 
plasma.  This  is  most  likely  due  to  the  presence  of a  large  amount  of VWF  in  this 
concentrate.  The most rapid thrombin generation occurred in the absence of VWF, which 
mirrors the results of the FXa generation assay.  In the absence of VWF, thrombin/FXa is 
generated  more  rapidly  as  FVIII/VWF  complex  does  not  need  to  dissociate  to  allow 
thrombin generation.  The  VWF/FVIII  complex dissociates by thrombin  cleavage at Arg 
1689  (Nogami  et  al,  2000)  thereby  allowing  PL  to  bind  to  the  FVIII  molecule,  then 
thrombin  can  be  generated  unhindered.  In  the  absence  of VWF,  PL  can  bind  to  FVIII
177without competition.  This is presumably a quicker reaction and therefore in the absence of 
VWF, thrombin or FXa generation  will  be more rapid.  It can therefore be seen that if a 
FVm-VWF deficient plasma is used in the one-stage or chromogenic assay then different 
lag-times  will  occur  in  thrombin  or  FXa  generation,  resulting  in  an  inaccurate  potency 
determination.  It is therefore necessary to equalise VWF levels by using a FVIII deficient 
plasma which contains normal VWF levels, and this has been reported on several occasions 
(Barrowcliffe et al, 1993b;Mazuner et al,  1990).
It  was  thought  that  platelets  may  affect  the  thrombin  generation  profile  of  FVIII 
concentrates due to the interaction of VWF with platelets.  Beguin et al have demonstrated 
that VWF is important in platelet activation. Reduced thrombin generation was observed in 
PRP  without  VWF,  which  was  greater than  blocking  platelet  VWF  receptors  GPIb  and 
aiibfb  (Beguin  &  Keularts,  1999).  However  we  found  no  significant  differences  in 
thrombin  generation  between  concentrates  containing  different  amounts  of  VWF, 
suggesting that platelets are not necessary for thrombin generation of FVIII concentrates. 
Presumably  because the  FVIII  deficient plasma  supplied  sufficient VWF  to  equalise the 
different VWF levels between the concentrates.
Kogenate seemed to consistently generate thrombin  more slowly than other concentrates, 
although  this  was not always  a  significant finding.  This  may suggest that  less  FVIII  is 
present,  which  would  suggest  an  overestimation  of  potency  by  chromogenic  assay. 
However Kogenate was assayed against the 6th IS, which is itself a full-length recombinant 
product, suggesting that potency determination is correct and that the slower generation of 
thrombin is due to functional differences in this concentrate.
The generation of large amounts  of thrombin  with  very low FVIII concentrations was an 
unexpected finding as the perceived wisdom  is that haemophilic plasma can only generate 
minimal thrombin.  A more important parameter of thrombin generation especially at low 
FVni concentrations  may be the  rate at which  thrombin  is produced and not the overall 
amount.  A decrease in the rate of thrombin formation may led to a weaker clot which may 
then be more prone to re-bleeding.
178FVIlIa binds to FIXa on PL surfaces to form the tenase complex.  These binding sites occur 
in  the  A2  and  A3  domains of FVIII  (Mertens  et al,  1999).  FIX  is  present  in plasma at 
concentrations of 90nM (Osterud et al,  1978) which is a 90 fold excess compared to FVIII 
(InM).  However, it is unlikely that all FIX is activated during haemostasis.  Lawson et al 
reported  normal  thrombin  generation  with  one  percent  of FIX  activated  (Lawson  et al, 
1994), which would correspond to an approximate  1:1  ratio, which assuming that all FVIII 
is activated corresponds to the 1:1  stoichometry.  Lawson et al found that full activation of 
the  cofactors  FVTIIa and  FVa  were  required  for  maximum  thrombin  generation.  In  the 
TGT used  in  these  studies  a  high  FIXa  concentration  would  correspond  to  a  ratio  of 1  
FVIII: 16.7 FIXa at  1   IU/ml, for the low concentrations of FIXa used this is equivalent to a 
ratio of 1FV1II:0.26 FIXa at 1   IU/ml FVIII.  At low FVIII levels FIXa would be in a much 
greater excess  for example at 0.01  IU/ml  this  would correspond to  1:1670 for high FIXa 
concentration, and  1:26 at low FIXa concentration.  It has been found in an epidemiology 
study of normal population that FVIII levels are correlated with FIX (Lowe et al, 1997).
It  is  currently  unclear  how  FIXa  increases  thrombin  generation  at  low  FVIII  levels, 
however, two mechanisms are likely.  Firstly,  increasing the concentration of FIXa would 
increase  the  amount  of FVIII  in  complex,  the  Kd  of this  association  is  0.5nM  (Jesty, 
1990;Rawala-Sheikh et al,  1990).  Secondly, at higher concentrations of FIXa inactivation 
of FVIIIa through A2 subunit dissociation is reduced (Fay et al, 1996).
FIXa was also found to protect FVIII from a polyclonal antibody.  This could in complex 
with PL and Ca2 ,  protect infused  FVIII  from  inactivation by circulating antibodies  in an 
inhibitor patient.  It is also possible that FIXa could be used alongside FVIII to increase the 
effectiveness  of  FVIII  in  non-inhibitor  patients  and  thereby  allowing  a  reduced 
consumption of FVIII.
The main bar to the use of FIXa in a therapeutic setting is the highly thrombogenic nature 
of FIXa.  Increased  levels  of FIX  have  been  associated  with  increased  risk  of venous 
thrombosis  in  case-control  studies  (Lowe  et  al,  2000),  this  study  did  however  find
179associations  with  other  coagulation  components.  FIXa  as  a  contaminant  of  FIX 
concentrates has been found to cause thrombosis in animal models (Gray et al, 1995;Kusch 
et al,  1998).  However, as those with haemophilia have a bleeding tendency they may not 
suffer from the adverse effects of FIXa.
Although estimates have been made of the amount of FIXa generated in vivo these have all 
been based on in vitro or computational models.  In addition, it is unclear how much FEXa 
is generated in in vitro experiments with 5pM TF which is the preferred trigger.  Knowing 
this would allow greater understanding of the role of FIXa in thrombin generation.
In conclusion, the TGT has shown that there are no differences between concentrates when 
measured by the chromogenic assay, this suggests that there are no differences in vivo.  The 
concentration of FIXa used to trigger TGT is crucial and can promote thrombin generation 
with low FVIII levels.  In addition, FIXa in a complex with FVIII, PL and Ca2  is able to 
protect FVIII from antibodies, which could be useful therapeutically.
The fluorogenic TGT is a version of the TGT which could potentially be used on a routine 
basis.  The  fluorogenic  method  was  found to  be  comparable to  the  clotting  method;  the 
main difference is in the time-to-peak which is delayed in the fluorogenic,  which  implies 
that  the  substrate  interferes  with  thrombin  generation.  The  reproducibility  of  the 
fluorogenic assay was found to be high with inter-assay variability of 6.4-8.8% in time-to- 
peak.  The  assay  also  has  an  increased  level  of  sensitivity  (0.001  IU/ml)  over  the 
chromogenic and one-stage assays.  A further advantage is the minimal amount of handling 
required of the sample and also the small volume of the sample (40gl) per measurement. 
This  method  can  also be carried  out  both  without and  with  platelets  which  would allow 
testing to be as close as possible to the in vivo situation.  The fluorogenic TGT is an easy 
assay  to  use  and  apart  from  the  cost  of the  fluroimeter all  other  reagents  including  the 
substrate are inexpensive.  This assay therefore has the potential to become a routine assay.
180Future work
The TGT  has  shown  great promise for the detection  of very  low levels  of FVIII.  More 
work  would  need  to  be  done  to  see  if  thrombin  generation  is  a  good  parameter  for 
measuring treatment.  It may be an important tool for evaluating outcome of gene therapy 
trials.  An increase in base-line thrombin generation after gene-therapy would demonstrate 
an  increased  FVIII  level  which  is  beyond  the  sensitivity  of  current  assays.  Another 
interesting  use  would  be  to  examine  a  large  group  of patients  at  a  long  duration  post- 
mfusion  to  see  if there  is  a  correlation  between  thrombin  generation  profile  and  other 
clinical measure like joint bleeding and FVIII usage.
Further work needs to be performed to examine the protective effect of FEXa/PL/Ca2" on 
FVm as there is potential for a therapeutic product, if thrombosis is not found to occur in in 
vivo models.
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